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1. Introduction  
 
1.1  Pancreatic cancer 
 
1.1.1  Clinics and prognosis of pancreatic cancer 
Pancreatic adenocarcinoma is a comparably rare cancer, but the fourth leading cause of 
cancer deaths as a result of its bad prognosis (Conroy et al. 2016). With a five-year survival 
rate of less than 6 %, the mortality of this disease almost equals its incidence. Discomfort 
occurs only in an advanced stage, and even then, symptoms are not specific. Although 
several risk factors are known, there is no established screening program for early 
detection, and 80 % of the patients display distant metastases or locally advanced tumors 
upon diagnosis and are not eligible for surgery, the only potentially curative treatment 
(Kamisawa et al. 2016). 
In contrast to other solid tumors, for pancreatic cancer there is a low chance to render it a 
chronic disease if yet curation is not achievable. Most of the patients die within the first year 
after diagnosis, and chemotherapy, although alleviating symptoms in a palliative care 
setting, hardly improves survival. It is estimated that deaths from pancreatic cancer will 
further increase, as known risk factors remain highly prevalent (male sex, family history, 
cigarette smoke, alcohol abuse and chronic pancreatitis) or become even more frequent 
(obesity, diabetes) combined with the lack of improved therapeutic options (Conroy et al. 
2016). 
1.1.2  Characteristics and biomarkers for pancreatic cancer 
Adenocarcinoma, derived from ductal epithelial cells, account for 95 % of pancreatic cancer. 
Although not unique to this tumor, it is genetically highly heterogenic with extensive tumor 
cell plasticity making it hardly accessible for targeted therapies as the main driver mutations 
cannot yet be successfully targeted (Falasca et al. 2016). Like in other tumors, some genetic 
alterations occur at specific stages of tumorigenesis and characterize the genetic landscape 
of pancreatic cancer. Oncogenic KRAS mutations are found in 90-95 % of tumors and occur 
in a very early stage, promoting tumor cell growth and metabolism. Intermediate alterations 
are found with deletions or epigenetic silencing of the cell cycle regulator CDKN2A/p16 
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(cyclin-dependent kinase inhibitor 2A), which are also found in 95 % of pancreatic tumors. 
Late events concern mutations or deletions of the tumor suppressor p53 (50-75 %) and the 
transcription factor DPC4/SMAD4 (deleted in pancreatic cancer 4/mothers against 
decapentaplegic homolog 4) which is a chromatin remodeling enzyme and involved in the 
transforming growth factor beta signaling pathway. Around 10 % of pancreatic cancers have 
a familial basis, most of which are germline mutations in the tumor suppressor BRCA2 
(breast cancer 2) (Ying et al. 2016). Global genomic analyses of pancreatic cancers gained 
insight in altered core signaling pathways and mutation patterns. An average of 63 genes 
were found to be mutated in each pancreatic cancer sample. Although none of the mutations 
except the above described was overrepresented, this large number of mutations could be 
reduced to twelve core signaling pathways, among them apoptosis (altered in 100 % of the 
tumors), cell cycle regulation (altered in 100 % of the tumors) and DNA damage signaling 
(altered in 80 % of the tumors) (Falasca et al. 2016). In knowledge of gemcitabine acting 
mainly through the induction of DNA damage, these results underline the importance of 
investigating the DNA damage response (DDR) as potential target to increase gemcitabine 
sensitivity.  
 
1.1.3  Therapeutic options 
Surgery of locally defined pancreatic cancer remains the only curative treatment, but is an 
option for only 20 % of patients. The five-year survival rate is increased to 25 % for resected 
patients, but 80-90 % eventually relapse. Efficient neoadjuvant chemotherapy may increase 
both the number of patients eligible for surgical therapy and its therapeutic success. For all 
patients with advanced disease, chemotherapy is the only option. Ever since 
monotherapeutic gemcitabine has proved beneficial in 1997, it has governed pancreatic 
cancer therapy, and all other single and combination therapies as well as targeted therapies 
have since been compared to its success. However, only a minority of patients respond to 
that treatment at all, and it prolongs median survival only to 5.65 months after diagnosis 
compared to 4.41 months after treatment with 5-fluor-uracil (5-FU) (Burris et al. 1997). The 
combination of gemcitabine with the epidermal growth factor inhibitor erlotinib marginally 
increased response and overall survival. Furthermore, recent studies established the 
combination with nanoalbumin-bound mitotic spindle inhibitor paclitaxel (nab-paclitaxel, 
Abraxane), which improved response to 23 % and overall survival to 8.5 months. The best 
option for patients with advanced and metastatic pancreatic cancer is the FOLFIRINOX 
regimen (5-FU and folinic acid, irinotecan, oxaliplatin), which prolonged survival to almost 
eleven months, but brings along extensive side effects and is therefore only eligible for 30-
40 % of  patients: those under 65 years of age and with a very good performance state 
Introduction                       3 
 
(Conroy et al. 2016). In case of acquired resistance to primary therapeutic regimens and 
onset of a progressive disease after chemotherapy, a second line treatment can be 
discussed although there is no robust clinical data for a clear benefit of it.  
Progress in the treatment of pancreatic cancers ranks far behind improved treatment 
options for other cancers, resulting in the need for even more research efforts. 
 
1.2  DNA damage 
 
The maintenance of genomic integrity is the major prerequisite for health and functionality 
of the human body from conception to death and for the creation of following generations. 
Besides the proper distribution of chromosomes during mitosis, the maintenance of the 
genetic code within the DNA is crucial for tissue renewal. Even without exposure to 
mutagens, it is estimated that a single cell has to cope with 50,000 to 100,000 DNA lesions 
per day (Hoeijmakers 2009; Swenberg et al. 2011; Takahashi et al. 1990). Most of them 
occur spontaneously or as consequence of metabolic processes like the generation of 
reactive oxygen species (ROS) resulting from the respiratory chain of a cell. They most 
frequently affect single bases, resulting in single base adducts and abasic sites (De Bont 
and van Larebeke 2004; Jackson and Loeb 2001; Swenberg et al. 2011). If not repaired 
before, those bases are eventually mispaired during DNA replication by low fidelity 
polymerases, leading to heritable mutations (Marnett and Plastaras 2001). The cell has 
evolved DNA repair mechanisms that sense and emit altered bases or mismatched base 
pairs by base excision repair (BER), nucleotide excision repair (NER) and mismatch repair 
(MMR). These mechanisms form a steady state with DNA lesions in a constant challenge 
for genomic integrity and mutations accumulate with age provoking the onset and 
progression of cancer. While single base adducts do not activate the full DDR, major insults 
can occur when the damaged site is cleaved into a double-strand DNA break, for example 
by topoisomerases, or results in single-strand DNA breaks if the base adduct blocks DNA 
replication (Marnett and Plastaras 2001).  
The accumulation of mutations resulting in genomic instability is cause as well as 
consequence of the malignant transformation of a cell. Mutations in coding regions or 
promoter regions of the genome inactivate tumor suppressors, and tumors are 
characterized by a defective system to cope with DNA lesions which in turn results in the 
accumulation of mutations (De Bont and van Larebeke 2004; Hoeijmakers 2009; Jackson 
and Loeb 2001; Stratton et al. 2009). 
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It is generally underlined that a constant baseline of DNA damage occurs endogenously 
and that the contribution of exogenous factors is comparably small. Nevertheless, it can 
trigger and prepone the onset of mutations (De Bont and van Larebeke 2004; Jackson and 
Loeb 2001). Finally, the massive induction of exogenous DNA damage has its clinical use 
in chemotherapy. 
 
1.2.1  DNA damage induced by UV radiation 
Sunlight is essential for the evolution of life. On the other hand, ultraviolet (UV) radiation 
causes DNA damage and is the most frequent source of exogenous DNA damage in all 
organisms. According to its wavelength, it is divided into UV-C (240-290 nm), UV-B (290-
320 nm) and UV-A (320-400 nm). While UV-C is absorbed by the atmosphere and does not 
hit living organisms to a relevant extent, UV-A and -B cause damage to cells in nature. UV 
radiation and visible light are absorbed by the DNA, especially by the pyrimidine bases 
thymine and cytosine, but only UV-B and UV-C provide energy high enough to excite carbon 
double bonds and induce the formation of cyclobutane-pyrimidine dimers (CPD) and 6-4 
photoproducts (6-4-PP) between two bases, of which the primary structure is detailed in 
Figure 1.1 (Herrlich et al. 2008; Li et al. 2006). In prokaryotes and most eukaryotes, these 
products are restored by specialized photolyases using visible light energy, but those 
enzymes seem to be missing in mammals. Although 6-4-PPs cause only 25 % of UV-
induced DNA damage and are repaired much faster than CPDs, they threat genomic 
integrity more than CPDs, which cause 75 % of the UV-specific adducts. First, 6-4-PPs 
cause nicks in the sugar-phosphate backbone of DNA which makes strand breaks more 
likely, while CPDs do not alter the DNA structure but only the angle to neighboring bases. 
Second, 6-4-PPs cause mispairing and loss of bases after replication by low fidelity 
polymerases, whereas CPDs do not (Rastogi et al. 2010). 
UV radiation affects compacted chromatin, too, but its ability to induce a DDR is increased 
in actively transcribed regions of DNA where access is better for damage-sensing proteins. 
UV-induced damage is finally of note when a cell replicates its DNA. Then, pyrimidine 
dimers cause stalling of DNA and RNA polymerases and lead to the formation of single 
stranded DNA (ssDNA) at stalled replication forks, as detailed in chapter 1.3.2 and 1.3.3 
(Herrlich et al. 2008).  
We used UV irradiation to induce DNA damage in our experiments for two reasons: First, 
we exploited the possibility to switch DNA damage induction on and off at an exactly defined 
time point. Second, and compared to gemcitabine-induced DNA damage, the cellular 
context does not mediate the formation of UV-induced DNA adducts as their amount does 
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not change in cellular compared to naked DNA (Cadet et al. 2005). Thus, influences of drug 
metabolism is excluded as a confounder for readouts if we shall neglect that UV is a potent 
inductor of ROS and protein malformation. Still and so far known, pyrimidine dimers and 
gemcitabine lead to similar DDR patterns.  
The advantage of UV-C is that its high energy is best absorbed by the DNA, thus leading to 
a high ratio of DNA lesions compared to the above mentioned secondary cytoplasmatic 
effects.  
 
1.2.2  Chemotherapy with nucleoside analogs and antimetabolites 
Chemotherapy constitutes one column of anticancer treatment. In resectable solid tumors, 
it is used to prepare surgery to define a tumor’s size and borders (neoadjuvant treatment) 
or to support the surgical outcome by diminishing the load of remaining malignant cells 
(adjuvant treatment). In malignant hematological diseases as well as in metastatic solid 
tumors, chemotherapy, besides immunotherapy, represents the predominant treatment 
option. Usually, chemotherapy does not consist of one single agent, but of a combination 
of agents that target the DNA of a cell by different mechanisms. This effect can be supported 
 
 
Figure 1.1 UV-induced DNA lesions. 
Pyrimidine bases absorb the energy from UV light, leading to the formation of cyclobutane pyrimidine dimers 
(CPD) or 6-4 photoproducts with neighboring bases. Both change the primary structure of DNA and induce 
DNA damage signaling (figure adapted from Li et al. 2006 with permission from the Journal of Biological 
Chemistry). 
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by the inhibition of key signaling pathways by small molecules and by binding surface 
markers of a malignant cell with antibodies. 
Due to their interference with DNA replication, nucleoside analogs and antimetabolites 
specifically target cells going through S-phase. While nucleoside analogs are incorporated 
into a nascent DNA strand during replication, antimetabolites interfere with enzymes which 
are essential for the cellular supply of deoxynucleotide triphosphate (dNTPs) (Ewald et al. 
2008). This is of therapeutic advantage for two reasons: First, malignant tumors are 
generally characterized by a high proliferation rate and a much higher turnover of DNA than 
are healthy tissues, therefore suffering replicative stress. Second, high susceptibility to 
genotoxic stress is a hallmark of malignant cells, which is enhanced during S-phase when 
DNA-related processes need to be densely regulated (Hanahan and Weinberg 2000).  
Despite the high structural similarity, different nucleoside analogs display a broad spectrum 
of effects within a cell. As example, structural analogs of deoxycytidine, the 
chemotherapeutics Ara-C (2’-deoxycytidine) and gemcitabine (2’2’-difluoro-deoxycytidine), 
only differ in the substitution on the 2’-carbon of ribose, but have largely differing 
applications (Galmarini et al. 2002) (see Figure 1.2). Ara-C is predominantly used as single 
and combination treatment in acute myeloic leukemia. It is incorporated into the DNA and 
provides a poor substrate to the DNA polymerase to attach further nucleotides on the 3’-
carbon resulting in slow DNA replication and eventually in a replication block (see section 
1.3.2) (Ewald et al. 2008). 
A typical antimetabolite is hydroxyurea (HU), which is used as cytostatic agent in malignant 
hematological diseases, too. It depletes the cellular dNTP pool and thereby inhibits DNA 
synthesis, which leads to a growth arrest of highly malignant cells only, followed by the 
 
 
Figure 1.2 Structure of the nucleoside analog gemcitabine. 
Gemcitabine is a derivative of deoxycytidine. As functional substitutes, it contains two fluorine atoms at the 
2’-position of the ribose backbone neighboring the 3’-carbon where in naturally occurring nucleotides DNA 
strand elongation takes place (figure from Ewald et al. 2008 with permission from Oncogene).  
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induction of apoptosis. Hydroxyurea (HU) and Ara-C are both not effective in solid tumors 
which contain a comparably high portion of non-replicating cells, which is possibly 
compensated by the slower metabolism of gemcitabine (Galmarini et al. 2002). 
Gemcitabine, instead, combines features of an antimetabolite and a nucleoside analog and 
targets much more processes in a cell than does Ara-C (Ewald et al. 2008). Additionally, it 
is retained inside the cell for a much longer period of time and metabolized only slowly, 
which opens the opportunity to target those cells that are not in the replication process at 
the time of administration (Huang et al. 1991). 
Although nucleoside analogs are one of the oldest antineoplastic substances in clinical use, 
only little is known about their mode of action and the cellular response which they elicit. 
Modulators of the DDR and different DNA repair pathways have been proposed as target 
for chemosensitization (Ewald et al. 2008). To date, there is no targeted therapy approved 
to enhance DNA damage and pro-apoptotic signaling induced by nucleoside analogs. 
Researchers and clinicians argue that there is a need for better understanding of the above 
processes in order to improve therapeutic efficacy of nucleoside analogs especially in solid 
tumors. 
 
1.2.3  Gemcitabine 
Gemcitabine has been studied in a variety of malignant diseases since its cytostatic effect 
had been discovered in the 1990s. As single and first line treatment, it governs the 
therapeutic regimens for pancreatic cancer, but it is used in combination therapy in a 
spectrum of solid tumors including non-small cellular lung cancer, bladder cancer and 
breast cancer (Ewald et al. 2008). 
Gemcitabine is taken up into the cell by specific nucleotide transporters (hNTs), 
predominantly by the concentration-dependent equilibrative transporter hENT1, and needs 
to be phosphorylated by deoxycytidine kinase (dCK) to be activated (Mini et al. 2006). The 
phosphorylation event is the effect-limiting step in the clinics because dCK is saturated at a 
dose of 15-20 µM plasma gemcitabine concentration, and intracellular gemcitabine 
concentrations are not achieved by higher dosage but only by prolonged infusion rate 
(Veltkamp et al. 2008). The triphosphate is incorporated into the DNA instead of 
deoxycytidine in a concentration-dependent manner. The DNA polymerase then attaches 
one single nucleotide to gemcitabine and immediately pauses replication, an event called 
“masked chain determination” (Mini et al. 2006). Different reasons for that have been 
suggested: First, the incorporation of gemcitabine alters the torsion angle for the following 
base. This retires its 3’-C and reduces its reactivity as substrate of DNA polymerases, 
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leading to a non-permanent stalling of replication forks. This is supported by the finding that, 
in primer extension assays, DNA fragments of greater molecular weight are found than 
would be expected with gemcitabine in the penultimate position. Second, the fluorine atoms 
of gemcitabine are highly electronegative, altering the electrostatic surface of a 
polynucleotide, and thereby reducing the reactivity of the 3’-C-hydroxyl group that is 
necessary for strand elongation and possibly for the binding capacities of proteins involved 
in DNA-dependent replication processes (Konerding et al. 2002).  
Gemcitabine appears resistant to conventional DNA repair mechanisms for single base 
defects, possibly due to its induction of only relatively small sterical changes to DNA. BER 
as well as NER pathways, which are usually involved in repair of unnatural bases, do not 
influence gemcitabine sensitivity (Crul et al. 2003). Additionally, the proofreading function 
of DNA and RNA polymerases is not able to detect and excise gemcitabine (Gandhi et al. 
1996). Gemcitabine is incorporated into RNA, too, and inhibits RNA synthesis, although to 
a much lesser extent than it inhibits DNA synthesis (Huang et al. 1991; Mini et al. 2006). It 
further inhibits ribonucleotide reductase, an enzyme which is crucial for the generation of 
deoxynucleotide triphosphates (dNTPs) and thereby leads to imbalance in the cellular dNTP 
pool. This causes an imbalance of cellular dNTPs as DNA components, which already 
affects DNA replication, and which facilitates the frequency of its own incorporation, a 
mechanism termed self-potentiation (Ewald et al. 2008). However, while the direct DNA-
damaging effect of gemcitabine occurs immediately, the consequence of dNTP depletion 
occurs only after hours and the initial DDR, and apoptosis induced by gemcitabine cannot 
be rescued by the addition of a balanced dNTP mix (Huang et al. 1991).  
In conclusion, targeting DNA repair pathways has not been a suitable strategy for 
gemcitabine chemosensitization so far. The manipulation of DNA damage checkpoints has 
proven effective to sensitize cells towards this treatment (Ewald et al. 2008), but the 
identification of other new targets in order to enhance gemcitabine-induced DDR is required 
in order to improve the therapeutic efficacy of gemcitabine. 
 
1.2.4  Targeting resistance to gemcitabine treatment 
With a high fraction of pancreatic tumors already showing intrinsic resistance to 
gemcitabine, every tumor acquires resistance in the course of treatment. Resistance 
mechanisms are essentially unknown and probably highly heterogeneous among tumor 
cells. The best-characterized resistance mechanisms are involved in gemcitabine uptake 
and metabolism. The expression of the involved enzymes is highly predictive for the 
gemcitabine response but has not been established as predictive marker or therapeutic 
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targets in clinical practice. Hypoxic conditions in the tumor microenvironment confer a 
selective pressure for resistance-driving somatic mutations, and hypoxia itself induces 
cellular reprogramming and activates resistance-associated signaling cascades. A large 
compendium of genetic alterations associated with gemcitabine resistance has been risen 
over the years, but none of them has been exploited for the profit of cancer patients, possibly 
due to the high intra- and interpersonal variety of resistance mechanisms (Akada et al. 2005; 
Harsha et al. 2009). 
Inhibition of the checkpoint kinase 1 (Chk1) to increase gemcitabine induced replicative 
stress has been tested in many clinical trials but has been abandoned due to inacceptable 
side effects (Ma et al. 2011). 
 
1.2.5  Ionizing radiation and neocarzinostatin 
In contrast to DNA damage induced by nucleoside analogs and UV, ionizing irradiation 
primarily induces replication-independent DNA breaks after its energy is absorbed by bases 
of the DNA and the sugar phosphate backbone. While the above chemotherapeutics target 
mostly replicating cells, ionizing radiation is less selective and causes chromosome breaks 
also in heterochromatin and in healthy as well as in malignant cells. DNA double-strand 
breaks (DSBs) are repaired by homologous recombination (HR) or non-homologous end 
joining (NHEJ) but still constitute the most apoptotic DNA lesion (Ciccia and Elledge 2010; 
Stucki and Jackson 2006). The establishment of ionizing radiation in cancer therapy is 
based on the fact that malignant cells are often defective in the above-mentioned repair 
pathways and therefore anyway suffer genomic instability, which makes them highly 
susceptible for cell death upon DSB induction. Yet, ionizing radiation needs to be targeted 
precisely to the tumor to reduce extensive side effects in surrounding healthy tissue. It is 
therefore mostly applied for locally defined tumors or local complications of a tumor. 
In the 1990s, radiomimetic agents that induce DSBs have been extensively studied in 
clinical trials. One example is neocarzinostatin (NCS), a small molecule complex consisting 
of an enediyne chromophore which is highly unstable. It is therefore tightly tethered to a 
small apoprotein that stabilizes the molecule and delivers it to the DNA where it is released. 
The chromophore is activated in the reductive milieu inside the cell, where it forms a 
biradical that abstracts hydrogen atoms from DNA and leads to DNA cleavage (Nicolaou et 
al. 1993). NCS induces sequence-specific ssDNA breaks (primarily 80 %) and DSBs 
(primarily 20 %) (Povirk 1996). It was tested for clinical use in primary liver cancer, small 
cell lung cancer and acute myeloic leukemia (Creech et al. 1984; Ishii et al. 2003; McKelvey 
et al. 1981) and in an antibody-coupled fashion for colorectal and pancreatic cancer 
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(Takahashi et al. 1990). While none of the radiomimetics have been approved for cancer 
treatment, some of them are still in lab use for the immediate induction of replication-
independent DNA breaks, and some are highly specific for the induction of DSBs (Nicolaou 
et al. 1993; Smith and Nicolaou 1996). We used NCS in our experiments to induce DSBs. 
 
1.3  DNA damage response 
 
Cells have evolved mechanisms to cope with DNA damage in order to prevent the 
accumulation of mutations, leading to genomic instability and the development of cancer. 
DDR is activated in early states of cancer as a barrier to tumor development (Bartek et al. 
2007), and genetic as well as epigenetic downregulation of DDR factors occur early during 
cancer progression (Halazonetis et al. 2008). Having in mind the vast amount of DNA 
lesions a cell has to cope with, DDR is not an occasional event, but a steady state of highly 
regulated enzyme cascades active enough to repair DNA efficiently but defined enough to 
not hamper cellular processes if not necessary. If DNA is damaged, transcription and 
replication need to be stopped near the damaged DNA in order to make it accessible for 
repair factors. If damaged DNA exceeds the cellular repair capacities, the damaged cell 
needs to be eliminated from the proliferative pool via the induction of apoptosis or 
senescence (Ciccia and Elledge 2010). Current models of the DDR differentiate between 
damage sensors, transducers and effectors, although this is artificial as many factors are 
known to play a role at more than one step of the DDR. While sensors bind to damaged 
DNA and recruit or activate signal transducers, the latter serve as amplifiers of the damage 
signal: They activate effectors that carry out alterations in cellular processes as mentioned 
above and recruit DNA repair factors (Zhou and Elledge 2000). 
A fast-acting DDR is driven by posttranslational modifications of proteins such as 
phosphorylation and ubiquitination, and kinases involved in the DDR are well characterized 
to date. Their inhibition is already subject to clinical research aiming to sensitize cells 
towards DNA-damaging agents (Blackford and Jackson 2017).  
Subsequent to immediate reactions to damaged DNA, lasting processes in the DDR come 
up and are far less understood than DNA damage-induced kinase signaling. These cellular 
responses consist of chromatin remodeling and transcriptional reactions which integrate the 
DDR over time and might decide on the fate of a cell after genomic insults (Blackford and 
Jackson 2017). An overview of the immediate response to DNA damage as well as its 
consequences is given in figure 1.3. 
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There are many ways to sense and repair damaged DNA. For example, the excision of 
mispaired or unphysiological single DNA bases or oligonucleotides is carried out by BER 
and NER, respectively. In this thesis, we will introduce into detail only the pathways which 
are relevant for the work, namely the response to stalled replication forks and single-strand 
DNA (ssDNA) breaks on the one hand and to DSBs on the other hand.  
1.3.1 A fast reaction: kinase signaling in the DNA damage response 
Although involved in a complex network, there are three kinases of the PIKK 
(phosphoinositol-3-kinase-related kinase) family which have been identified to form an 
intersection for signal transduction in the DDR. ATM (ataxia-teleangiectasia mutated), ATR 
(ataxia-teleangiectasia and Rad3-related) and DNA-PK (DNA-dependent protein kinase)  
 
 
Figure 1.3 Core signaling pathways in the DNA damage response. 
Central sensor kinases are activated by DSBs and ssDNA after replicative stress, respectively. All 
phosphorylate H2AX and p53, and contributions of each pathway strongly depend on the type of lesion and 
extent of damage. There are many other common but also pathway-specific downstream targets. Crosstalks 
and mutually activating events occur on several intersection points. Consequences are the activation of cell 
cycle checkpoints, chromatin remodeling and DNA repair, damage-responsive gene transcription and 
apoptosis. 
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share the minimal phosphorylation motif and the majority of more than 700 substrates (Kim 
et al. 1999; Matsuoka et al. 2007). Still, as the affinity to the substrates might differ and 
some of the downstream targets are specifically activated by ATM or ATR, distinct response 
pathways arise. DNA-PK has the smallest amount of substrates and those are mainly 
shared with ATM, a fact that ascribes a smaller or redundant function to DNA-PK in the 
DDR. DNA-PK binds to DNA at DSBs where it stabilizes DNA and allows DNA end-binding 
during the repair pathway of NHEJ (Jette and Lees-Miller 2015; Meek et al. 2008). Although 
downstream signaling of ATR and ATM overlaps and, for example, the transcription factor 
and tumor suppressor p53 as well as the histone variant H2AX are substrates of both, ATM 
and ATR are activated in response to different stimuli. While ATM is mainly involved in the 
response to DSBs, ATR is needed for DNA damage signaling following replicative stress 
and ssDNA breaks at stalled replication forks (see fig. 1.3 and following chapters) (Blackford 
and Jackson 2017; Ciccia and Elledge 2010).  
 
1.3.2  Response to replicative stress and single-strand DNA breaks: the ATR/Chk1 
pathway 
Fast replicating tumor cells suffer a high level of endogenous replicative stress and are 
susceptible to additional stresses induced by chemotherapy (Blackford and Jackson 2017). 
During replication, DNA helicases unwind the DNA ahead of DNA polymerases, which then 
synthesize the complementary strand. DNA polymerases stall when they encounter a 
replicative block, for example any event that interferes with strand elongation, for example 
a conformational change of the DNA induced by UV or gemcitabine. The unwinding of DNA 
is consecutively uncoupled and long fibers of ssDNA emerge, which are immediately coated 
and therefore stabilized by RPA (replication protein A) to avoid secondary DNA structures, 
as schematically illustrated in figure 1.4. RPA then recruits ATR through its essential 
cofactor ATRIP (ATR-interacting protein) (Zou and Elledge 2003). The additional 
colocalization of another factor, the 9-1-1 complex (RAD9-Hus1-RAD1 complex) occurs 
largely independent from ATR binding. It is, however, critical for ATR activation that 
TOPBP1 (DNA topoisomerase 2-binding protein 1) binds to the 9-1-1 complex and, brought 
in close proximity to ATR, potentiates and sustains ATR activity (Cimprich and Cortez 
2008). The assembly of the scaffolding complex mentioned above and the activation of ATR 
promotes replication fork stability and DNA repair, as well as the activation of many 
downstream targets (Ciccia and Elledge 2010). Among the major targets of ATR are the 
histone variant H2AX and the checkpoint kinase Chk1. The expression of Chk1 is increased 
in S-phase of the cell cycle and it is phosphorylated on Ser317 and Ser345 by ATR (Zhao 
and Piwnica-Worms 2001). Whereas ATR is largely immobilized to DNA, the active form of 
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Chk1 is released from chromatin and can diffuse throughout the cell to phosphorylate further 
substrates (Cimprich and Cortez 2008). Chk1 attenuates DNA replication, promotes DNA 
repair or lesion bypass of stalled replication forks and slows down progression through the 
cell cycle (Dai and Grant 2010). Further, it induces the proapoptotic tumor suppressor p53, 
linking ATR/Chk1-mediated DDR to apoptosis. Mice lacking either ATR or Chk1 are not 
viable due to a high occurrence of replicative stress and apoptosis. Cultured cells depleted 
of ATR or Chk1 exhibit strong DNA damage signaling and a phenotype resembling mitotic 
catastrophe. The dependance of highly replicating tumor cells on ATR/Chk1 signaling might 
be a reason for both proteins hardly being found mutated in tumors (Lecona and Fernandez-
Capetillo 2014).  The dependance of a cell on the replicative stress response could explain 
the previously mentioned extensive adverse effects seen in clinical trials with the objective 




Figure 1.4  Activation of the ATR/Chk1 pathway in response to ssDNA. 
When replication forks stall, arising ssDNA is coated by RPA to stabilize it and to scaffold ATRIP and the 9-
1-1 complex. ATRIP binds and immobilizes ATR to chromatin, which leads to its activation. Chk1 is 
phosphorylated by ATR when both are brought together by Chk1’s essential cofactor claspin. Activated Chk1 
partially diffuses from chromatin. Not upstream of ATR activation, but potentiating ATR activity is the 9-1-1 
clamp complex which requires another cofactor, 53BP1, to bind ATR.  
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1.3.3  Response to double-strand DNA breaks: the ATM/Chk2 pathway 
DSBs of DNA result from extensive DNA lesions, for example induced by ionizing radiation 
or during replication, when DNA polymerases encounter stretches of ssDNA breaks. 
Another major source of DSBs is the collapse of replication forks, which occurs when repair 
factors and polymerases cannot overcome a replication block. The highly unstable fork is 
then cleaved into DSBs by endonucleases, which allows for the second line repair 
mechanism of DSB repair (see also chapter 1.4.2.1 and fig. 1.7) (Branzei and Foiani 2010). 
DSBs are sensed by PARP (poly-ADP-ribosylating) enzymes, which immediately 
synthesize PAR (poly-ADP-ribose) chains on histones around the DNA lesion and on 
themselves. ATM, which forms the central kinase for the cellular response to DSBs, can 
then directly bind to PAR chains or is recruited via the MRN protein complex (consisting of 
MRE11, RAD50 and NBS1) which itself binds to PAR-marked DNA independently of the 
presence of ATM (see also fig. 1.5). Like ATR, ATM is able to phosphorylate H2AX to 
amplify DNA damage signaling. Additionally, in the presence of phosphorylated H2AX and 
the MRN complex, another complex called MDC1 (mediator of DNA damage checkpoint 1) 
binds to damaged DNA and coordinates a multitude of chromatin modifying processes in 
response to DNA damage (Stracker et al. 2004; Stucki and Jackson 2006). Immobilized 
onto DNA, ATM activates its major downstream kinase, the checkpoint kinase Chk2, by 
phosphorylating it on Thr68 (Matsuoka et al. 2000). Constantly expressed throughout the 
cell cycle, Chk2 is activated when DNA damage occurs and is rapidly released into the 
whole nucleus to target its substrates, which are mainly involved in cell cycle regulation, 
DNA repair and apoptosis (Bartek and Lukas 2003). 
 
Figure 1.5 Response to double strand breaks.  
Either by processing of ssDNA breaks or by the collapse of stalled replication forks, DSBs arise. Those are 
sensed by PARP enzymes, which start to synthesize PAR chains in proximity to a DSB as primary scaffold 
for an adequate DDR. ATM can either directly bind to PAR or through the MRN complex, which potentiates 
its activity. Another amplifier is the MDC1 complex, which facilitates binding of MRN complex components 
and thereby intensifies the ATM-mediated phosphorylation of H2AX around DSBs as well as the recruitment 
of repair factors.  
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1.3.4  Phosphorylation of the histone variant H2AX 
DNA is organized by a multitude of attached factors, the chromatin, that organize virtually 
every DNA-associated process. One organizational subunit is the nucleosome, which 
consists of four histone variants (H2A, H2B, H3, H4) and the smaller linker histone H1. 
H2AX is a variant of the histone H2A and constitutes 2-25 % of the cellular H2A pool 
depending on cell type and organism (van Attikum and Gasser 2009). While H2A is 
completely wrapped by DNA, H2AX possesses a 20 amino acid tail on its C-terminus that 
harbors a Ser139 phosphorylation site and that protrudes from the nucleosome. It is 
therefore accessible for kinases (Rogakou et al. 1998). 
Following DNA damage, ATM, ATR and DNA-PK phosphorylate H2AX on Ser139. The 
resulting phospho-H2AX is then referred to as γH2AX. When DSBs are induced, ATM 
seems to be the major kinase phosphorylating H2AX, leading to γH2AX foci formation at 
sites of DSBs, whereas during replicative stress, γH2AX is induced by ATR (Burma et al. 
2001; Fernandez-Capetillo et al. 2004). DSB-induced γH2AX is detectable to a relevant 
amount already 1-3 min after the induction of damage, and reaches its maximum after 30 
min (Rogakou et al. 1999). 
When present on chromatin, the above mentioned MDC1 directly binds to γH2AX, a 
substantial event for the recruitment of more ATM. This leads to an amplification of the 
γH2AX signal up to 2 MB surrounding a DSB and thereby allows the stable recruitment of 
more DNA repair factors (Paull et al. 2000). Thus, the initial onset of γH2AX is essential for 
its own signal amplification but onset and amplification of γH2AX rely on distinct 
mechanisms. 
To allow DNA repair processes to take place, γH2AX must be released from DNA in order 
to give access to repair factors. Spread γH2AX needs to be removed after sufficient repair 
to limit damage signaling. The underlying mechanisms are not fully understood (Srivastava 
et al. 2009). It was shown that γH2AX underlies the regular exchange of histones, and it is 
estimated that 50 % of H2AX is exchanged within 3-4 h, which is done by TIP60/KAT5 
(lysine histone acetyl transferase 5), that acetylates and later evicts γH2AX from DNA 
(Misteli and Soutoglou 2009). Generally, posttranslational modifications of H2AX are 
reversible. When ejected from DNA, γH2AX is rapidly dephosphorylated by protein 
phosphatases, PP2A (protein phosphatase 2A) at DSBs and PP4 (protein phosphatase 4) 
at sites of replicative stress as well as WIP1 (wild type p53-induced phosphatase) 
(Chowdhury et al. 2005; Chowdhury et al. 2008; Keogh et al. 2006). As all phosphatases 
colocalize with γH2AX, it is presumable that they dephosphorylate DNA-bound γH2AX, too 
(Svetlova et al. 2010). Of note, H2AX is also and constantly phosphorylated on Tyr142 by 
the kinase WSTF/BAZ1B (williams syndrome transcription factor). It is dephosphorylated at 
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this site upon DNA damage by EYA1/2 (eyes absent homolog 1/2), which is a prerequisite 
for the binding of MDC1 and the induction of DNA repair. In contrast, the persistent 
phosphorylation of Tyr142 together with Ser139 phosphorylation upon DNA damage was 
shown to impair DNA repair and to trigger apoptosis instead, establishing an additional role 
of γH2AX in the decision of a cell’s fate (Cook et al. 2009). Cells depleted of H2AX fail to 
induce cell cycle arrest upon DNA damage, possibly because they lack sufficient induction 
of DNA damage signaling, and H2AX-deficient mice display a high level of chromosomal 
aberrations (Celeste et al. 2002).  
As γH2AX is reliably induced at damaged DNA and removed after sufficient repair, it has 
become a hallmark of DNA damage and a standard readout for the overall DDR.  
 
1.3.5  Cross-talks between main DNA damage response pathways 
Although the ATR/Chk1 as well as the ATM/Chk2 pathway are activated by different kinds 
of DNA lesions, both pathways interact on more than one point to mediate and coordinate 
the DDR (see also fig. 1.3).  
On the sensor level, ATR is activated when DSBs are processed and stretches of ssDNA 
arise, for example during the process of HR. On the other hand, the collapse of replication 
forks gives rise to DSBs which activate ATM signaling (Ciccia and Elledge 2010). 
Complemented by the above-mentioned DNA-PK, all kinases are responsible for H2AX 
phosphorylation, as detailed above. ATM and ATR can additionally induce p38/MK2 
signaling, which will be detailed in section 1.6, and the tumor suppressor p53. 
Despite their wide range of shared substrate specificity (Matsuoka et al. 2007), both 
pathways have unique functions in the recruitment of suitable repair factors. Nonetheless, 
the partial activation of all DDR pathways sets a standby situation to take over the task if 
the preferential pathway fails (Shiotani and Zou 2009).  
Of note, while the replicative stress response cannot be taken over by ATM signaling and 
germline mutations of ATR and Chk1 are lethal, ATM/Chk2-deficient mice indeed display 
defects in DNA damage signaling and high risk of developing tumors, but develop a 
functional organism (Brown and Baltimore 2000; Elson et al. 1996). 
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1.4  Consequences of the DNA damage response 
 
1.4.1  Cell cycle regulation 
One of the hallmarks of malignant cells is their constant proliferation, which means that they 
need to undergo a specific program with the objective of duplicating their genome. The cell 
cycle is divided into different phases based on the amount of DNA of a cell. Passing through 
the cell cycle is usually carried out by the tightly regulated transcription of phase-specific 
genes and is dominated by the E2F/Rb-pathway as well as by the tumor suppressor p53 
(Stracker et al. 2009). However, transcriptional reactions are comparably slow, and the cell 
has established transcription-independent, damage-inducible cell cycle checkpoints ahead 
of every phase in order to quickly react to DNA damage within seconds. As mentioned 
before, the activation of either ATR/Chk1 or ATM/Chk2 signaling induces a cell cycle 
checkpoint, which causes a transient delay in cell cycle progression and provides time to 
repair DNA (Kastan and Bartek 2004). An overview of the induction of cell cycle checkpoints 
is given in figure 1.6. 
1.4.2  The G1/S checkpoint 
The G1/S checkpoint can be activated by either ATR/Chk1 or ATM/Chk2 signaling 
depending on the type of DNA damage. Its purpose is to prevent cells from entering S-
phase when they have accumulated DNA lesions that would affect replication. The 
 
Figure 1.6  Cell cycle checkpoints upon DNA damage. 
In G1 phase, ATM/Chk2 stabilize p53, which transcriptionally activates p21, an inhibitor of CDKs. A fast-
acting G1-arrest is carried out by the direct phosphorylation and thereby degradation of CDC25 phosphatases 
by ATM/Chk2. Cdc25s usually activate CDKs through the removal of their inhibitory phosphorylation. In S-
phase, replication blocks and ssDNA activate ATR/Chk1 and lead to the degradation of Cdc25 and thus to 
reduced deinhibition of CDK2. In late G2 phase, constant Chk1 signaling prevents the deinhibition of CDK1 
by reduction of Cdc25C levels. Chk1 activity is limited through the inhibitory phosphorylation by PLK2 and 
through the removal of activating phosphorylations by WIP1. 
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transcription factor p53 plays the key role for that checkpoint. It stimulates the transcription 
of its main target p21, which is an inhibitor of CDKs (cyclin-dependent kinases) that, if 
activated, promote cell cycle progression. P21 activity induces prolonged or even 
permanent G1 arrest, the latter called senescence. P53 is a direct target of ATM, ATR, Chk1 
and Chk2. In the absence of functional p53, this checkpoint is thought to be defective. As it 
was shown that resection of DSBs in G1 does not generate high amounts of ssDNA, this 
checkpoint might predominantly activate ATM/Chk2 in the absence of functional p53 
(Kastan and Bartek 2004).  
Another fast but transient induction of the G1/S-checkpoint is discussed to take place via 
the direct phosphorylation of the phosphatase Cdc25A (cell division cycle 25 A) by all of the 
above-mentioned kinases, then resulting in its degradation. The continuous inhibitory 
phosphorylation of CDK1 as direct target of Cdc25A is then stabilized, limiting CDK activity 
and therefore progression through cell cycle (Kastan and Bartek 2004). 
  
1.4.3  The intra-S checkpoint 
S-phase is possibly the most vulnerable phase of the cell cycle since preexisting or 
replication-induced DNA lesions can impair proper DNA replication. All known mechanisms 
to induce the intra-S checkpoint can be activated independently of p53 and transiently delay 
ongoing S-phase through the CDK-mediated inhibition of not yet fired origins of replication 
(Bartek et al. 2004). 
Replicative stress-induced S-phase delay can be caused by the inhibition of DNA 
polymerases, altered DNA structure and depletion of the dNTP pool. It activates the above 
detailed ATR/Chk1 pathway which, besides DNA damage signaling and repair, reduces fork 
speed, recruits fork-stabilizing factors and impairs the replication restart from not yet fired 
origins (Branzei and Foiani 2010). 
DSB-induced S-phase delay takes place independently from the presence of replication 
forks after for example ionizing radiation, when DSBs occur spontaneously, but also after 
the collapse of replication forks and after topoisomerase-induced DSBs. It primarily and 
globally activates ATM, whereas ATR assembles on stretches of ssDNA after DSBs have 
been processed. Both effector kinases, Chk1 and Chk2, target Cdc25 phosphatases. 
Increased phosphorylation of those mediate their degradation, increasing the inhibitory 
phosphorylation of their main substrate CDKs, which therefore decrease activity and directly 
as well as through mediator proteins impair the resumption of replication from dormant 
origins (Branzei and Foiani 2010). 
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1.4.4  The G2/M checkpoint 
The aim of the checkpoint at this transition point is to prevent cells from entering mitosis 
when errors during G1- and S-phase have not been repaired properly. It involves both 
pathways, ATR/Chk1 and ATM/Chk2. In contrast to G1- and S-phase, the effectors Cdc25C 
phosphatase and its target CDK1 execute the G2-arrest (Kastan and Bartek 2004). Chk1 
activity remains high until G2 and prevents mitotic entry of a cell. Two rate-limiting 
mechanisms have attracted attention: First, the PLK2 (polo-like kinase 2) is transcribed in 
late S-Phase and phosphorylates Chk1, which upon this mark is degraded. Second, the 
phosphatase WIP1 reduces phosphorylation of Chk1 as well as its targets and was shown 
to reduce phosphorylation of the effector proteins γH2AX, p38 and p53, too (Lu et al. 2005; 
Shreeram et al. 2006). 
The role of ATR/Chk1 in S-phase is underlined by the fact that transcription of Chk1 is highly 
restricted to S- and G2-phase, whereas Chk2 is constantly expressed. Furthermore, the 
constitutive phosphorylation of Cdc25A by Chk1 places a regulatory element during 
replication also in unperturbed S-phase, whereas upon DNA damage, the induction of 
ATR/Chk1 and to a certain extent ATM/Chk2 seems to be crucial for checkpoint activation 
(Bartek and Lukas 2007). 
 
1.4.5  DNA repair 
Cells are equipped with a variety of DNA repair mechanisms to face diverse DNA lesions. 
For example, there are repair mechanisms that already excise damaged or mispaired bases 
from DNA before replication blocks or DSBs result. It is still unclear if and in which manner 
nucleoside analogues can be excised (Ewald et al. 2008). Still, mutations in DNA repair 
pathways are a common mediator of resistance to chemotherapy (Jackson and Bartek 
2009).  
 
1.4.5.1  Repair of stalled replication forks 
As mentioned above, ATR/Chk1 signaling induced upon replicative stress regulates the 
progression through S-phase and promotes the stabilization of stalled replication forks until 
they are repaired and DNA replication can be resumed. When a replication fork is terminally 
blocked, the progression through S-phase is generally attenuated. In order to ensure 
complete genome replication, another replication fork downstream of the lesion is fired, but 
still a gap of unreplicated ssDNA persists (Branzei and Foiani 2010).  
Introduction                       20 
 
The highly conserved platform protein PCNA (proliferating cell nuclear antigen) is an 
inherent part of the replisome and cofactor of many DNA polymerases which are tethered 
to DNA in this way. It rapidly accumulates at sites of DNA damage, where it loads repair 
factors (Moldovan et al. 2007). Through its ubiquitination motif, PCNA decisively influences 
the DNA repair or damage tolerance mechanism at a stalled fork. When mono- or 
polyubiquitinated at Lys164, the error prone translesion synthesis (TLS) is activated in 
mammalian cells, while ubiquitination at Lys63 promotes error-free template switch repair 
(TS) in yeast (see figure 1.7) (Haracska et al. 2004; Hoege et al. 2002). While during TLS 
the replicative DNA polymerase is replaced by a low fidelity TLS-polymerase which accepts 
base alterations in order to overcome a lesion, template switch repair is an accurate 
mechanism using the nascent strand of the sister chromatid as template, a process partially 
HR (Branzei and Foiani 2010).  
If DNA repair is not achieved by the above mentioned processes, endonucleases such as 
MUS81 (MMS and UV sensitive 1), which are usually inhibited by Chk1, can cleave stalled 
replication forks inducing their collapse and therefore converting them into DSBs (Forment 
et al. 2011). This processing opens up the opportunity for DSB repair to belatedly, but finally 
resume replication (Hanada et al. 2007). At already collapsed forks, remaining high activity 
levels of Chk1 promote the error-free repair pathway of HR (Stracker et al. 2009). 
 
Figure 1.7 Repair of stalled replication forks. 
When encountering a replication block, DNA polymerases stall. This leads to the accumulation and 
ubiquitination of PCNA. Dependent on the ubiquitination motif, either the accurate repair of a stalled fork is 
induced and resumption of replication using the DNA of a sister chromatid as template can take place,or the 
induction of TLS as damage tolerance, but not DNA repair mechanism is induced. If both ways to resume 
replication fail, the endonuclease MUS81 cleaves stalled forks to open up the way for DSB repair as a backup 
mechanism. 
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1.4.5.2  Repair of double-strand DNA breaks 
The repair of DSBs follows another class of repair mechanisms which are mainly HR and 
non-homologous end joining (NHEJ). While HR takes place in G2 and S-Phase when sister 
chromatids are available, NHEJ can be realized in any phase of the cell cycle.  
Following double strand breaks, ATM phosphorylates the tumor suppressor BRCA1 (breast 
cancer 1), which is essential for its recruitment to damaged sites of DNA (Cortez et al. 1999), 
and the nuclease CtIP (CT Binding Protein Interacting Protein), which processes DNA ends 
at DSBs and promotes HR. Both factors bind to damaged DNA in an MRN-dependent 
manner. On the other hand, the induction and stabilization of 53BP1 (53 binding protein1) 
by ATM stabilizes DNA at DSBs and favors NHEJ. 
The mechanistic basis of how both processes counteract each other remains unclear, but 
cell cycle dependency and the chromatin context of DSB emergence might constitute critical 
factors (Lukas et al. 2011). 
 
1.5  Apoptosis 
 
If a cell’s DNA is extensively damaged and cannot be repaired properly to preserve the 
accumulation of mutations, apoptosis as programmed cell death is induced. This is 
governed by p53, which has already been introduced as to its role in activating cell cycle 
checkpoints. Although there is hardly any protein that gains as much attention as p53, the 
exact mechanism how a cell decides whether to die or to permanently arrest remains 
unclear and might depend on the cellular context, the extent of DNA damage and on the 
predominance of p21-induced cell cycle arrest (Vousden and Prives 2009). 
Apoptosis is not only relevant for the elimination of malignant cells but also for 
developmental processes and tissue renewal. It is marked by characteristic events such as 
the blebbing of cellular membranes, the fragmentation of chromatin and the loss of 
intercellular contacts, all of which occur during programmed cell death but do not seem 
crucial for its induction. Apoptosis can be induced via an intrinsic pathway which responds 
to stress signals and an extrinsic pathway which is activated by cell surface receptors in 
response to death signals. Although p53 interconnects both pathways, its role is more 
pronounced in the intrinsic induction of apoptosis (Vousden and Lane 2007). 
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1.5.1  Activation and regulation of the tumor suppressor p53 
in response to DNA damage 
The involvement of p53 in cell death and proliferation as crucial events of organism survival 
implicates a need for tight regulation. P53 is involved in regulating all types of DNA repair 
and in the same way targeted by factors of each repair pathway. It triggers chromatin 
relaxation at repair sites, rescues stalled replication forks – thus preventing them from 
collapsing into DSBs – and promotes error-free homologous repair (Gatz and Wiesmuller 
2006).  
P53 is activated by many stimuli, among them DNA damage and oncogenic signaling, as 
depicted in figure 1.8. The major and priming event for p53 activation is its phosphorylation 
on Ser15 by virtually all central DNA damage kinases. Except for acetylations which take 
place on the C-terminus, the major proportion of posttranslational modifications is located 
in p53’s N-terminal domain, where phosphorylation on Ser15 facilitates the phosphorylation 
and acetylation of other target sequences. First, this disrupts the interaction of the ubiquitin 
ligase MDM2 (mouse double minute 2 homolog) with p53 as core mechanism to influence 
p53 stability. MDM2 is the main negative regulator of p53 as it transfers ubiquitin to p53, 
targeting it for proteasomal degradation. If the interaction is impaired, p53 is stabilized. 
Second, patterns of posttranslational modifications are relevant for the binding of 
downstream proteins. And third, phosphorylation enhances the transcriptional activity of 
p53.  
Most known negative feedback loops to regulate p53 activity include MDM2, whose 
transcription is in turn induced by p53. Therefore, p53 self-limits its activation (Harris and 
Levine 2005; Lavin and Gueven 2006).  
 
Figure 1.8  Regulation of p53 activity in response to genotoxic stress. 
During the DDR, p53 is phosphorylated by several damage kinases, which interrupts the interaction with 
MDM2. Acting as main negative regulator of p53, MDM2 can no longer ubiquitinate p53 to target it for 
proteasomal degradation. The transcription of MDM2 is dependent on p53 activity, so p53 self-limits its 
activity. 
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It has been shown that MDM2 itself is phosphorylated after DNA damage, which also 
reduces the capacity of MDM2 to degrade p53 (Khosravi et al. 1999). Further, MDM2 self-
ubiquitinates after DNA damage, promoting its own degradation and thereby stabilizing p53 
(Lavin and Gueven 2006). MDM2 is further bound and inhibited by the RAS-inducible tumor 
suppressor p19ARF (Zhang et al. 1998). 
 
1.5.2  The tumor suppressor and transcription factor p53 in apoptosis 
While the induction of cell cycle arrest in response to oncogenic signaling might be the 
mechanism through which p53 prevents tumorigenesis, its ability to induce apoptosis is 
critical for its control of tumor growth and malignancy (Vousden and Prives 2009). P53 
exerts transcription-dependent and -independent functions in apoptosis. Once activated, it 
binds to the promoters of more than 100 known genes to transactivate them, thus executing 
a dominating role in the transcriptional response to DNA damage (Laptenko and Prives 
2006). Among the activated genes are some that induce cell differentiation, DNA repair and 
apoptosis.  
Besides the transcriptional response, p53 induces pore-forming factors that permeabilize 
the outer mitochondrial membrane to release many pro-apoptotic factors. One of those is 
cytochrome C, which assembles and activates a subset of caspases (cysteine-dependent 
aspartate-directed proteases). Those caspases are part of a now irreversible proteolytic 
cascade leading to the cleavage of cellular adhesion molecules, cytoskeleton proteins and 
to the activation of nucleases which cleave DNA into fragments (Taylor et al. 2008; Vaseva 
and Moll 2009). Two late and reliable cleavage events are the cleavage of PARP and the 
downstream effector caspase-3, which we use as readouts for ongoing apoptosis in this 
work (Taylor et al. 2008).  
Due to its central role in the interconnection of the DDR, checkpoint signaling and apoptosis, 
tumor cells have a high selective pressure to inactivate p53 in order to increase proliferation 
and malignancy. 
 
1.6 The MK2/Chk1 system in the DNA damage response 
 
Whereas the DNA damage kinases ATM and ATR execute their function bound to DNA, the 
downstream kinases Chk1 and Chk2 disperse throughout the nucleus and cytoplasm upon 
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activation to interfere with non-DNA-bound cellular processes (Bartek et al. 2004). A third 
kinase, the MAPKAPK2 or MK2 (mitogen-activated protein kinase-activated protein 
kinase 2) gained attention in recent years and is regarded partially in line with, but also as 
antagonist of Chk1. 
 
1.6.1  Activation of MK2 
MK2 is one of three downstream kinases of the p38/MK signaling pathway in mammals. 
Although all MK-kinases share homology in their catalytic domain, they do not function 
redundantly and are involved in different cellular processes (Gaestel 2006).  
When inactive, MK2 is constitutively bound to its activating kinase p38 forming a mutually 
stabilizing complex, which is underlined by the fact that knockdown of either one of both 
proteins leads to a strong decrease of protein levels of the other (Kotlyarov et al. 2002). 
MK2 is activated via phosphorylation by p38 on Thr334 and is then able to alter cellular 
signaling by various possibilities: Its phosphorylation motif is related to binding sites for 14-
3-3 proteins typically involved in complex formation, which suggests that phosphorylation 
by MK2 prepares targets for interaction with other proteins. Further, as a kinase, MK2 can 
simply activate or inactivate downstream targets by adding one or more phosphate residues 
(Gaestel 2006; Meng et al. 2002). In its inactive state, MK2 is located in the nucleus but can 
alter its subcellular localization and can be exported to the cytoplasm or retained in the 
nucleus dependent on the stimulus (Engel et al. 1998; Kopper et al. 2013).  
 
1.6.2  Activation of MK2 upon DNA damage 
MK2 was originally identified as a stress-dependent kinase involved in inflammation 
(Kotlyarov et al. 2002). When it was then found that activation of p38 was substantial to 
induce the G2/M checkpoint after UV irradiation, MK2 was further studied as a damage 
kinase. MK2 shares substrate specificity with the damage kinases Chk1 and Chk2, and is 
able to phosphorylate Cdc25B and -C, thereby inhibiting them, acting in line with Chk1 and 
Chk2 functions (Manke et al. 2005). 
Whereas Chk1 is predominantly and directly activated by ATR during replicative stress, the 
activation of MK2 following DNA damage is less studied. One study argues that MK2 is 
activated in response to DNA-damaging agents such as chemotherapeutics in an ATM/ATR 
dependent fashion with the activation of TAO (thousand and one) kinases as intermediates 
(Raman et al. 2007). Another study finds the activation of MK2 being dependent on 
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ATM/ATR following a subset of chemotherapeutics, but identified a damage kinase-
independent activation of MK2 after UV treatment (Reinhardt et al. 2007). 
Work in our lab has contradicted the above-mentioned kinase function of MK2 being in line 
with other checkpoint kinases, but establishes MK2 as an antagonist of Chk1 during 
replication of damaged as well as undamaged DNA. While the application of gemcitabine 
leads to stalling of replication forks and subsequent accumulation of γH2AX, this can be 
antagonized by MK2 inhibition. On the DNA level, MK2 promotes stalling of replication forks 
and slows down DNA replication. Interestingly, inhibition of MK2 can not only rescue the 
accumulation of γH2AX induced by Chk1 inhibition alone or together with gemcitabine 
treatment, but also rescues the enhanced stalling of replication forks and enhanced origin 
firing after Chk1 inhibition. Those effects rely on the presence of the ahead mentioned TLS 
polymerases as the replication promoting effect of MK2 inhibition is completely abolished in 
the absence of TLS (Kopper et al. 2013). 
  
1.7  Chromatin remodeling in response to DNA damage 
 
Each step of chromatin alterations can be affected by genotoxic stress, and the other way 
around, chromatin perturbations affect all pathways from DNA damage signaling to repair 
and cell cycle progression (Lukas et al. 2011) already in the absence of DNA damage 
(Bakkenist and Kastan 2015). For example, chromatin needs to be opened after DNA 
damage and histones need to be removed from damaged sites in order to allow repair 
factors to assess damaged DNA, and the more open chromatin is, the more efficient DNA 
repair seems to be. On the other hand, damage-adjacent chromatin needs to be silenced 
to impair interference of transcription with repair processes. According to current models, 
chromatin remodeling factors are classified in three categories: writers that add 
posttranslational modifications to N-terminal domains of core histones, readers that harbor 
recognize and binds to histone modifications and either assemble more factors or induce 
signaling cascades, and erasers that remove posttranslational histone modifications or 
remove the whole histone or nucleosome from DNA (Cai et al. 2015; Nair and Kumar 2012).  
The modification of histones and other chromatin-bound proteins as well as DNA 
methylation at silenced chromatin are mutually influencing processes involved in the 
formation of gene-rich and actively transcribed euchromatin and transcriptionally inactive 
and gene-poor heterochromatin (Briones and Muegge 2012). The chromatin environment 
of DNA is too complex and heterogenous to be understood in the model of a signaling 
cascade with upstream factors and downstream targets. It rather embeds the process of 
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chromatin remodeling following DNA damage in a context- and cell type-specific manner 
(Bakkenist and Kastan 2015). 
Nonetheless, epigenetic information on histones or on DNA is both passed on to daughter 
cells and affects genomic stability. It can therefore, and due to transcriptional activation of 
oncogenes or repression of tumor suppressor genes, not only leave a footprint of occurred 
DNA damage, but can also drive or inhibit cancer progression (Hargreaves and Crabtree 
2011; Jones and Baylin 2007; Roberts and Orkin 2004). Due to its complexity and cell type 
specificity, chromatin remodeling has been targeted by anti-cancer therapies only in recent 
years (Cai et al. 2015). 
Alterations in chromatin profiles can be arranged by two different mechanisms: The wide 
variety of histone modifications as well as ATP-dependent chromatin remodeling which 
disrupts histone-DNA contacts and is able to displace histones and entire nucleosomes 
(Lans et al. 2012). 
 
1.7.1  Histone modifications after DNA damage  
Dynamic modifications of histones are carried out by specific enzymes that covalently attach 
small molecules to exposed histone tails. The most prominent histone modification among 
DNA damage, the phosphorylation of H2AX, has been detailed before. Just as the addition 
of PARP residues as the earliest histone modification during the DDR, other histone 
modifications tether DNA damage signaling and repair factors to damaged DNA (Polo and 
Jackson 2011). Further, the methylation, ubiquitination and acetylation of histones play a 
well-established role in the DDR. While acetylation is a marker of chromatin relaxation, 
methylated histones display a more diverse signaling pattern and can be markers for either 
relaxed or condensed chromatin (Kouzarides 2007).  
 
1.7.2  ATP-dependent chromatin remodeling 
ATP-dependent chromatin remodeling enzymes use the energy of ATP to exchange, evict 
or slide histones or entire nucleosomes. Central communality of all is a SWI2/SNF2-type 
helicase/ATPase (SWItch/sucrose non-fermentable) domain which is evolutionary highly 
conserved. Based on the ATPase-flanking regions, chromatin remodelers are commonly 
grouped into four families, which are SWI/SNF, ISWI (imitation SWI), INO80 and CHD 
(chromodomain-helicase-DNA-binding protein). All chromatin remodelers are involved in 
transcriptional regulation via the alteration of higher order chromatin structures or direct 
binding to promoters and recruitment of transcription factors and polymerases. Thus, 
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defects of their function mostly result in occasionally lethal developmental defects of certain 
organs or whole embryos (Murawska and Brehm 2011). Most of those remodelers are found 
in multisubunit complexes which specify their activation and function (Hargreaves and 
Crabtree 2011). Additionally, all families of chromatin remodelers are implicated in the DDR 
(Lans et al. 2012). 
DNA damage can occur in any part of a chromosome, but different chromatin environments 
initially form a barrier to active damage signaling and repair (Murga et al. 2007). It is thus 
the role of chromatin remodelers to prime DNA for repair as they actively remove histones 
from damaged DNA in order to allow access for repair factors, which is done by the sliding 
or eviction of nucleosomes. Later, they restore chromatin after DNA repair is accomplished, 
possibly leaving an imprint of former rundown DNA damage (Soria et al. 2012). Indeed, the 
necessity of histone movement in the DDR and DNA repair is stressed by the fact that, 
although spreading of γH2AX occurs bidirectionally around DSBs, there is a loss of γH2AX 
and other core histones within 3 kb from the damaged site, but also a restoration within 
several hours (Polo 2015). 
Detailed mechanistic research has been done on ATP-dependent chromatin remodelers in 
yeast, and most of those proteins are highly conserved. The fact that the way of action of 
chromatin remodeling is cell type and context specific brings along difficulties to transfer 
knowledge from yeast to human cancers. Thus, the following is focused on what is known 
about chromatin remodelers in mammalian cells. 
 
1.8  The CHD family of chromatin remodeling enzymes 
 
 
1.8.1 CHD structure and function 
The fourth family of ATP-dependent chromatin remodeling enzymes is evolutionary the 
least conserved and only exists in mammals, with the exception of a CHD1/2 homolog in 
yeast (Murawska and Brehm 2011). There are nine members, which share, in addition to 
the SNF2-like helicase/ATPase members of this family, an N-terminal double 
chromodomain and in some cases a DNA binding domain, as visualized in figure 1.9 (Sims 
and Wade 2011). This DNA binding domain is established only for CHD1 while the other 
family members do not have a canonical but putative DNA binding domain. The tandem 
chromodomain was shown to interact with acetylated and methylated histones as was 
especially shown for H3K4me and is a unique feature to CHD proteins among other 
chromatin remodelers (Flanagan et al. 2005). CHD3 and CHD4 have two PHD zink finger 
domains which provide an additional DNA binding site, while CHD5-9 harbor additional 
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domains which have been interpreted as interaction domains though without a yet clarified 
mechanism (Hall and Georgel 2007). 
Each of the domains that bind to chromatin is indispensable and CHD remodelers obviously 
attach to chromatin through various sites as the mutation of single domains consequently 
lead to a dissociation of the proteins from chromatin (Marfella and Imbalzano 2007). 
CHD remodelers can either act as transcriptional activators or repressors with ascribed 
functions in multisubunit complexes. They affect each step of transcription, and the decision 
between transcriptional activation or repression depends on which promoters or 
transcription factors they bind. The only remodelers with clear repressive functions are 
CHD3/4, which are part of the NuRD-complex (nucleosome remodeling deacetylase) that 
also contains histone deacetylases (HDACs) and is involved in gene repression (Hall and 
Georgel 2007). 
 
1.8.2  CHD in DNA damage response and disease 
A role in disease and response to damaged DNA is established for some of the CHD 
chromatin remodelers. Recently, genetic and transcriptomic analysis of all CHD genes 
strengthened the significance of CHD in cancer, of which some have mechanistically been 
 
Figure 1.9 Structure and functional domains of CHD8. 
The structure of CHD family members is highly heterogenic. Minimal structure similarities are the two N-
terminal tandem chromodomains involved in nucleosome binding, the SWF/SNF2-like ATPase/helicase 
domain as core functional domain which hydrolyses ATP to move histones and nucleosomes, and a helicase 
C-terminal domain. Only CHD1/2 contain a defined DNA-binding domain, which is not present in any other 
family member. Those potentially bind chromatin through all other domains. For CHD8, deletion of each 
domain abrogates its tethering to chromatin. CHD8 possesses two BRK domains of unknown specificity 
which otherwise exist in CHD7 and CHD9 only, so that these form a subfamily. Figure modified from Hall and 
Georgel, 2007 with permission from Biochemistry and Cell Biology. 
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involved in the DDR (Chu et al. 2017). A CHD1-like protein, referred to as ALC1 (amplified 
in liver cancer) localizes to sites of DNA damage where it promotes DNA repair (Lans et al. 
2012). CHD1 as such is required for the conservation of stemness during embryonic 
development through the prevention of heterochromatin formation (Gaspar-Maia et al. 
2009). A tumor-suppressive role is established for CHD5. It is required for the transcription 
of the tumor suppressor CDKN2A which controls progression through the cell cycle. In 
contrast to other chromatin remodeling functions, this role seems to be universal throughout 
cell types. Mutations in CHD5 frequently occur in human gliomas (Kolla et al. 2014). CHD3 
and CHD4 are part of the NuRD complex which is involved in DNA repair through the 
creation of a permissive chromatin environment (O'Shaughnessy and Hendrich 2013). 
Upon ionizing radiation, CHD4, a target of ATM, is transiently recruited to DSBs within 
minutes in a PARP- but not γH2AX-dependent manner and shows enhanced accumulation 
after ATM depletion. CHD4 controls p300-dependent p53 acetylation, which is enhanced 
after CHD4 depletion leading to accumulation of p21 and therefore arrest in G1 of the cell 
cycle (Polo et al. 2010). 
Haploinsufficiency of CHD7 leads to the CHARGE syndrome in humans. This genetic 
disease with distinct organ anomalities is reproducible in mice experiments showing a 
misregulated gene expression during development and hyperactivation of p53 (Bosman et 
al. 2005; Van Nostrand et al. 2014; Vissers et al. 2004). Furthermore, CHD7 was recently 
suggested as biological marker for the outcome of gemcitabine-treated pancreatic cancer. 
In vitro, depletion of CHD7 lowers DNA damage signaling as indicated by reduced Chk1 
phosphorylation, but leads to a higher percentage of γH2AX-positive cells and reduced 
survival after treatment with gemcitabine. Patients receiving neoadjuvant treatment with 
gemcitabine showed a significantly better survival when CHD7 expression was low (Colbert 
et al. 2014). 
 
1.8.3  The chromatin remodeling factor CHD8 
CHD8 is one of the less characterized ATP-dependent chromatin remodelers. Mutations in 
the CHD8 gene are associated with autism spectrum disorders, and CHD8-heterozygous 
mice display a haploinsufficient phenotype with large abnormalities in brain development 
due to a lack of differentiation and perturbed gene expression patterns. CHD8 knockout 
mice die during early embryogenesis with a phenotype of widespread apoptosis and 
cardiovascular and brain anomalies. CHD8 is highly expressed in embryonic tissues and 
stem cells in mice with emphasis on neuronal tissue, but expression levels seems to 
decrease with differentiation (Nishiyama et al. 2009). 
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1.8.3.1  Structure and function of CHD8 
CHD8 was described to exist in two isoforms which are produced by alternative splicing: 
the large isoform harboring the domains as depicted above and the small isoform lacking 
the C-terminal domains (Nishiyama et al. 2009). However, only the large isoform was found 
to be expressed in human and mouse tissues (Shingleton and Hemann 2015). It is localized 
to the nucleus and expression of CHD8 seems to be uniform throughout the cell cycle 
(Mjelle et al. 2015; Nishiyama et al. 2009). To date, the three-dimensional structure of CHD8 
has not been resolved and there are no proteomic analyses for the identification of CHD8 
binding partners. Some single experimental results have described CHD8 as being part of 
multisubunit complexes (see below). Mechanistically, CHD8 is able to slide and bind 
nucleosomes at DNA. This process requires hydrolysis of ATP, which is stimulated by 
chromatin 10-fold more than by DNA alone. Compared to other CHD chromatin remodelers, 
CHD8 requires comparably large DNA fragments for this activity and has low affinity to 
nucleosomal substrates, which restricts CHD8 remodeling function to large linker DNA or 
spaced nucleosomes of highly transcribed DNA regions. CHD8 can thus condense DNA 
with highly spaced nucleosomes as well as decondense compacted chromatin establishing 
a fixed DNA-nucleosome spacing (Manning and Yusufzai 2017). 
 
1.8.3.2  CHD8-regulated processes 
Originally, CHD8 was identified as a negative regulator of Wnt signaling, a pathway which 
is often constitutively activated in human cancers. Characterization of CHD8 functions 
comprises the involvement of CHD8 in positive or negative regulation of transcription 
(Logan and Nusse 2004). 
While CHD8 directly binds to ß-catenin upon induction of Wnt signaling, the binding and 
recruitment of histone H1 via an H1-binding domain on CHD8 is necessary for the 
transcriptional repression of Wnt-dependent gene transcription. In the same way, the 
authors suggested CHD8 to be a negative regulator of p53 and detected increased 
transcription of p53-dependent genes after depletion of CHD8 (Nishiyama et al. 2012; 
Nishiyama et al. 2009). 
Another mechanism through which CHD8 might regulate transcriptional repression is the 
maintenance of insulator functions. Chromatin insulators form borders between differentially 
regulated gene transcription and between eu- and heterochromatin. CHD8 binds to the 
chromatin insulator CTCF (CCCTC-binding factor), which serves as boundary between 
differentially regulated chromatin domains. Like CHD8, CTCF can activate and suppress 
transcription. Two ways for transcriptional repression are the prevention of enhancers from 
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binding to promoters and a barrier formation of CTCF which prevents the spreading of 
heterochromatin to euchromatic regions, where CHD8 is essential for both (Ishihara et al. 
2006). The dysregulation of insulator activities is associated with an epigenetic suppression 
of tumor suppressor genes, and CHD8 together with CTCF was found to be lowered during 
prostate carcinogenesis (Damaschke et al. 2014). 
The activation of transcription by CHD8 might function through the association with RNA 
polymerase II, which was shown to promote the transcription of CHD8-dependent genes of 
which some are S-phase specific (Rodriguez-Paredes et al. 2009; Subtil-Rodriguez et al. 
2014). Another, yet therapeutic involvement of CHD8 in malignancies is through the binding 
of the chromatin reader BRD4 (bromodomain-containing protein 4), which drives oncogenic 
gene transcription in myeloic leukemia and, as has been shown recently, in a subset of 
gynecological cancers. CHD8 is bound to BRD4 through the histone methyltransferase 
NSD3 and depletion of either factor leads to growth delay and induces differentiation. Thus, 
inhibition of BRD4 is subject to clinical trials (Jones and Lin 2017; Shen et al. 2015). 
Last, CHD8 is part of histone methyl transferase complexes containing the MLL1-protein 
(mixed-lineage leukemia-1). It promotes malignancy through the methylation of hox genes 
promotors and induces a CpG methylator phenotype in colorectal cancer cells (Fang et al. 
2014; Yates et al. 2010).  
Taken together, CHD8 has established roles during embryogenesis and differentiation, 
mainly by coordinating the transcriptional network. There are contradictory findings as to 
whether this chromatin remodeler has proto-oncogenic properties as seem to dominate for 
hematologic malignancies, or whether it executes a tumor suppressor function as seen in 
many solid tumors. 
So far, CHD8 has no established role in the DDR. 
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1.9  Scope of the thesis 
 
Chemotherapeutics that target replicating tumor cells have been in clinical use for many 
decades. In contrast to a new generation of small molecules as cancer therapeutics, the 
cellular mechanisms to cope with genotoxic stress caused by DNA damaging agents are 
incompletely understood, especially in the case of replicative stress. This is of fundamental 
interest given that chemotherapy still forms the main column of anticancer treatment and 
resistance mechanisms to gemcitabine are bound to develop in the course of treatment. 
Further, loss of tumor suppressive function of mutant p53 together with arising oncogenic 
functions is an adverse condition which is found in the majority of cancers. Thus, our work 
on factors that mediate the cellular response to gemcitabine does not only serve 
mechanistic research on replicative stress, but meets a major clinical challenge. 
We used two approaches to determine mediators of the response to gemcitabine. First, we 
focused on the kinase MK2 that emerged as damage-responsive in recent years. Previous 
work in our lab found it to potentially inhibit translesion synthesis as damage tolerance 
mechanism to gemcitabine in an osteosarcoma cell line, antagonizing Chk1 at that point. 
We aimed to establish the MK2/Chk1 system as determinant of the DDR and cell 
proliferation in a pancreatic cancer model, too. Interestingly, our results challenge the 
general view on Chk1 inhibitors as chemosensitizing agents. 
Second, we operated a small interfering RNA (siRNA) screening approach on pancreatic 
cancer cells in order to identify new regulators of the gemcitabine response that could be 
exploited mechanistically. Following up on the results obtained, we characterized the 
chromatin remodeling factor CHD8, in terms of the response to different types of DNA 
damage and its consequences on transcriptional regulation, cell cycle control and 
apoptosis – and to the regulation of mutant p53.
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2. Materials 
2.1  Technical devices 
 
Table 2.1 Technical devices 
Device Company 
Biomek® 2000 Laboratory 
Automation Workstation  
Beckman Coulter Indianapolis, Indiana,  
United States 
Blotting chamber Biozym, Hessisch Oldendorf, Germany 
Cell counting chamber  
Neubauer improved Brand, Wertheim, Germany 
Centrifuge 5415R Eppendorf, Hamburg, Germany 
Centrifuge 5810R Eppendorf, Hamburg, Germany 
Centrifuge Megafuge 1.0R 
Heraeus, Thermo Scientific, Waltham, MA, 
United States 
Chemoluminescence imager 
Chemocam HR 16 3200 
Intas Science Imaging Instruments,  
Göttingen, Germany 
Cytometer Celígo Cyntellect,San Diego, CA United States 
DNA Gel chamber Biotech Service Blu, Schauenburg, Germany 
Electrophoresis System for  
SDS-PAGE 
Amersham Bioscience, GE Healthcare, Little 
Chalfont, United Kingdom 
Flow cytometer  
Guava EasyCyte plus Millipore, Merck, Darmstadt Germany 
Foil swelding machine  
Vacupack plus Krups, Groupe SEB, Lyon, France 
Freezer -20 °C Liebherr, Bulle, Switzerland 
Freezer -80 °C 
Heraeus, Thermo Scientific, Waltham, MA, 
United States 
Heating Block  
Grant Instruments, Hillsborough, NJ,  
United States 
Heating Block HLC HLC Biotech, Ditabis, Pforzheim, Germany 
Ice Machine B100 Ziegra, Isernhagen, Germany 
Incubator for bacteria plates Memmert, Schwabach, Germany 
Incubator for bacteria vials Minitron Infors HT, Basel, Switzerland 
Incubator for cell culture  
Hera Cell 150 
Heraeus, Thermo Scientific, Waltham, MA, 
United States 
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Laminar flow cabinet for sterile 
handling of cell culture 
Heraeus, Thermo Scientific, Waltham, MA, 
United States 
Liquid nitrogen tank LS 480 Taylor-Wharton Theodore, AL, United States 
Magnetic stirrer MR 3001 Heidolph, Schwabach, Germany 
Microscope Axiovert 40C  Zeiss, Oberkochen, Germany 
Microscope Axioscope 2 Plus Zeiss, Oberkochen, Germany 
Microscope, automated fluorescence 
Pathway 855 
Becton Dickinson, Franklin Lakes, NJ,  
United States 
Microscope, Confocal Zeiss  
Confocal LSM 510 meta Zeiss, Oberkochen, Germany 
Microwave Cinex, Lippstadt, Germany 
Mini centrifuge MCF-2360 LMS, Tokyo, Japan 
PCR machine for qPCR  
CFX96, C1000 
Biorad Laboratories, Hercules, CA,  
United States 
PCR machine for generation of 
cDNA Thermocycler T personal Biometra, Göttingen, Germany 
pH-meter WTW-720 WTW, Weilheim, Germany 
Pipet multichannel (8-channel) 
Research Plus Eppendorf, Hamburg Germany 
Pipet, electric Portable-XP Drummond, Broomal, PA, United States 
Pipets Eppendorf Research Series 
2100 (0.1-2.5 µl, 0.5-10 µl, 10-100 µl, 
50-200 µl, 100-1000 µl) Eppendorf, Hamburg, Germany 
Power supply unit for electrophoresis 
and immunoblotting  
Powerpack P25T Biometra, Göttingen, Germany 
Refrigerator 4 °C Liebherr, Bulle, Switzerland 
Reservoir 30 ml for multichannel 
pipet 
Beckman Coulter Indianapolis, Indiana 
United States 
Reservoir 2x 15 ml for multichannel 
pipet (divided by length) 
Beckman Coulter Indianapolis,  
Indiana, United States 
Roller RM5 V-30 CAT, Staufen, Germany 
Scales Acculab ALC-6100.1 Sartorius, Göttingen, Germany 
Scale LE623S Sartorius, Göttingen, Germany 
Scanner CanoScan 8600F Canon, Tokyo, Japan 
Sequencer, automated for DNA 
sequencing ABI 3100 Applied Biosystems, Life Technologies 
Shaker PROMAX 2020 Heidolph, Schwabach, Germany 
Sonication Device Bioruptor Diagenode, Liège, Belgium 
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Spectrophotometer NanoDrop ND-
1000 PeqLab, Erlangen, Germany 
Thermomixer comfort Eppendorf, Hamburg, Germany 
Timer Oregon Scientific, Portland, OR, United States 
Ultraviolet crosslinker CL-100 UVP Analytic Jena AG, Jena, Germany 
UV-transilluminator Intas UV system 
Gel Jet Imager 
Intas Science Imaging Instruments,  
Göttingen, Germany 
Vaccum pump IBS Integra Biosciences, Fernwald, Germany 
Vortex Genie 2 
Scientific Industries, Bohemia, NY,  
United States 
Water bath TW20 (to prewarm cell 
culture media) Julabo Labortechnik, Seelbach, Germany 
 
 
2.2  Consumables 
 
Table 2.2 Consumables 
Product Company 
8-well microscope chamber slides Nunc, Thermo Scientific 
96-well plates for microscopy, clear bottom 
Becton Dickinson, Franklin Lakes, NJ, 
United States 
96-well plates for microscopy, clear bottom Corning, Corning, NY, United States 
96-well plates for microscopy and automated 
imaging Cytometer Celígo, clear bottom Corning, Corning, NY, United States 
96-well plates for qPCR 4titude, Wotton, United Kingdom 
Bacteria Culture Dishes (14 cm diameter) Sarstedt, Nümbrecht, Germany 
Bacteria culture vials (14 cm) 
Becton Dickinson, Franklin Lakes, NJ, 
United States 
Cell scraper (16 cm, 25 cm) Sarstedt, Nümbrecht, Germany 
Cover slips Menzel, Thermo Scientific  
Cryo tubes for freezing of cells Cryoline Nunc, Thermo Scientific 
Filter tips (10 µl) Starlab, Hamburg, Germany 
Filter tips (20 µl, 200 µl, 1000 µl) Sarstedt, Nümbrecht, Germany 
Glass slides Lab Tek # 154534 Thermo Fisher Scientific 
Parafilm Brand, Wertheim, Germany 
Pipet tips (0.5-10 µl, 20-200 µl, 100-1000 µl) Greiner, Essen, Germany 
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Pipet tips for Biomek automated work station Greiner, Essen, Germany 
Protran nitrocellulose transfer membrane Whatman, Dassel, Germany 
Reaction tube (0.2 µl) Sarstedt, Nümbrecht, Germany 
Reaction tube (0.5 µl, 1.5 µl, 2 µl) Eppendorf, Hamburg, Germany 
Reaction tube (15 ml, 50 ml) Greiner 
Safe-lock reaction tube (1.5 µl) Eppendorf, Hamburg, Germany 
Sealing foil for 96-well plates 
Becton Dickinson, Franklin Lakes, NJ, 
United States 
Sterile filter Millipore, Merck, Darmstadt Germany 
Syringes (different gauge) 
Henke-Sass, Wolf, Tuttlingen, 
Germany 
Syringe canulas (different sizes) Braun, Melsungen, Germany 
Transparent sealing foil for 96-well plate 4titude, Wotton, United Kingdom 
Whatman paper Whatman, Dassel, Germany 
 
 
2.3  Chemicals and reagents 
  
Table 2.3 Chemicals and reagents 
Product Company 
Agar 
Sigma Aldrich, St. Louis, MO,  
United States 
Agarose Roth, Karlsruhe, Germany 
Albumin Fraction V (Bovine Serum 
Albumine, BSA) Roth, Karlsruhe, Germany 
Ammonium persulfate (APS) Roth, Karlsruhe, Germany 
Ammonium sulfate ((NH4)2SO4) Roth, Karlsruhe, Germany 
Ampicillin AppliChem, Darmstadt, Germany 
Bromphenol blue 
Sigma Aldrich, St. Louis, MO,  
United States 
Chloroform Roth, Karlsruhe, Germany 
Complete Mini Protease Inhibitor Roche, Basel, Switzerland 
Copper sulfate (CuSO4 x 6H2O) Roth, Karlsruhe, Germany 
Dimethyl sulfoxide (DMSO) AppliChem, Darmstadt, Germany 
DNA ladder GeneRuler Fermentas, Thermo Scientific 
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Deoxynucleotide triphosphates (dNTPs) Bio-Budget, Krefeld, Germany 
Deoxyribonucleotide triphosphates 
(dNTPs) in single tubes as dATPs, dGTPs, 
dCTPs, dTTPs) Primitech, Minsk, Belarus 
Dithiotreitol (DTT) 
Sigma Aldrich, St. Louis, MO,  
United States 
Ethanol 99,8 % Roth, Karlsruhe, Germany 
Ethanol 99,9 % p.a. (EtOH) for analysis Merck, Darmstadt Germany 
Ethidium Bromide (EtBr) 
Sigma Aldrich, St. Louis, MO,  
United States 
Ethylene diamine tetraacetate (EDTA) Roth, Karlsruhe, Germany 
Fetal calf serum (FCS) HyClone Thermo Fisher Scientific, Germany 
Formaldehyde 37 % solution Roth, Karlsruhe, Germany 
Glycerol  Roth, Karlsruhe, Germany 
Glycine Roth, Karlsruhe, Germany 
Guava ICF cleaning solution Millipore, Merck, Darmstadt Germany 
Hoechst 33342 Invitrogen, Life Technologies 
Hydrogen chloride (HCl) Roth, Karlsruhe, Germany 
Immersion oil Zeiss, Oberkochen, Germany 
Isopropanol Th. Geyer, Renningen, Germany 
Lipofectamine 2000 Invitrogen, Life Technologies 
Magnesium chloride water free (Mg(Cl)2)  
for PCR Fermentas, Thermo Scientific 
Magnesium chloride hexahydrate  
(Mg(Cl)2 x 6 H2O Roth, Karlsruhe, Germany 
Methanol >99 % (MetOH) Roth, Karlsruhe, Germany 
Milk, powdered Roth, Karlsruhe, Germany 
Nail Polish DM Drogerie Markt, Karlsruhe, Germany 
Nuclease free water Ambion, Life Technologies 
Page Ruler Prestained Protein Ladder Fermentas, Thermo Scientific 
Pefabloc SC protease inhibitor Roth, Karlsruhe, Germany 
Phenol, Roti-Phenol Roth, Karlsruhe, Germany 
Ponceau S Roth, Karlsruhe, Germany 
Potassium Chloride (KCl) Roth, Karlsruhe, Germany 
Potassium dihydrogene phosphate 
(KH2PO4) Roth, Karlsruhe, Germany 
Propidium iodide (PI) 
Sigma Aldrich, St. Louis, MO,  
United States 
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Protein ladder for high molecular weight 
proteins (Spectra  Multicolour High range 
protein marker  #26625) Fermentas, Thermo Scientific 
RNAse inhibitor Fermentas, Thermo Scientific 
Sodium chloride (NaCl) Roth, Karlsruhe, Germany 
Sodium deoxycholate AppliChem, Darmstadt, Germany 
Sodium dodecyl sulfate (SDS) Roth, Karlsruhe, Germany 
Sodium hydroxide (NaOH) pellets 
Sigma Aldrich, St. Louis, MO,  
United States 
Sodium hydrogen phosphate heptahydrate 
(Na2HPO4 x 7H2O) Roth, Karlsruhe, Germany 
Sucrose 
Sigma Aldrich, St. Louis, MO,  
United States 
SYBRgreen Invitrogen, Life Technologies 
Tetracycline 
Sigma Aldrich, St. Louis, MO,  
United States 
Tetramethyethylendiamine (TEMED) Roth, Karlsruhe, Germany 
Trasylol Bayer, Leverkusen, Germany 
Trehalose 
Sigma Aldrich, St. Louis, MO,  
United States 
Trisamine (Tris) Roth, Karlsruhe, Germany 
Triton X-100 AppliChem, Darmstadt, Germany 
Tween 20 AppliChem, Darmstadt, Germany 
Tryptone # 8952.2  Roth, Karlsruhe, Germany 
Urea # 3941.1 Roth, Karlsruhe, Germany 
Yeast extract 
Sigma Aldrich, St. Louis, MO,  
United States 
β-Mercaptoethanol Roth, Karlsruhe, Germany 
 
 
2.4  Buffers and Solutions 
All buffers and solutions were prepared at room temperature (RT) and automatically stirred 
until all components were dissolved. All buffers and solutions were stored at 4 °C, except 
for PBS (phosphate buffered saline), PBS++, TBST (Tris buffered Saline) and Ponceau S 
which were stored at RT and qPCR reaction mix which was shock frozen in liquid nitrogen 
and stored at -20 °C. Blocking solution for immunofluorescence was freshly prepared before 
use, all others where storable. 
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RIPA lysis buffer, pH 7,5 
Triton X-100 1,0 % 




NaCl 150 mM 
EDTA  10 mM 




dissolved in deionized H2O, pH optimized by 
titration with dilute NaOH and HCl, 
respectively 
 
Laemmli buffer, 6x 
Tris pH 6,8 0.35 M 
Glycerol 30.00 % 
SDS 10,00 % 




dissolved in deionized H2O, pH optimized by 
titration with dilute NaOH and HCl, 
respectively 
 
Cell lysis buffer 
Urea 2.5 M 
To obtain lysates for SDS-PAGE, 6x 
Laemmli is added 1:5 
 







Phosphate buffered saline (PBS), pH 7,5, 
10x 
Sodium Chloride (NaCl) 240.0 mM 
Potassium chloride (KCl) 2.7 mM 
Sodium hydrogen 
phosphate heptahydrate 






dissolved in deionized H2O, pH optimized by 
titration with dilute NaOH and HCl, 
respectively. For use, diluted 1:10 in 
demineralized H2O 
 
Enriched phosphate buffered saline 
(PBS++), pH 7.5 
Calcium Chloride 








dissolved in 1x phosphate buffered saline 
(PBS), pH 7.5 
 
Western blot washing solution: Tris 
buffered saline + Tween, pH 7.6 







dissolved in deionized H2O, pH optimized by 
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dissolved in TBST, pH 7.6 
 
Ponceau S solution 




dissolved in deionized H2O 
 
 
SDS-PAGE running buffer 
Tris 25.0 mM 





dissolved in deionized H2O 
 
Western blot transfer buffer 
Tris 25 mM 




dissolved in deionized H2O 
 
DNA gel loading buffer, 6x 
 
  
IF blocking solution 




dissolved in PBS 
 
qPCR reaction buffer, 10x 







dissolved in nuclease free water 
 
qPCR reaction mix, 25x 
10x qPCR reaction buffer 10 % 
SYBRGreen 1:80,000 
Water-free MgCl2 for 
PCR 
3 mM 
Trehalose in 10 mM 
Tris, pH 8.5 
300 mM 
dNTPs, mix 0.2 mM 




dissolved in nuclease free water
Sucrose 40.00 % 





 dissolved in deionized H2O
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2.5  Chemotherapeutics and pharmacological inhibitors 
  
Table 2.4 Chemotherapeutics 












Sigma-Aldrich, Sigma Aldrich, St. 
Louis, MO, United States 
Nocodazole  
Sigma-Aldrich, Sigma Aldrich, St. 
Louis, MO, United States 
 
 
Table 2.5 Pharmacological inhibitors 




Chk1 Calbiochem, Merck, Darmstadt, 
Germany 
MK2 Inh 
MK2 III,  
Cat. #475864 
MK2 Calbiochem, Merck, Darmstadt, 
Germany 





Caspases Sigma-Aldrich, Sigma Aldrich, St. 
Louis, MO, United States 
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2.6  Enzymes and buffers 
 
Table 2.6  Enzymes and buffers 
Reagent Company 
Buffer for M-MuLV RT, 10x 
New England Biolabs, Ipswich, MA, United 
States 
Buffer for Taq with KCl, 10x Fermentas, Thermo Scientific 
Buffer R Fermentas, Thermo Scientific 
M-MuLV Reverse transcriptase (RT) 
New England Biolabs, Ipswich, MA, United 
States 
RNase A Quiagen, Venlo, Netherlands 




Table 2.7 Kits 
Name Company 
BigDye Terminator v3.1 Cycle sequencing kit Invitrogen, Life Technologies 
Click-iT® EdU Alexa Fluor Azide High-
throughput Imaging Assay 
Invitrogen, Life Technologies 
Guava Check Kit for FACS 
 
Millipore, Merck, Darmstadt Germany 
Pure Yield Plasmid Midiprep System Promega, Madison, WI, United States 
Invisorb Spin Plasmid Midi Kit Two  Invitec/Stratec molecular, Berlin, 
Germany 
Pierce® BCA Protein Assay Kit Thermo Scientific 
HRP substrate solutions:  
Immobilon Western HRP Substrate Peroxide 
Solution 
Millipore, Merck, Darmstadt Germany 
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2.8  Oligonucleotides 
All siRNAs are Silencer Select siRNAs from Ambion, Life Technologies. 
For the high-content siRNA-screen we used a customized siRNA library which was obtained 
from Ambion, catalog number 4392425 and 4390836. It contained siRNAs against gene 
products which were associated with DNA damage, genomic integrity and cancer and was 
composed by the European GENICA Consortium (see table 2.20). The gene list was 
obtained by personal communication. 
Only those siRNAs used for further validation of candidates resulting from the secondary 
screen are shown in table 2.8 below. All other sequences are available from the library. 
 















s814 UCGUAAGUAAGCGCAACCCtt GGGUUGCGCUUACUUACGAtt 
CHD8 A  s33582 CACCUAGAGUACGAAAACAtt UGUUUUCGUACUCUAGGUGtg 
CHD8 B s33580 GGCACGAUGUCAUCGAAUUtt AAUUCGAUGACAUCGUGCCtg 
CHD8 C s33581 GUACUUAUAUGAACGUAUUtt AAUACGUUCAUAUAAGUACct 
CHEK1 
(Chk1) 
AM51331  GCAACAGUAUUUCGGUAUAtt UAUACCGAAAUACUGUUGCca 
CTCF A s20966 not available not available 
CTCF B s20968 not available not available 
HELLS A s6505 GGAUAGAGAGUCGACAGAAtt UUCUGUCGACUCUCUAUCCca 
HELLS B s6507 GAGUUGUUGUUAGAUCGAAtt UUCGAUCUAACAACAACUCta 
HELLS C s6506 GGAUCAAGAGAGAAGGUCAtt UGACCUUCUCUCUUGAUCCtt 
MAPKAPK2 
(MK2) 
 CAGUAUCUGCAUUCAAUCAtt UGAUUGAAUGCAGAUACUGga 
MDM2 4390828  GCCAUUGCUUUUGAAGUUAtt UAACUUCAAAAGCAAUGGCtt 
MCM10 A s30853 GACGAUUUCUCGGAACAAAtt UUUGUUCCGAGAAAUCGUCtg 
MCM10 B s30852 GCACUCUUGAAGCAACAGAtt UCUGUUGCUUCAAGAGUGCtg 
MCM10 C s30854 CGGUGAAUCUUAUACAGAAtt UUCUGUAUAAGAUUCACCGtc 
TP53 (p53) s605 GUAAUCUACUGGGACGGAAtt UUCCGUCCCAGUAGAUUACca 
STAG2 A s21090 CCACUGAUGUCUUACCGAAtt UUCGGUAAGACAUCAGUGGaa 
STAG2 B s21089 GGUAGAUGAUUGGAUAGAAtt UUCUAUCCAAUCAUCUACCac 
STAG2 C s21091 CCAUCUACAGGAAAACGGAtt UCCGUUUUCCUGUAGAUGGtt 
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Primers were designed manually with the help of the following databases: 
The cDNA sequence for a protein of interest with indicated intron-exon-borders was 
obtained from ensembl. 
Primers were then manually designed according to the PREMIER Biosoft primer design 
guidelines. 
Primers were analyzed for secondary structures, like self- or hetero-dimers, hairpin-
structures or melting temperatures using the oligo analyzer tool from Integrated DNA 
Technologies. 
The reverse primer complement was calculated using the Sequence Manipulator Suite:   
The reverse primer complement was again analyzed for secondary structures. Both 
sequences were then blasted against the whole human genome and transcriptome using 
BLASTN, BLAST, US National Library of Medicine in order to validate target specificity. 
For details of the above-mentioned databases and online tools, see table 2.20. 
 
 
Table 2.9 Primers 
 
Name/target Sequence Application 
CHD8 forward 5’-TTG TCA AGT ACA AGA ACT ACT CC-3’ qPCR 
CHD8 reverse 5’-ACT GTG AGA CTC ATC CAA TAT CC-3’ qPCR 
HELLS forward 5’-CTC GCA TGT CTT GGG ATA G-3’ qPCR 
HELLS reverse 5’-CCT CAT AAC TGG CTT CTC TTC-3’ qPCR 
MCM10 forward 5’-GGC TTC ACC TCC AGA TCC-3’ qPCR 
MCM10 reverse 5’-AAC CCC AAA TGT CAC CCA ATC-3’ qPCR 
STAG2 forward 5’-AGA TAC CGT GAT GCG ATA GC-3’ qPCR 
STAG2 reverse 5’-GCC CTT GTA GAG CAG TAA GAC-3’ qPCR 
USP11 forward 5’- CGC AAG AAA GAT GGC ACT TGG -3’ qPCR 
USP11 reverse 5’- GCC ACA GAT GCC TGG CTG AC -3’ qPCR 
Random nonamer 5’-NNNNNNNNN-3’ RT-PCR 
GAPDH forward 5’-TGA AGG TCG GAG TCA ACG GAT TTG GT-3’  qPCR 
GAPDH reverse 5’-GCA GAG ATG ATG ACC CTT TTG GCT C-3’  qPCR 
36B4 forward 5’-GAT TGG CTA CCC AAC TGT TG-3’ qPCR 
36B4 reverse 5’-CAG GGG CAG CAG CCA CAA A-3’ qPCR 
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2.9  Plasmids 
 
Table 2.10 Plasmids 
Name Source Description 
pcDNA3 Invitrogen, Life 
Technologies 
Empty vector, expression vector for the transient 
expression of proteins in transfected eukaryotic 






Expression vector for the transient expression of 
the human large isoform of CHD8 in transfected 
eukaryotic cells under the control of a CMV 





Expression vector for the transient expression of 
the murine small isoform of CHD8 in transfected 
eukaryotic cells under the control of a CMV 
promoter; ampicillin resistance 
pcDNA3-GFP Lab inventory Expression vector for the transient expression of 
GFP in transfected eukaryotic cells under the 
control of a CMV promoter; ampicillin resistance 
 
→ Expression constructs pcDNA3-HA-hCHD8L and pcDNA3-HA-mCHD8S were obtained 
from K.I. Nakayama, Department of Molecular and Cellular Biology, Medical Institute of 
Bioregulation, Kyushu University, Japan (Nishiyama et al. 2009). 
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2.10  Antibodies 
 


















rAb mouse 1:1,000 in BSA #2344 Cell Signaling 
Chk2 A-12 mouse 1:1,000 in milk sc-5278 Santa Cruz 
Chk2 pThr68 C13C1 rabbit 1:1,000 in BSA 2197 Cell Signaling 
Cleaved 
caspase 3 
Asp175 rabbit 1:500 in milk #9664 Cell Signaling 
HA-tag C29F4 rabbit 1:1,000 in milk 3724 Cell Signaling 
H2AX pS319 JBW301 mouse 1:1,000 in milk 05-636 Millipore, Merck 
Hsc70 B-6 mouse 
1:15,000 in 
milk 
sc-7298 Santa Cruz 
MDM2 Ab-1 mouse 1:1,000 in BSA OP46 Calbiochem 
PARP  rabbit 1:2,000 in milk 9542 Cell Signaling 
p53 DO-1 mouse 1:1,000 in milk sc-126  Santa Cruz 
p53 pS15  mouse 1:1,000 9286S Cell Signaling 




100  Abcam 
Rad 51  mouse 1:1,000 in BSA ab213 Abcam 
All primary antibodies for immunoblotting were dissolved in Western Blot blocking solution. 
Phospho-antibodies were dissolved in BSA. 
 








CPDs TDM-2 mouse 1:300  Cosmo Bio, Tokyo, Japan 
H2AX 
pS319 
JBW301 mouse 1:1,000 05-636 Millipore, Merck 
HA-tag C29F4 rabbit 1:1,000  3724 Cell Signaling 
All primary antibodies used for IF were diluted in IF blocking solution. 
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HRP-coupled AffiniPure F(ab’)2 









HRP-coupled AffiniPure F(ab’)2 









All secondary antibodies were dissolved in Western Blot blocking solution. 
 
Table 2.14 Secondary antibodies for immunofluorescence 
Antibody Cat. Number Company 
Alexa-Fluor-488 goat anti mouse A-11017 Invitrogen,Life Technologies 
Alexa-Fluor-488 goat anti rabbit A-11034 Invitrogen,Life Technologies 
Alexa-Fluor-546 goat anti mouse A-11003 Invitrogen,Life Technologies 
Alexa-Fluor-546 goat anti rat A-21434 Invitrogen,Life Technologies 
All secondary antibodies for IF were diluted 1:2000 in IF blocking solution. 
 
 
2.11  Human cell culture 
 
Table 2.15 Human cell lines 
Cell line Origin Patient 
BxPC-3 Pancreatic adenocarcinoma, epithelial phenotype Female, 61 years 
MIA PaCa-2 Pancreatic adenocarcinoma, epithelial phenotype Male, 65 years 
PANC-1 
Ductal pancreatic adenocarcinoma, 
epitheloid phenotype 
Male, 56 years 
PaTu8902 
Ductal pancreatic adenocarcinoma, 
mesenchymal phenotype 
 
U2OS Osteosarcoma, epithelial morphology Female, 15 years 
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Ciprofloxacin 10 µg/ml Bayer, Leverkusen, Germany 
Dulbecco’s Modified Eagle Medium (DMEM), 
powder 
2 % Gibco, Life Technologies 
Fetal Calf Serum (FCS) 10 % Gibco, Life Technologies 
L-glutamine 200 µM Gibco, Life Technologies 
PBS tablets - Gibco, Life Technologies 
Penicillin/Streptomycin 50 U/ml Gibco, Life Technologies 
RPMI Medium - Gibco, Life Technologies 
Tetracyclin 5 mg/ml Gibco, Life Technologies 





  DMEM 
without supplements  DMEM with supplements  
DMEM, powder 10.0 g  Fetal Calf Serum (FCS) 10 % 
NaHCO3 3.7 g  Penicillin/Streptomycin 50 U/ml 
HEPES 5.96 g  L-glutamine 200 µM 
   Tetracyclin 5 mg/ml 
dissolved in 500 ml deionized  
H2O, sterile filtered 
Ciprofloxacin 10 µg/ml 
dissolved in 500 ml DMEM without   
supplements 
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2.12  Bacteria culture and media 
 
Table 2.17 Bacteria strains 
Strain Description 
DH10B Chemically competent E. coli 
 
 
Table 2.18 Bacteria culture media 
2YT medium  
Tryptone 1.6 % 
Yeast extract 1.0 % 
Sodium Chloride (NaCl) 0.5 % 
  












2.13   Software and databases 
 
Table 2.19 Software 
Name Company 
Adobe Photoshop CS5 Adobe Systems, San Jose, CA, United States 
AttoVision BD pathway software 
Becton Dickinson, Franklin Lakes, NJ,  
United States 
Celígo Software Cyntellect,San Diego, CA, United States 
CFX Manager Software  
for qPCR cycler Biorad Laboratories, Hercules, CA, United States 
Guava Express Software Millipore, Merck, Darmstadt, Germany 
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INTAS lab ID 
Intas Science Imaging Instruments, Göttingen, 
Germany 
Microsoft Excel, Word and 
Powerpoint 
Microsoft, Redmond, WA, United States 
NanoDrop Software PeqLab, Erlangen, Germany 
Fiji for image processing General Public License 
R-program General Public Licence, R-Project 
Biomek 2000 Laboratory 
Automation Workstation Software 
Beckman Coulter Indianapolis, IN,  
United States 
Chemostar Imager Software Intas Science Imaging Instruments, Göttingen 
 
  
Table 2.20 Databases 
Name Source/description 
BLASTN, BLAST, US 




blast primer sequences against the whole human genome and 




https://david.ncifcrf.gov   
Database for Annotation, Visualization and Integrated 
Discovery, different integrated tools and databases for 
functional annotation of large lists of genes (Huang da et al. 
2009a, 2009b)  
ensembl 
www.ensembl.org 
Acquisition of cDNA sequences for a protein of interest (Yates 
et al. 2016) accessed on 01.04.2016 





Analyzing primers for secondary structures like self- and 




Online database for information on proteins and 
posttranslational modifications, including information from 





Calculation of reverse primer sequences, accessed on 
01.04.2016 
  
        Materials                                      51 
 
UniProtKB www.uniprot.org  
Knowledge base for the collection of functional annotations on 
proteins, including their splice variants, mRNA sequence, protein 










Guidelines for primer design and tool to customize oligonucleotides 
accessed on 01.04.2016 




3.1  Cell biology 
 
3.1.1  Culturing of human cells 
All cell culture work was performed under sterile conditions. The lids of dishes and tubes 
containing living cells, except for UV irradiation, were only opened under a hood provided 
with continuous positive air pressure and laminar air flow at the opening. Before and after 
use, the place was cleaned with 70 % ethanol and the hood was sterilized using UV 
radiation for 30 min after use. Cells were cultured in an incubator at 37 °C at humidified 
ambient air atmosphere enriched with 5 % CO2 to sustain the medium’s carbonate buffer. 
All cell lines grew adherent to coated petri dishes. The cells were cultured in suitable 
medium with supplements and antibiotics (table 3.1). If the number of cells was not 
expanded for a specific experiment, they were cultured in 10 cm dishes. When a visually 
estimated confluence of 90 % was reached, cells were passaged as follows: The medium 
was removed, the plate was once washed with pre-warmed phosphate-buffered saline 
(PBS), then 5 ml of 0.1 % trypsin/EDTA (Ethylene diamine tetraacetate) was added and 
cells were incubated for 5 min. Then, the trypsinization was stopped by the addition of the 
same volume of fresh medium and the plate was rocked until all cells had detached. Then, 
1/12 to 1/3 of the cell suspension was reseeded for further culturing. Medium was added to 
a total volume of 10 ml in each dish and the dish was rocked cautiously to equally distribute 
the cells. 
 
Table 3.1 Culture media for human cell lines 
Cell line Culture medium 
BxPC3 RPMI with supplements and antibiotics 
MiaPaCa-2 DMEM with supplements and antibiotics 
except ciprofloxacin 
PANC-1 DMEM with supplements and antibiotics 
(PANC-1 can also be grown in RPMI) 
PaTu8902 DMEM with supplements and antibiotics 
U2OS DMEM with supplements and antibiotics 
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For the usage of cells in experiments, trypsinized cells were counted under a bright field 
microscope using a Neubauer counting chamber. Thereafter, the desired cell number was 
seeded in 6-well, 12-well or 96-well plates and medium was added to a total volume of 2 ml, 
1 ml or 150 µl, respectively (table 3.2). 
   
Table 3.2 Number of cells which were usually seeded for different cell lines 
 Cell count per well 
Cell line 6-well plate 12-well plate 96-well plate 
BxPC3 300,000 150,000  
MiaPaCa-2 200,000 120,000 8000 
PANC-1 200,000 120,000 5000 
PaTu8902 150,000 90,000 5000 
U2OS 180,000/200,000 90,000/120,000 7000 
 
3.1.2  Freezing and thawing of cells 
For long term storage, cells were conserved in liquid nitrogen. To this end, near confluently 
grown cells from a 15 cm dish with a low passage number were used. After trypsinization 
and ending of trypsinization as described above, cells were transferred to a 15 ml tube and 
centrifuged at 900 g for 7 min. Then, the supernatant medium was removed and the cell 
pellet was resuspended in 3.6 ml pre-cooled FCS (fetal calf serum) and 0.6 ml (10 %) 
DMSO. The suspension was transferred to a cryo tube with 1 ml each and slowly cooled 
down to -80 °C for 24 h. To this end, the vials were either stored in a thermo box isolated 
with glycerol or wrapped in multiple paper towels. After 24 h, cells were moved to a liquid 
nitrogen tank. 
To thaw cells at low passage number, a cell aliquot was rapidly warmed up in a water bath 
and the thawed cell suspension was then transferred to a tube containing 10 ml of the 
respective pre-warmed medium. The tube was vortexed and then centrifuged at 900 g for 
7 min. The supernatant was removed, the cell pellet was resuspended with another 10 ml 
of pre-warmed medium and the washed suspension was transferred to a petri dish for 
further culturing. The next day, the medium was replaced in order to remove all cells which 
had not survived the thawing process. 
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3.1.3  Transfection of human cells 
Cells were transiently transfected with nucleotides to either knockdown a specific protein 
(siRNA transfection) or to artificially express a protein (transfection of DNA from an 
expression vector). 
  
3.1.3.1  Transient transfection with siRNAs  
For the specific depletion of a protein in an experiment, cells were transfected with siRNA. 
To this end, the transfection reagent Lipofectamine 2000 (LF 2000 from here) has been 
optimized to be most efficient in all pancreatic cancer cell lines and has been established 
for efficient knockdown in U2OS cells in our lab. All pancreatic cancer cell lines were 
forward-transfected as this increased efficiency in optimization experiments (data not 
shown), that is, cells were seeded at least 12 h before transfection. U2OS cells were 
forward- as well as reverse-transfected with comparable transfection efficiencies. For 
reverse transfection, the transfection mix was prepared in the wells, and a suspension of 
freshly trypsinized cells was added. 
For the preparation of the transfection mix, siRNA dissolved in nuclease free water was 
taken from a 500 nM stock and diluted in DMEM without any supplement or antibiotic 
(solution A, see table 3.3). Then, LF 2000 was separately dissolved in DMEM without 
supplements (solution B, see table 3.3) and incubated for exactly 5 min at RT. After that, 
solution B was added to the dissolved siRNA (solution A), cautiously shaken and incubated 
at RT for another 20 min. For reverse transfection, cells were now trypsinized, counted, and 
the desired cell number was added to a volume that equaled that of the transfection mix 
(see table 3.3). For forward transfection, the medium of the wells for transfection was then 
removed, and a volume of DMEM that equaled that of the transfection mix and that already 
contained supplements and antibiotics was added to the cells. After 20 min, the transfection 
mix was added to the cells and the plate was swayed gently. If not stated differently, the 
medium that contained transfection mix was replaced by fresh medium with all supplements 
24 h after transfection. The further treatment of the cells was initiated 36 h to 48 h after 
transfection, depending on the period of time for treatment. 
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Table 3.3 Volumes of culture medium, siRNA and transfection reagent used for 




























6-well 400 µl 200 µl DMEM (-) 
+ 12 µl siRNA 
200 µl DMEM (-) 
+ 4 µl LF 2000 
800 µl 2 ml 
12-well 200 µl 100 µl DMEM (-) 
+ 6 µl siRNA 
100 µl DMEM (-) 
+ 2 µl LF 2000 
400 µl 1 ml 
96-well 50 µl 25 µl DMEM (-) 
+ 1.25 µl siRNA 
25 µl DMEM (-) 
+ 0.5 µl LF 2000 
100 µl 100 µl 
For siRNAs used, see table 2.8. 
 
3.1.3.2  Transient transfection with expression vectors 
For the overexpression of a protein, we used expression plasmids, which were transfected 
into the cells using LF 2000. For the overexpression of CHD8, we obtained an expression 
vector with a pcDNA3 backbone and the cloned sequence of the HA-tagged human large 
isoform and the murine small isoform of CHD8 from the Keiichi I. Nakayama lab (Nishiyama 
et al. 2009). The transcription from this DNA sequence is under control of a CMV promoter. 
For the expression of a protein, we exclusively used forward transfection. U2OS or PANC-
1 cells were seeded the day before transfection to reach a visually estimated confluence of 
around 80 %. The transfection mix was prepared as follows: Plasmid DNA was dissolved in 
the respective volume of DMEM without supplements (DMEM-, solution A, table 3.4). Then, 
LF 2000 was dissolved in DMEM- (solution B, table 3.4) and incubated for exactly 5 min at 
RT. Afterwards, solution A was added to solution B, carefully shaken, and then incubated 
for 20 min at RT. Meanwhile, the medium was removed from the wells, and a volume of 
culture medium without antibiotics, but with FCS and glutamine as in table 3.4 was added. 
After the transfection mix had incubated for 20 min, it was added dropwise to the pre-
pipetted medium, and the plate was swayed for a minute to equally distribute the 
transfection mix. Then, the cells were placed back into the incubator. After 4 h, the 
transfection mix was removed, fresh culture medium with all supplements was added, and 
the cells were incubated at 37 °C. Cells were further treated with UV or gemcitabine 24 h 
after transfection, and harvested depending on the treatment time. 
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Table 3.4 Volumes of culture medium, siRNA and transfection reagent used for 

























100 µl DMEM-  
+ 1.2 µg DNA 
100 µl DMEM-     
+ 4 µl LF 2000 




25 µl DMEM-     
+200 ng DNA 
25 µl DMEM        
+ 0,5 µl LF 2000  
15 µl 100 µl 
For expression vectors used, see table 2.10. 
 
If it was desired to determine the transfection efficiency before the transfected cells were 
used for further experiments, 10 % of the plasmid DNA was replaced by a GFP (Green 
Fluorescent Protein) expression vector, for example 0.12 µg and 20 ng GFP-DNA per plate 
for 12-well plates and 96-well plates, respectively. The number of GFP-expressing cells was 
assessed under a fluorescence microscope (Microscope Axiovert 40C, Zeiss, Oberkochen, 
Germany) 10 to 20 h after transfection. 
 
3.1.4  Chemical treatment, EdU-labeling and UV irradiation 
 
3.1.4.1  Chemical treatment 
Chemotherapeutics and pharmacological inhibitors were pre-dissolved and stored in H2O 
or DMSO. For treatment, the respective chemical was dissolved to its final concentration in 
a tube containing pre-warmed culture medium (see table 3.4). Controls were treated with 
the same amount of H2O or DMSO which was used for drug dilution. If not stated differently, 
cells were treated for the time periods listed in table 3.5. 
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Chk1 Inh 2.5 mM 2.5 µM DMSO 24 h 
gemcitabine 100 µM 50-500 nM H2O 
50-300nM: 24 h 
500 nM: 4 h 
MG132 10 mM 20 µM DMSO max. 4 h 
MK2 Inh 10 mM 10 µM DMSO 24 h 
Neocarzinostatin 
(NCS) 
50 mg/ml 100 ng/ml 




Nocodazole 1 mg/ml 100 ng/ml DMSO max. 17 h 
         For details, see section 3.2.1.9 below, cell synchronization with nocodazole block 
Z-VAD 20 mM 50 µM DMSO 24-48 h 
 
3.1.4.2  Labeling of cells with EdU 
The nucleoside analogue 5-Ethinyl-2’-desoxyuridine (EdU) is incorporated into the DNA of 
replicating cells without influence on this process, as the sites for nucleotide crosslinking 
are not substituted. The substitution of a comparably small ethinyl group does not, like a 
brome substitution in 5-Bromo-2’-Desoxyuridin (BrdU), sterically alter nucleotide positioning 
and therefore DNA conformation (Salic and Mitchison 2008). 
Additionally, the detection of BrdU is carried out by antibody staining and the DNA needs to 
be denatured first in order to give the antibody access to this nucleoside analogue. Because 
this is done by the harsh process of HCl addition, other proteins associated with the DNA 
are washed out and especially lowly expressed proteins cannot be stained any more. Time 
consumption of the extensive washing steps before staining after DNA denaturation is 
another disadvantage of using BrdU for labeling replicating DNA. Compared to that, EdU is 
incorporated into DNA like BrdU, but its detection relies on a chemical reaction. Cellular 
DNA and chromatin-associated proteins can therefore remain in their natural state at the 
time of detection. This click-reaction is a quantitative coupling of the ethynyl group that is 
attached to the uridine with an azide group that is bound to an Alexa-dye, whose 
fluorescence can afterwards be detected and even quantified. 
For the labeling of cells with EdU, the cells were grown and transfected in a 96-well plate. 
2 h before gemcitabine treatment, the medium was aspirated and the cells were incubated 
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in 75 µl of cell culture medium containing 7.5 µM EdU diluted from a 10 mM stock. The 
applied medium had to be incubated in a petri dish before adding the EdU at least for 1 h. 
This was to adapt the temperature and pH of the later EdU working solution to the medium 
in which the cells were already incubated and to avoid pH and temperature variations which 
would affect the sensitive process of DNA replication. Cells were incubated with EdU 
working solution for 2 h. Then, EdU was shortly washed out twice and once incubated for 
5 min with pre-incubated culture medium before gemcitabine containing medium was 
added. For the detection of EdU, see section 3.3.4.  
With this procedure, it was possible to identify cells going through S-phase at the beginning 
of a treatment with S-phase specific drugs like gemcitabine or at the beginning of UV 
radiation. Generally, EdU can also be added in parallel to gemcitabine treatment or 
afterwards. As this drug initiates replication fork stalling, DNA replication and consequently 
nucleotide incorporation is severely slowed down so that higher EdU concentrations or 
longer incubation times are needed to obtain an EdU-associated fluorescence signal. Still, 
it is possible to judge the cell’s ability to resume DNA replication after gemcitabine treatment 
this way, either by abrogating DNA damage and cell cycle checkpoints or by repairing the 
damaged DNA. 
 
3.1.4.3  UV irradiation  
For UV irradiation, UVC-light with a wavelength of 254 nm from a UV crosslinking chamber 
(UVP, Thermo Fisher Scientific) was used. Prior to irradiation, the medium of each well was 
aspirated, and the control wells were covered with light proof sealing foil. Then, the cells 
were irradiated and quickly covered with fresh medium to minimize the stress from drying. 
For 6-well and 12-well plates, the energy of 20 J/m2 was used and the cells were harvested 
1 h, 4 h or 12 h after irradiation. For 96-well plates, the energy needed to be increased to 
50 J/m2 because the walls of the wells form a high and small cylinder that absorbs UV light 
and consequently leads to less DNA crosslinks and less DNA damage signaling. This effect 
was taken into account when we used a micro pore filter cautiously lain on the surface of 
the cell layer aiming to limit the cell’s exposure to UV irradiation to small foci. To compensate 
for the reduced amount of irradiation reaching the cell through the pores when comparing it 
to the 20 J/m2 that were used for uncovered cells in 12-well plates, an energy of 500 J/m2 
was applied to micro pore filters. 
3.1.5 Generation of cell lysates for SDS-PAGE 
For immunoblot analysis following SDS-PAGE, whole cell lysates were generated. To this 
end, cells were grown, transfected and treated in 6-well plates or 12-well plates. For cell 
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harvest, the plate was put on ice, the supernatant was aspired and the wells were once 
washed with 4 °C cold PBS. Then, 1000 µl (6-well plate) or 500 µl (12-well plate) PBS was 
added, and the cells were scraped off the well surface. The suspension was then transferred 
to a 1.5 ml tube and centrifuged at 1400 g for 4 min. The supernatant was discarded and 
the cells were re-suspended in 120 µl (12-well plate) or 60 µl (12-well plate) lysis buffer and 
sonicated for 5 minutes to shear the DNA and thus avoid high viscosity of the protein lysate 
caused by DNA smear. For the denaturation of proteins and the reduction of disulfide bonds, 
the samples were boiled for 5 min at 95 °C and 1400 rpm. When cooled down on ice, the 
lysates were either loaded on a polyacrylamide gel or stored at -20 °C. 
For the detection of apoptosis, the supernatant was harvested, as well, in order to include 
detached and floating apoptotic cells. The supernatant of the well was collected in 1.5 ml 
tubes, centrifuged and the supernatant of the tube without suspended cells was discarded. 
The cells that remained in the well were then scraped off in PBS without prior washing, and 
the suspension in PBS was added to the cell pellet in the tube. The tubes were vortexed, 
centrifuged again and the sample was once washed with PBS. All following steps were 
performed as above. 
If protein lysates from different cell lines or cell populations with different confluence should 
be compared, the respective protein concentration was determined using the Pierce BCA 
Protein Assay Kit according the manufacturer’s instructions. The protein concentrations 
were adjusted by diluting concentrated lysates with RIPA buffer. After that, 6x Laemmli 
buffer was added to a dilution of 6:1. All following steps were performed as above. 
 
3.1.6 Isolation of RNA 
For the quantification of gene expression, the specific mRNA levels were quantified in 
relation to the mRNA levels of a control gene using real-time PCR. Total RNA of a cell was 
isolated and transcribed into cDNA. To obtain the total cellular RNA, the phenol-chloroform 
extraction method was used (Chomczynski and Sacchi 1987, 2006). Cells were grown and 
treated in 6-well plates. For harvest, the medium was discarded and the cells were once 
washed with PBS. Then, 1 ml Trizol reagent was added and samples were incubated for 
5 min at RT to lyse cells and separate nucleotides from proteins. The lysates were 
transferred to a 1.5 ml reaction tube and 200 µl chloroform was added. After vigorously 
shaking the tubes and incubating them for 3 min at RT, the samples were centrifuged at 
4 °C and 12,000 g for 15 min to reach a clear phase separation. The colorless upper phase 
contained the RNA and was transferred into a fresh tube. Then, 500 µl isopropanol were 
added, the sample was shaken and incubated for 10 min at RT again followed by 
        Methods                                      60 
 
centrifugation for 15 min at 12,000 g. The supernatant was discarded and the pellet once 
washed with 75 % EtOH and centrifuged at 4000 g and 4 °C for 5 min. After aspirating the 
supernatant, another purification step was performed to reduce protein contamination: The 
RNA-containing pellet was resuspended in nuclease free water and again precipitated by 
addition of 300 nM sodium acetate (NaAc) and 75 % EtOH. After centrifugation at 4000 g 
and 4 °C for 5 min, the supernatant was discarded. The pellet was again washed in 75 % 
EtOH, centrifuged and, after removal of the supernatant, dried at room atmosphere for 5-
30 min. The pellet was then resuspended in 30 µl nuclease free water and purity as well as 
RNA concentration was determined using the NanoDrop Spectrometer. To this end, the 
absorbance was measured after excitation with different wavelengths and the quotient was 
taken to assess RNA purity:  A quotient of A260/A280 > 1.8 and A260/A230 > 2.0 was considered 
to be sufficient, with a lower quotient at A260/A230 indicating residual phenol contamination 
and lower quotients at A260/A280 indicating protein contamination. The RNA concentration 
was determined using the absorbance at 260 nm wavelength. 
 
3.1.7 Proliferation assay 
To determine the effect of a certain knockdown or treatment on cell proliferation, the 
confluence of a cell population was measured in the course of several days. To this end, 
the Celígo cell cytometer was used. It contains a bright field microscope and takes images 
which cover each well. These were then overlain by a manually optimized mask to 
determine cell borders by image contrast. The mask varied between the cell lines, but the 
same mask setting was used throughout an experiment. Based on that, the confluence of 
a well was calculated. 
Cells were seeded in triplicates to sub-confluent densities of at least 10 %, then having 
entered exponential growth. After 24 h, the confluence was determined for the first time and 
the cells were treated with gemcitabine and inhibitors. 24 h later, the treatment was washed 
out and the confluence was again measured. Thereafter, the confluence was determined 
daily and the medium was exchanged every 48 h.  
To test the effect of a knockdown on proliferation, cells were transfected with siRNAs in a 
6-well plate as described in section 3.1.3.1. The transfection mix was replaced by fresh 
medium already 12 h after transfection. 24 h after transfection, the cells were trypsinized, 
counted and plated in a 12-well plate in triplicates. 24 h later (48 h after transfection), the 
confluence was determined for the first time, and gemcitabine was added to the wells and 
washed out as described in the figures. Cell confluence was determined every day and 
medium was exchanged every second day. 
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3.1.8  Flow cytometry 
To assess the cell cycle profile of a population, the amount of DNA within the cells is 
quantified (Krishan 1975). The profile is generated by the assignment of the number of cells 
to their specific DNA content. This results in typical peaks which represent phases of the 
cell cycle, and the whole profile represents the period of time or the probability with which 
a cell is found to be in that respective phase of the cell cycle. A cell in G0 or G1-phase has 
a single copy of its DNA. While going through S-phase, the DNA content increases 
continuously and reaches its maximum in G2- and M-phase, when the amount of DNA has 
doubled compared to G0/G1-phase, right before the cell divides to enter G1-phase again. A 
typical cell cycle profile is depicted in figure 3.1 below: 
The fluorophore propidiumiodide (PI) intercalates in nucleotides of DNA and RNA and is 
therefore suitable to stain and afterwards quantify the DNA via the fluorescence intensity of 
a cell. PI does not penetrate the membranes of living cells, and that is why the cells need 
to be fixed before staining. For the specific correlation of fluorescence intensity to DNA 
content, the cellular RNA needs to be discomposed by the incubation with RNAse. The PI-
molecule itself emits light when it is excited, but the emission is strongly enhanced by 
nucleobases (for example in DNA and RNA) forming the direct neighborhood. Because only 
the size and DNA content of single cells is suitable for analysis, adherently grown cells need 
to be accurately trypsinized before they are fixed in order to avoid clotting of cells. 
Cells were thus seeded and treated in a 12-well plate according to the particular 












Figure 3.1 Cell cycle profile.  
Unsynchronized U2OS cells were harvested 
and analyzed as described in this chapter. 
Arrows point to phases of the cell cycle. 
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collected in a 15 ml tube which was placed on ice. The well was washed with 500 µl PBS, 
which was added to the tube. Then, 500 µl 0.1 % trypsin/EDTA were added to the well and 
incubated for 5 min. Afterwards, 500 µl culture medium containing trypsin inhibitor were 
added and those cells which were still attached or formed clots were loosened by up- and 
down pipetting. Then, the suspension was added to the tube which already contained the 
supernatant. The tubes were then centrifuged at 4 °C and 400 g for 7 min and directly 
afterwards cautiously put back on ice. The supernatant was aspirated and the cell pellet 
was resuspended in 500 µl 4 °C cold PBS ++ on ice. Fixation was done by the dropwise 
addition of 1.5 ml 100 % EtOH, which was pre-cooled to -20 °C, while the tube was slowly 
vortexed. When the final volume of 2 ml was reached, the tube was vortexed for 1 min at 
maximum velocity. Then, the sample was transferred to a 2 ml tube and incubated at least 
for on 1 h or stored at -20°C. 
The preparation of the cells for flow cytometer analysis took place on ice, with the centrifuge 
and solutions pre-cooled to 4 °C. Cells were centrifuged at 400 g for 10 min. The 
supernatant was removed and the cells were resuspended in 1 ml PBS++ and rehydrated 
for 10 min. Then, the cells were again centrifuged and the supernatant was removed. 100 µl 
RNAse A in a concentration of 1 mg/ml were then added and the tube was vortexed and 
incubated at 37 °C for exactly 30 min. After that, 400 µl PBS++ were added to a total volume 
of 500 µl per sample. Directly before flow cytometer analysis, 15 µl of PI staining solution 
was added to 500 µl of cell suspension to reach a final concentration of 30 µg/ml. 
For each sample, 10,000 counts/cells were measured to obtain a representative cell cycle 
profile. If the number of cells was expected to be too low to obtain this event count within 
the period of 10 min, less volume of PBS++ was used for the resuspension and then the 
volume of PI staining solution needed to be proportionally adapted.   
 
3.1.9  Cell synchronization with nocodazole block 
The cell cycle profile of randomly distributed, unsynchronized cells is only influenced if a 
treatment or knockdown has strong impact on a cell cycle checkpoint. Slight effects on cell 
cycle progression are usually equalized by the asynchronous cell cycle in exponentially 
growing cells. To assess more decent changes in cell cycle progression, cells can be 
arrested in different phases of the cell cycle and are thereby synchronized. One possibility 
to synchronize cells in G2/M-phase is the mitotic shake-off after nocodazole block. 
Nocodazole is an inhibitor of microtubule polymerization and prevents the formation of 
spindles in early metaphase. Therefore, cells treated with nocodazole enter mitosis, but are 
no longer able to assemble their chromosomes on the metaphase plate and are unable to 
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enter cell division (Nusse and Egner 1984; Tan et al. 2006). One morphological and 
functional feature of cells which enter mitosis is the detachment from other cells or a matrix 
in order to prepare cell division. Those detached cells can be collected and reseeded after 
the treatment is washed out. 
To this end, U2OS cells were seeded in a 10 cm or 20 cm petri dish and transfected with 
siRNA. After 24 h, the transfection mix was replaced by fresh culture medium, and the cells 
were incubated for another 24 h. After that, the cells were incubated with 100 ng/ml 
nocodazole for 16 h. The plate was then strongly hit against an object and the medium was 
pipetted strongly onto the cell layer in order to loosen detaching cells in mitosis that had not 
properly detached before. The supernatant with suspended mitotic cells was collected in a 
50 ml tube and centrifuged at 400 g for 7 min. The supernatant was aspired and the cells 
were resuspended in 20 ml pre-warmed culture medium, then centrifuged again at 400 g 
for 7 min. The supernatant was again discarded and the pellet was resuspended in 400 µl 
culture medium. Cells were counted and 180,000 cells/well were seeded in a 12-well plate 
and harvested at specific time points (figure 4.22). 
 
 
3.2  Molecular biology 
 
3.2.1  Polymerase chain reaction 
The polymerase chain reaction (PCR) is the method of choice to amplify whole genome 
DNA or DNA fragments in vitro on an enzymatic basis (Mullis and Faloona 1987). Thus, no 
organismal background is needed. It takes advantage of a thermostable polymerase which 
is activated or inactivated by up- and downregulation of the temperature only. When 
activated, it needs a starting point to bind to a specific part of the DNA and to start 
synthesizing a complementary DNA strand. Then, it continues its work as long as the DNA 
is not denatured, the polymerase activity is not reduced by temperature changes or the DNA 
template is finished. Such a starting point is formed by specific primers, which are DNA 
oligonucleotides complementary to the 3’-end of a sense and antisense DNA-sequence, for 
example of a gene of interest. The polymerase then adds the nucleotides to the free 3’-end 
of the primers which are complementary to the template. Three steps are thus repeatedly 
conducted during a PCR: First, the double stranded DNA is denatured by heat to become 
single stranded. Second, the temperature is lowered so that the primers can anneal to their 
specific DNA sequences. The temperature and primers are adapted, so that the primer’s 
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melting point (the temperature, when it dissociates from the DNA) is above the annealing 
temperature and that the annealing temperature is not low enough to allow the primers to 
pair with the DNA unspecifically. Third, the temperature is increased to the optimal reaction 
temperature for the thermostable polymerase, which then starts to synthesize a 
complementary DNA strand using dNTPs that are added to the reaction mix. We used 40 
repetitions of that cycle leading to a nearly exponential amplification of the DNA. PCR was 
used for cDNA synthesis from RNA and for the quantification of a gene transcript to either 
verify a specific knockdown or to assess the influence on gene transcription of a protein. 
Further, this method forms the basis for the microarray hybridization as described in 4.6. 
 
3.2.2  Quantification of messenger RNA by PCR 
The quantification of messenger RNA (mRNA) is used to investigate the expression of a 
gene on a transcriptional level. On the one hand, RNAi acts at this part of gene expression, 
and qPCR is a suitable method to quantify the knockdown efficiency. On the other hand, 
many proteins act as transcriptional regulators or even transcription factors, most prominent 
p53, and this method can be used to give insight in the influence of a specific knockdown 
or treatment on the transcription of another gene. 
RNA cannot be amplified by the thermostable polymerase used for PCR. Aside from that, it 
is not stable enough for multiple heating cycles. Therefore, it needs to be transcribed into 
DNA as described below before PCR is applied. 
 
3.2.2.1 Reverse transcriptase PCR 
RNA which was isolated as in 4.1.6 was reverse transcribed using the enzyme reverse 
transcriptase (RevT), which is expressed by various viruses. Here, the viral M-MuLV RevT 
derived from a murine leukemia virus was used to obtain complementary DNA (cDNA) from 
RNA. The most essential difference to genomic DNA is that cDNA lacks introns, but is a 
copy of the transcriptome of the cell, meaning that cDNA results only from the minority of 
genomic DNA that is actively transcribed. 
For the cDNA synthesis, 1 µg of total extracted RNA was used and mixed with 2 µl of 100 µM 
mixed primers consisting of oligo-dT primers and random nonamers. While the oligo-dT 
primers are complementary to the poly-A-tail of an mRNA and used for the specific mRNA 
reverse transcription, random nonamers ensure reverse transcription of transcripts that lack 
a poly-A-tail. The addition of 4 µl dNTPs (2.5 mM each) ensured that substrate for DNA 
synthesis was abundantly available. Then, nuclease free water was added to a total volume 
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of 16 µl and the mix was heated to 70 °C for five minutes to resolve precipitated RNA and 
secondary RNA structures. 
The RevT reaction mix was prepared as in table 3.6. 
   
Table 3.6 Reaction mix for reverse transcription of RNA. 
Component Volume  
10x RT buffer 2.0 µl 
RNAse inhibitor 0,25 µl 
Reverse transcriptase M-MuLV 0.125 µl 
Nuclease free H2O 
 
1.625 µl 
Total volume 4 µl 
 
After the addition of the reaction mix to the 16 µl per sample RNA, primers and dNTPs, the 
samples were incubated at 42 °C for one hour to facilitate reverse transcription. Afterwards, 
the enzyme was inactivated at 95 °C for 5 min and the sample was slowly cooled down. 30 
µl nuclease free water was added to a total volume of 50 µl and the samples were stored 
at -20 °C. For every sample, a control without the addition of RevT was run as quality 
control. If qPCR should generate a specific transcript from this sample, it would indicate 
contamination with genomic DNA.  
 
3.2.2.2  Quantitative real-time PCR 
For qPCR, PCR is applied. Multiple cycles of DNA synthesis lead to nearly exponential 
amplification of a specific DNA fragment. If compared to the amplification of a control gene, 
it is possible to quantify relative gene expression. For the quantification of gene 
transcription, cDNA derived from total RNA extracts was used. Then, primer pairs were 
designed as described in section 2.8. The aim of the primer pair is to bind to specific DNA 
sequences within the cDNA of a gene of interest. The forward primer binds to the cDNA 
that in parts resembles the genomic DNA sequence of the gene, leading to the synthesis of 
a complementary DNA strand. The reverse primer can then bind to this complementary 
strand which leads to the synthesis of a DNA strand whose sequence is part of the cDNA 
strand. Thus, during all cycles, a DNA fragment which is spanned by the primer pair is 
amplified exponentially. In order to exclude the amplification of genomic DNA, the DNA 
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fragment spanned by a primer pair should exceed exon borders or be located in two different 
exons. The composition of the reaction mix for qPCR is detailed in table 3.7. 
  
Table 3.7 Reaction mix for qPCR. 
Component Volume 
25x qPCR reaction mix as detailed in 3 1.4 14 µl 
Forward primer (10 pmol/µl) 0.75 µl (final conc.: 0.3 pmol/µl) 
Reverse primer (10 pmol/µl) 0.75 µl (final conc.: 0.3 pmol/µl) 
cDNA 1 µl 
Nuclease free water 
 
8.5 µl 
Total volume: 25 µl 
 
The concentration of DNA is quantified after every replication cycle. This is achieved by the 
addition of SYBRGreen, a fluorescent dye whose light emission upon excitation is strongly 
enhanced when bound to DNA. The fluorescence intensity of a sample amplifying a gene 
of interest can thus be determined after every cycle and can be compared to the 
fluorescence intensity reached by the amplification of the DNA from a control gene, whose 
transcription is usually not influenced by treatments (in our experiments, either GAPDH or 
36B4 was used). Further, the melting point of the product in each sample is determined 
after every cycle, which serves as a control of product purity. A specific melting temperature 
is only achieved when a specific product is formed. All steps and time periods of the cycle 
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Table 3.8 Cycler program for qPCR. 
Temperature Time Operation  
95 °C 2 min Initial denaturation of 
cDNA 
 
95 °C 15 s DNA denaturation  
~ 60 °C, depending on 
melting temp. of primers 
30 s annealing  
 
72 °C ~ 2 min, depending on 
DNA fragment length 
elongation 40x 
55 °C -95 °C with 0.5 °C 
increment 
variable melting curve  
12 °C pause   
 
To quantify a PCR product, Ct values were used. The Ct-value is a measure for the number 
of amplification cycles at which the fluorescence of a sample reaches a previously defined 
threshold. Using the ΔΔCt method, it is now possible to calculate the original amount of 
cDNA template, assuming that the amplification was exponential and the PCR product 
doubled with every cycle. ΔCt values for the gene of interest and the reference gene can 
thus be calculated for the untreated sample:  
ΔCt (control) = Ct (ref. gene) – Ct (target gene)  
In the same way, the ΔCt value is calculated for the treated sample, for example after 
knockdown:  
ΔCt (treated) = Ct (ref. gene) – Ct (target gene) 
 If now the ΔCt values of treated and untreated samples are subtracted, this results in the 
ΔΔCt value, which is the logarithm to the base 2 of the relative template amount/mRNA 
expression or the relative gene expression: 
Relative gene expression = 2 ΔΔCt =2 (ΔCt (control) – (ΔCt (treated)) 
For every qPCR analysis, three technical replicates were done, and the average +/- SD 
gene expression was calculated. 
 
3.2.3 Heat-shock transformation of chemically-competent bacteria 
In order to amplify plasmid DNA to be used later for the artificial expression of a protein in 
eukaryotic cells, the chemically-competent bacteria strain DH10B was used. Plasmid DNA 
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which contained an ampicillin resistance gene was stored and shipped on filter paper. Prior 
to use, the DNA was extracted in the supernatant after the paper was soaked with nuclease 
free water and centrifuged. Afterwards, the nucleic acid concentration was determined. One 
vial of bacteria was taken from -80 °C storage, was thawed on ice and 50 µl of the bacterial 
suspension was incubated with 100 ng of plasmid DNA on ice for 30 min. Then, the vials 
were rapidly put to a 37 °C heating block and again incubated for 10 min, afterwards cooled 
down for 10 min on ice. After the addition of 50 µl of 2YT medium, 50 µl of the suspension 
was directly plated on a 2YT agar plate containing ampicillin. The plates were then 
incubated at 37 °C overnight to allow efficiently transformed bacteria to form colonies. For 
the further amplification of plasmid DNA, colonies were picked and grown in 2YT medium 
containing 200 µg/ml ampicillin (200 ml for MidiPrep and in 5ml 2YT medium for MiniPrep) 
overnight. 
 
3.2.4 Isolation of plasmid DNA 
Plasmid DNA was isolated from bacteria which were grown in 2YT medium overnight. For 
200 ml of bacteria culture the PureYield TM Plasmid MidiPrep System (Promega) and for 
5 ml bacteria culture the Invisorb Spin Plasmid Midi Kit Two (Invitec) was used according 
to the manufacturer’s protocol. Plasmid DNA as well as genomic DNA is denatured by an 
alkaline buffer. Whereas the comparably small plasmids are able to renature their DNA 
upon neutralization of the solution, genomic DNA remains denatured and can be 
precipitated. The plasmid-containing supernatants are led over silica columns which absorb 
the plasmid DNA. After washing with ethanol, the plasmids are incubated in an aqueous 
solution and are eluted from the column. 
 
3.2.5 Determination of nucleic acid concentrations and purity 
For the determination of nucleic acid concentrations and the purity of nucleic acid solutions, 
the NanoDrop Spectrometer was used. 2 µl of a sample were measured in duplicates. The 
concentration of RNA and DNA was determined using the absorbance at 260 nm 
wavelength. To determine the purity of a nucleic acid solution, the absorbance quotient was 
measured after excitation with different wavelengths and the quotient was taken to asses 
DNA and RNA purity: A quotient of A260/A280 > 1.8 and A260/A230 > 2.0 was considered to be 
sufficient, with lower quotients at A260/A280 indicating protein contamination.  
 
 




3.3.1 Separation of proteins by SDS-PAGE 
The separation of proteins of a whole cell lysate according to their molecular weight and 
subsequent detection with specific antibodies allows to investigate total protein levels and 
protein modifications as consequence of a treatment. Following the separation in an 
electrical field, the proteins are transferred to a membrane which is then decorated with an 
antibody against the antigen of interest. 
The SDS-PAGE (Sodium Dodecylsulfate Polyacrylamide Gel Electrophoresis) is based on 
the denaturation and subsequent coating of proteins by the anionic detergent SDS (Shapiro 
et al. 1967). Denaturation and the reduction of disulfate bonds excludes an influence of the 
secondary, tertiary and quaternary structures of the protein on its mobility in an electric field 
through pores in the gel (Laemmli 1970). The association of SDS to the protein occurs on 
positively charged amino acids, which are thus neutralized and bridged by the SDS 
molecule. As a consequence, a negative overall charge of the proteins results, which makes 
the proteins travel constantly towards the anode in the applied electrical field. The velocity 
is only hampered by pores in a polyacrylamide gel, which leads to the separation of the 
proteins according to their molecular weight. Additionally, the percentage of acrylamide in 
a gel determines the pore size with increasing acrylamide concentrations leading to a tighter 
crosslinking of the polymer and thus smaller pores. The best separation of proteins can 
therefore be achieved by adjusting the gel composition, with 6 % acrylamide leading to the 
best separation at high molecular weight proteins over 200 kDa and 12 % acrylamide 
accurately separating proteins smaller than 50 kDa, while in the rest of the gel, a stacking 
of proteins at a certain protein size predominates.  
The gels were manually prepared and consisted of two parts: The upper fourth was a 
stacking gel buffered by a Tris buffer with a pH of 6.8 and 5 % acrylamide, containing ten 
to twelve pockets to load the protein lysates. After loading, a constant voltage of 80 V was 
applied. The large pores and a lower pH led to a stacking and focusing of proteins at the 
border of the gel parts. After entering the resolving gel in the lower three fourth of the gel 
chamber, the voltage was increased to 120-140 V, a higher pH of 8.8 reduced remaining 
positive charges of the proteins and smaller pores ensured the separation of the proteins 
by their size.  
For orientation and to indicate the protein separation and size, a protein ladder with pre-
stained proteins of a defined size was loaded in one of the pockets of every gel.  
The composition of the gels is detailed in table 3.9. 
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Table 3.9 Composition of gels for SDS-PAGE. 
 Final concentration in gel 
Component stacking gel resolving gel 
Acrylamide-bisacrylamide 5 %  6 %, 10 %, 12 % 
Tris, pH 6.8 (1 M) 126 mM - 
Tris, pH 8.8 (1.5 M) - 375 mM 
SDS (10 % stock) 0.1 % 0.1 % 
APS (10 % stock) 0.1 % 0.1 % 
TEMED 0.3 % 0.4 % 
 
3.3.2 Immunoblotting/Western Blot 
Proteins separated by SDS-PAGE need to be transferred to a membrane to make them 
accessible for immunostaining (Towbin et al. 1979). When the proteins were sufficiently 
resolved by SDS-PAGE, the procedure was stopped and the proteins were 
electrochemically transferred to a nitrocellulose membrane using the wet blot technique. To 
ensure a proper contact with all parts of the membrane to the gel, every component was 
previously soaked in Western Blot transfer buffer (section 3.4) and the gel together with the 
membrane was padded in a stack between multiple layers of Whatman paper and sponges 
(fig. 3.2).  
 
Figure 3.2 Component assembly of a wet blot experiment. 
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The stack was fixed with two plane plastic clips and vertically placed into a blotting chamber. 
The chamber was filled with pre-cooled Western Blot transfer buffer and placed into an ice 
box. The blotting procedure was performed at 4 °C atmosphere temperature. A constant 
voltage of 100 V was applied for 90 min in case of 10 % and 12 % gels and 30 V were 
applied overnight or at least 8 h in case of 6 % gels. The proteins traveled to the anode side 
of the gel and were electrostatically immobilized on the nitrocellulose membrane. After 
disassembly of the blotting components, the efficient and even protein transfer to the 
membrane was controlled. To this end, it was incubated in Ponceau S solution (section 2.4) 
for unspecific staining of proteins. 
 
3.3.3 Immunostaining 
The amount of a protein or its posttranslational modifications can be detected by specific 
antibodies. A primary antibody directed against the protein or its modification forms the 
specific part of immunostaining. The primary antibody is then coupled to a secondary 
antibody that is specific for the constant region (Fc-part) of the organism from which the 
primary antibody is derived. The second antibody is coupled to horseradish peroxidase 
(HRP). When luminol is added as substrate, it is oxidized by HRP, which leads to emission 
of light. The intensity of that chemoluminescence is then detected by a camera and the 
signal can be quantified and digitally amplified for visualization. 
To perform the above described process, the membrane loaded with protein by 
immunoblotting was incubated with blocking solution (section 2.4) for 1 h at room 
temperature. After one washing step with TBST, the membrane was incubated with the 
primary antibody dissolved in blocking solution or BSA for 3 h at room temperature or 
overnight at 4 °C (for applied antibodies, see table 2.11) and then thoroughly rinsed three 
times with TBST solution, while for the third washing step, TBST was incubated for 5 min. 
The appropriate secondary antibody with a dilution of 1:10,000 in blocking solution was then 
added and the membrane was incubated for 1 h at RT (for applied secondary antibodies, 
see table 2.13). To reduce unspecific antibody binding, the membrane was afterwards 
washed in three steps as before. For the HRP reaction, luminol substrate was added 
dropwise to the membrane until it was completely covered and chemoluminescence was 
subsequently detected using a Chemocam HR 3200 imager and processed with the 
ChemoStar Imager software. 
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3.3.4  Staining for immunofluorescence microscopy 
Proteins or their modifications can be visualized within a cellular context by 
immunofluorescence microscopy. In contrast to immunoblot analysis, it is thus possible to 
register the cellular localization of a protein and to demonstrate the interaction with binding 
partners or subcellular structures. Using quantitative immunofluorescence, alterations in 
protein levels can be visualized and quantified as with immunoblotting, but a much higher 
sensitivity can be reached and the fluorescence signal can be easily quantified.  
In general, samples are incubated with a primary antibody to a protein of interest. The 
secondary antibody is then directed against the constant region (Fc-part) of the primary 
antibody, which is specific for the organism from which the primary antibody is derived. The 
secondary antibody is coupled to a fluorescent dye which upon excitation emits light of a 
specific wavelength. Thus, several proteins can be assessed at a time, as long as the 
primary antibodies have different source organisms and the spectrum of the emitted 
wavelengths of the secondary antibodies do not overlap. 
Immunofluorescence was used to assess the cellular localization of overexpressed HA-
tagged CHD8. To this end, U2OS cells were seeded in an 8-well chamber slide and 
transfected with HA-tagged CHD8 expression vector as described in section 3.1.3.2. 24 h 
after transfection, the cells were UV-irradiated with 50 J/m2 at 1 h, 30 min or 1 min before 
fixation or left untreated. For one well at each irradiation time point, the medium was 
aspirated and a pre-cut micro pore filter with a pore size of 3 µm was cautiously lain on the 
cell layer in the well. Those filter-covered wells were irradiated with 500 J/m2 (3.1.4.3). 
Afterwards, fresh culture medium was added and the filter swimming on the surface could 
be removed.  
The fixation of the cells and the staining for immunofluorescence took place at RT. Cells 
were fixed with 3.6 % formaldehyde in PBS++ for 20 min, then rinsed twice with PBS and 
permeabilized with 0.5 % Triton X-100 in PBS++ for 10 min. After that, cells were rinsed four 
times with PBS++ and a fifth time with PBS before the cells were incubated with IF blocking 
solution for 10 minutes. Then, the primary antibodies to HA-tag and CPDs were diluted in 
IF blocking solution (table 2.12) and incubated for 1h. Afterwards, the primary antibody was 
removed and the wells were washed three times with IF blocking solution which was 
incubated for five minutes at the third washing step. Then, the secondary antibody (rabbit 
anti Myc-tag and mouse anti CPDs, respectively) with a dilution of 1:1,000 in IF blocking 
solution was added to the wells for 45 min. To this solution, Hoechst was added with a 
dilution 1:2,000 to a final concentration of 0,5 µg/ml to stain nuclei. As Hoechst and Alexa 
dyes are light sensitive, the plate was covered with a light-proof box during incubation times. 
After washing three times with PBS, and after the third washing step had incubated for 
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5 min, the cells were covered with a cover slip and analyzed using a Zeiss Confocal LSM 
510 meta microscope. The slides were stored in the dark. 
For quantitative immunofluorescence, cells were grown, transfected and treated in a 96-
well plate in triplicates. Afterwards, the cells were fixed and stained as above. A mouse anti 
γH2AX antibody was used as primary antibody at a dilution of 1:1,500 and a secondary 
antibody Alexa546 anti mouse was diluted 1:2000. Again, Hoechst was added to the 
secondary solution to the above concentration to stain nuclei. After the last washing step, 
100 µl PBS was added to each well and the plate was covered with a light proof sealing foil. 
It was directly subjected to quantitative immunofluorescence or stored at 4 °C protected 
from light. 
If EdU labeling took place (section 3.1.4.2), its detection had to be carried out before adding 
any blocking solution to the wells. As already described, the ethinyl group and even more 
the later added azide and Alexa-dye are light sensitive, so the complete fixation and staining 
needs to take place protected from light. After fixation, permeabilization and washing of the 
cells, the Click-iT EdU Alexa Fluor High-throughput Imaging Assay kit was used according 
to modified manufacturer’s instructions. Thus, a click-iT® reaction cocktail was prepared as 
in table 3.10: 
 





The reaction cocktail was incubated for 30 min at RT, while the plate was swayed and 
protected from light. Then, the cells were washed twice with PBS and incubated with Click-
iT EdU reaction rinse buffer for 5 min. This buffer contained uncoupled azide to occupy all 
unspecific binding sites for an azide group and to displace the dye-coupled azide from 
these. After washing again with PBS, IF blocking solution was added and counter staining 
with antibodies was conducted as described above. The azide was coupled to an Alexa488 
dye so that for the counterstaining with antibodies, dyes with other excitation wavelengths 
 
Reaction components 
Number of wells 
10 50 100 
1X Click-iT EdU reaction buffer 
(1:15 from stock) 
510 µl 2.55 ml 5.1 ml 
CuSO4 24 µl 120 µl 240 µl 
Alexa Flour Azide 0.3 µl 1.5µl 3 µl 
1X Click-iT EdU buffer additive 60 µl 300 µl 600 µl 
Total volume 594 µl 2.97 ml 5.94 ml 
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and different emission spectra had to be used. For the counterstaining of γH2AX, the 
Alexa546 anti mouse antibody was used. 
Separate special conditions for high-content screening are specified below. 
 
3.3.5  Quantitative immunofluorescence microscopy 
H2AX phosphorylation and EdU incorporation were quantified using a high-content 
immunofluorescence microscope (BD Pathway 855). For this, cells were grown, treated, 
fixed and stained as detailed above in 96-well plates. Using the BD Pathway software, the 
protocol for microscopy was adapted for every experimental setting, for example occupied 
wells and used excitation and light detection channels as well as focus definitions were 
adapted. Firstly, the region of interest (ROI) was identified, which was the Hoechst-stained 
nucleus in our experiments. Within this ROI, the emitted light of each channel was quantified 
and either the median or average of all ROIs of a well was calculated. For screening, the 
EdU and γH2AX intensities were calculated for each single well as there were no replicates 
within one plate. For all other experiments, the medians or averages of all ROIs of a well 
were calculated. Then, Microsoft Excel was used to subtract background fluorescence and 
to calculate the average and standard deviations of triplicates for each treatment. 
 
3.4  Statistical analysis 
If not stated differently, average values of triplicate samples were calculated for quantitative 
immunofluorescence and cell proliferation experiments. Standard errors and standard 
deviations were calculated as described in the respective figure legend. To assess 
statistical significance, an unpaired, two-tailed student’s t-test was applied. P-values were 
assigned to asterisks as follows: 
p < 0.05 * 
p < 0.01 ** 
p < 0.001 *** 
n.s. not significant 
 
Calculations were done using Microsoft Excel.  
For statistical analysis of the high throughput siRNA screen, see below. 
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3.5  High-content screening procedure 
 
To shed light on novel factors which influence the cellular response to gemcitabine 
treatment, we performed a high-content screen using RNA interference (RNAi) to deplete 
pancreatic cancer cells of single proteins (Conrad and Gerlich 2010). 
3.5.1  siRNA library: content, design and preparation 
For the high-content screening procedure, a pre-designed siRNA library from the GENICA 
consortium was used. It contained 1,743 siRNAs targeting 551 human gene products which 
have previously been described to be involved in genomic integrity, cancer development 
and DNA modification. Positive and negative controls were customized. Within the library 
all siRNAs were SilencerSelect siRNAs obtained from Ambion. Every included gene product 
was targeted by three different siRNA sequences. The library was provided in 21 96-well 
PCR plates with 1 nmole of lyophilized siRNA in each well. To each plate, the negative 
controls SiSel_NC1 and SiSel_NC2 as well as the positive controls ATR, Mdm2, p53 and 
MK2 were added in a random order. The very right column of the plate was left unfilled for 
the manual addition of accessory controls. 
To the eight empty wells of the very right column, we manually transfected two additional 
negative controls and the knockdown of Chk1 itself as well as the ubiquitin ligase RNF8 as 
positive controls. RNF8 is recruited to sites of DNA damage and ubiquitinates the histone 
variants H2A and H2AX, leading to assembly of DNA repair proteins and to an amplification 
of the DDR. The upper four wells were treated with gemcitabine like the remaining plate, 
whereas the lower four rows were transfected in the same way but left untreated as quality 
control for the efficient impact of gemcitabine treatment. 
For the preparation of siRNAs, the PCR plates containing the lyophilized siRNA were 
thawed on ice and shortly centrifuged. The sealing foil was removed and 100 µl of nuclease 
free H2O were added to a final concentration of 10 µM in the original screening plates using 













= 10 µ𝑀 
Afterwards, dilution plates were installed and the library stock was diluted to a 500 nM stock 
which was used for screening. To this end, 152 µl nuclease free water was pipetted to the 
conic dilution plate and 8 µl of the 10 µM siRNA stock were added: 
𝑐(𝑠𝑖𝑅𝑁𝐴 − 𝑑𝑖𝑙) =
1
20






= 5 ∗ 10−7 = 500 𝑛𝑀 
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For each transfection of the screening procedure, 6 µl of the dilution plate were used as 
detailed below. The original screening plates as well as the dilution plates were covered 
with sealing foil and stored at -20 °C. 
 
3.5.2  Screening procedure 
5,000 PANC-1 cells were seeded in 96-well plates. After 24 h the transfection mix was 
prepared using the Biomek 2000 Laboratory Automated Workstation: 44 µl DMEM without 
any supplements were pipetted to each well of a conic 96-well plate. Then, 6 µl of the 
diluted, 500 nM siRNA were added and mixed by pipetting.  





∗ 500 𝑛𝑀 =
6
50






∗ 10−7 = 6 ∗ 10−8
𝑚
𝑙
= 60 𝑛𝑀  
The controls in the very right row were added manually. Then, 6 ml DMEM without 
supplements were mixed with 120 µl and incubated for exactly five minutes. Then, it was 
put to a reservoir for multichannel pipetting and 50 µl of the lipofectamine solution were 
added to the siRNA dilution. After 20 min incubation time, 50 µl of the transfection mix were 
added to the wells which contained the growing cells with 100 µl culture medium with all 
supplements. Thus, the amount of siRNA reached a final concentration of 10 nM.  
The following steps were performed manually: 24 h after transfection, the medium 
containing transfection mix was replaced by fresh medium and incubated another 24 h to 
let the cells recover. 48 h after transfection, the medium was removed and 70 µl 7.5 µM 
EdU were added to the cells as detailed in 3.1.4.2. After 2 h, the EdU-containing culture 
medium was removed and cells were washed twice with pre-incubated culture medium. 
Then, 300 nM gemcitabine diluted in pre-incubated culture medium with all supplements 
was added and incubated for 22 h. Cells were then fixed and stained as described in 3.3.4 
using a mouse anti γH2AX primary antibody diluted 1:1,500 in IF blocking solution and an 
Alexa546 anti-mouse secondary antibody with a dilution of 1:2,000 together with Hoechst-
dye for nuclear staining. 
 
3.5.3  Data acquisition and analysis 
The BD Pathway 855 System was used for automated microscopy and quantitative image 
analysis. To include most of the cells within a well, nine images of each well were taken. 
First, nuclei were identified by Hoechst staining and defined as regions of interest (ROI). 
Within the ROI, the Alexa488 and Alexa546 fluorescence intensity was quantified. For each 
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sample, a total ROI count of 800 to 2,500 was achieved. Of those, the median fluorescence 
intensity was calculated using an R-based analysis tool for EdU and γH2AX intensity. To 
establish a gate for replicating cells, the EdU threshold was defined as the doubled 
background fluorescence intensity for EdU, which included around 15-30 % of the cell 
population in each well. 
For the normalization of all samples within the wells and to achieve comparability of all 
plates, a robust z-score was calculated (Birmingham et al. 2009; Brideau et al. 2003). This 
avoids typical problems of control-based approaches, like treatment anormalities, positional 
effects, variation among controls and outliers among controls. For median-based analysis 
methods, it is assumed that all samples follow a normal distribution and candidates are 
identified as outliers. Compared to a z-score, the robust z-score is based on the plate’s 
median instead of its average and is therefore less sensitive to outliers for the calculation 
of a reference value for every plate. The robust z-score is the number of standard deviations 
of every sample from the median intensity of a plate. First, the median absolute deviation 
(MAD) was calculated. It equals the standard deviation of the median of each plate. 
Then, the robust z-score was calculated: 
𝑟 − 𝑧 − 𝑠𝑐𝑜𝑟𝑒
=
(𝑚𝑒𝑑𝑖𝑎𝑛 𝑅𝑂𝐼 − 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒) − (𝑚𝑒𝑑𝑖𝑎𝑛 𝑠𝑎𝑚𝑝𝑙𝑒 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑝𝑙𝑎𝑡𝑒)
𝑀𝐴𝐷
 
The median ROI-intensity of sample was calculated for every well, thus for every siRNA 
using the R-based analysis. The median sample intensity of a plate was calculated from the 
median of all sample values (median ROI-intensity of sample). Thus, the robust z-score 
could be calculated for every siRNA and is a measure for the impact of each siRNA 
corrected for plate to plate variations which occur during transfection and 
immunofluorescence staining.  
 
3.6  Microarray hybridization 
 
To identify genes whose transcription is promoted or suppressed by the presence of CHD8, 
we performed a whole genome gene expression analysis in U2OS cells using the 
Agilent/Affimetrix platform in an 8x60 K Array format. We transfected three different 
SilencerSelect siRNAs to knock down CHD8 and compared them to three control 
transfections with SilencerSelect NC1 and NC2 and a Silencer NC1 siRNA. U2OS cells 
were reversely transfected in a 6-well plate as described in 3.1.3.1. 14 h after transfection, 
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the medium was replaced by fresh culture medium and the cells were grown another 25 h. 
39 h after transfection, the total RNA was isolated (4.1.6). Total RNA extracts were given to 
Dr. Gabriela Salinas-Riester of the Transcriptome and Genome Analysis Laboratory (TAL) 
at the Georg-August-University of Göttingen. After quality control, the RNA was hybridized 
to an Agilent/Affimetrix chip for whole transcriptome analysis. Statistical analysis was done 
by Dr. Claudia Pommerenke. Candidate genes were defined as those whose transcription 
was doubled or reduced by half after CHD8 knockdown in all CHD8-depleted samples 
compared to all control samples. Statistical significance was assumed when the false 
discovery rate (FDR) was below 5 %.
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4. Results  
 
 
4.1 Preliminary work 
 
4.1.1  Sensitivity of pancreatic cancer cells towards gemcitabine treatment 
correlates with the amount of induced γH2AX 
The phosphorylation of the histone variant H2AX (then called γH2AX) has been proven to 
be a hallmark of DNA damage. It also serves as a global readout to determine to which 
extent DNA is damaged independent of the kind of damaging agent or process. However, 
as the aim of gemcitabine treatment is to drive cancer cells into apoptosis, modulators of 
gemcitabine sensitivity should not only provoke alterations in cellular γH2AX levels, but 
influence cell viability after that kind of chemotherapy.  
Pancreatic cancer cells differ largely in their intrinsic sensitivity towards gemcitabine. The 
higher the endogenous resistance of a cell, the less will be the potential influence of a target 
protein to increase resistance further. An intermediate sensitive cell line will provide the 
possibility to identify mediators that render the cells more sensitive on the one hand, but 
also identify factors that promote gemcitabine resistance on the other hand. 
We therefore performed cell proliferation assays with the four cell lines BxPC-3, 
MIA PaCa-2, PANC-1 and PaTu8902 (all derived from pancreatic adenocarcinoma) to 
determine their intrinsic gemcitabine sensitivity and identify cell lines with moderate 
sensitivity. All available cell lines harbor a p53 mutation and only BxPC-3 possess wild type 
KRAS, whereas this is mutated in MIA PaCa-2, PANC-1 and PaTu8902 (Ahmed et al. 
2008). As shown in figure 4.1.a, BxPC-3 are highly sensitive to gemcitabine, and already 
concentrations as low as 50 nM extensively impair cell growth. We ascribed moderate 
sensitivity to MIA PaCa-2 and PANC-1, as low gemcitabine concentrations do not affect cell 
proliferation, but treatment with 100 nM gemcitabine or more results in growth delay. 
PaTu8902, being the most resistant cell line, did not respond to gemcitabine concentrations 
lower than 200 nM and even recovered quickly from treatment with higher concentrations.  
The extent of gemcitabine resistance correlates not only with endogenous γH2AX 
levels (Fig. 4.1 b, untreated cells) – it is the ability of gemcitabine to induce γH2AX in those  
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Figure 4.1 Sensitivity of pancreatic cancer cells towards gemcitabine treatment correlates with the 
amount of gemcitabine-induced γH2AX. 
(a) Pancreatic cancer cells display high, intermediate or low sensitivity towards gemcitabine. BxPC-3, 
MiaPaCa-2, PANC-1 and PaTu8902 cells were seeded and cell confluence was determined the next day 
before gemcitabine was added in concentrations as indicated. After 24 h, the treatment was washed out and 
confluence was determined using bright field microscopy and digital image analysis every day for 18 days. 
(b) Corresponding endogenous and inducible γH2AX levels in pancreatic cancer cells. Cells where treated 
with 300 nM gemcitabine for 24 h, fixed and stained for immunofluorescence analysis and γH2AX levels 
where quantified. 
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cell lines that decreases with increasing resistance to this agent (Fig. 4.1 b, treated 
compared to untreated cells).  
We therefore conclude that endogenous and inducible γH2AX levels reflect gemcitabine 
sensitivity in pancreatic cancer cells: High endogenous γH2AX levels indicate resistance, 
and to a high extent inducible γH2AX levels indicate sensitivity towards gemcitabine 
treatment. More important for the high-content screening procedure is that, by using γH2AX 
as the main readout, it not only provides a measure for the influence of prospective 
candidates on DNA damage signaling, but also a chance to identify them as mediators of 
gemcitabine sensitivity. 
 
4.1.2 The kinases MK2 and Chk1 modulate gemcitabine sensitivity in pancreatic 
cancer cells in opposite directions 
As previously introduced, the kinase Chk1 is a potent determinant of DNA damage signaling 
following replicative stress after chemotherapy. It attenuates DNA replication, leads to cell 
cycle arrest and activates DNA repair or apoptosis pathways. Inhibition as well as 
knockdown of Chk1 leads to massively increased DNA damage signaling and apoptosis in 
U2OS and other cancer cell lines, which has made Chk1 an attractive drug target.  
The kinase MK2 is essential for the induction of H2AX phosphorylation after replicative 
stress. In contrast to the cellular reaction to Chk1 knockdown, depletion of MK2 reduces 
γH2AX levels induced by gemcitabine and UV treatment and helps the cells to overcome 
replicative stress induced by gemcitabine. MK2 has previously been characterized as 
mediator of the DDR after replicative stress and gemcitabine in osteosarcoma cells in our 
lab, antagonizing the effects of Chk1. As gemcitabine is one of the predominant treatment 
agents for pancreatic cancer, we evaluated the MK2/Chk1-system as a determinant of the 
gemcitabine response in pancreatic cancer cells, too. 
 
4.1.2.1  MK2 is a determinant of the gemcitabine response in  
pancreatic cancer cells  
To test whether MK2 mediates DDR in pancreatic cancer cells, too, we treated BxPC-3, 
MIA PaCa-2, PANC-1 and PaTu8902 cells with gemcitabine and MK2 inhibitor and 
determined the influence on γH2AX levels using immunoblot analysis. Indeed, H2AX 
phosphorylation induced by gemcitabine significantly decreased when MK2 was inhibited 
(Fig. 4.2 a-d). The same was true for PANC-1 cells depleted of MK2 (Fig. 4.2 e). The effect 
was most pronounced in gemcitabine-sensitive BxPC-3 cells and still distinct in those cell  
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lines with intermediate gemcitabine sensitivity, but hardly detectable in gemcitabine-
resistant PaTu8902 cells (Fig. 4.2 d). We therefore conclude that MK2 activity is 
essential for H2AX phosphorylation after gemcitabine treatment in pancreatic cancer cells, 
particularly in those sensitive to gemcitabine treatment. 
To assess whether this dependence also holds true for cell growth and survival, we 
performed a cell proliferation assay. While gemcitabine treatment induced growth arrest in 
all cell lines, this effect could be completely overcome by inhibition of MK2 in BxPC-3, 
PANC-1 and PaTu8902 cells and also partially in MIA PaCa-2 cells (Fig. 4.3). PaTu8902 
cells hardly responded to gemcitabine treatment, but MK2 inhibition provided a growth 
advantage in untreated as well as in gemcitabine-treated cells, which is probably due to a 




Figure 4.2 Inhibition or depletion of MK2 affects 
efficient H2AX phosphorylation in pancreatic 
cancer cells. 
(a) BxPC-3, (b) MIA PaCa-2, (c) PANC-1 and (d) 
PaTu8902 cells where treated with 100 nM 
gemcitabine for 24 h or left untreated, together with 
DMSO and MK2 inhibitor, respectively. H2AX 
phosphorylation was analyzed using immunoblot. (e) 
PANC-1 cells where depleted of MK2 by siRNA- 
mediated knockdown and 48 h after transfection left 
untreated or treated with 300 nM gemcitabine for 
22 h. Cells were then fixed and stained and γH2AX 
intensity was quantified using immunofluorescence 
analysis. Experiments of figures 4.2 a-d were 
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Thus, MK2 inhibition increases the proliferation rate in all pancreatic cancer cell lines and 
protects gemcitabine-sensitive pancreatic cancer cells from growth arrest induced by 
gemcitabine (Fig. 4.3 and (Kopper et al. 2014)). 
 
Figure 4.3 MK2 is a determinant of cell survival after gemcitabine-induced DNA damage. 
(a) BxPC-3, (b) MIA PaCa-2, (c) PANC-1 and (d) PaTu8902 cells were seeded and on day one left untreated 
or treated with 100 nM gemcitabine and DMSO or MK2 inhibitor for 24 h. Then, the treatment was washed 
out and new medium was added. Cell confluence was measured every day by bright field microscopy 
followed by digital image analysis. Data points represent average confluence with error bars representing SD 
of n=3. 
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4.1.2.2   Chk1 is a mediator of DNA damage signaling after gemcitabine treatment in 
pancreatic cancer cells and an antagonist of MK2  
To test whether MK2 activity is necessary for the effect of Chk1 inhibition as it is reported 
for U2OS cells (Kopper et al. 2013), we treated BxPC-3, MIA PaCa-2 and PaTu8902 cells 
with gemcitabine and either MK2 inhibitor, Chk1 inhibitor or both and analyzed γH2AX levels 
via immunoblot (Fig 4.4). Consistent with the results previously obtained in human 
osteosarcoma cells, Chk1 inhibition increased γH2AX levels after gemcitabine treatment in 
all pancreatic cancer cells and the extend correlated with their described gemcitabine 
sensitivity. However, this effect could be rescued by simultaneous MK2 inhibition. Thus, 
MK2 and Chk1 are crucial antagonistic players in the DDR after gemcitabine treatment in 
pancreatic cancer cells, too. 
4.1.2.3  Chk1 does not influence cancer cell proliferation after gemcitabine 
treatment in most pancreatic cancer cell lines  
In order to assess the impact of Chk1 inhibition on proliferation after gemcitabine treatment 
in pancreatic cancer cells, we performed a cell proliferation assay. Unexpectedly, Chk1 
inhibition did not sensitize three of four pancreatic cancer cell lines to gemcitabine 
treatment, but rather mediated resistance towards this chemotherapeutic (Fig 4.5). This is 
remarkable as Chk1 inhibition as well as its depletion both strongly enhanced γH2AX levels 
in all gemcitabine-treated cells (Fig. 4.4, 4.8), and it is obviously in contrast to a widely 





Figure 4.4 MK2 and Chk1 determine H2AX 
phosphorylation after gemcitabine treatment in 
pancreatic cancer cells. 
(a) BxPC-3, (b) MIA PaCa-2, (c) PaTu8902 cells 
were treated with 100 nM gemcitabine and DMSO, 
MK2 inhibitor, Chk1 inhibitor or both for 24 h. H2AX 
phosphorylation was analyzed by immunoblot. 
Conducted by Dr. Frederik Köpper 
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apoptosis as a consequence. Furthermore, our results demonstrate that in the case where 
Chk1 inhibition sensitizes pancreatic cancer cells towards gemcitabine treatment, which is 
in MIA PaCa-2 cells, this is highly dependent on MK2 activity, whereas all other cell lines 
do not show additional effects for inhibition of both, MK2 and Chk1. 
 
Figure 4.5 Inhibition of MK2 and Chk1 in gemcitabine-treated pancreatic cancer cells. 
(a) BxPC-3, (b) MIA PaCa-2, (c) PANC-1 and (d) PaTu8902 cells were seeded and on day one left untreated 
(left panel) or treated with 100nM gemcitabine (right panel) and DMSO, MK2 inhibitor, Chk1 inhibitor or both 
for 24 h. Then, the treatment was washed out and fresh culture medium was added. Cell confluence was 
measured every day by bright field microscopy followed by digital image analysis. Data points represent 
average confluence with error bars representing SD of n=3. 
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These results underline that the cell’s facilities to cope with induced DNA damage might be 
even more decisive for the cellular outcome than the extent of damage itself.  
In conclusion, these results suggest that the kinase MK2 is a potent mediator of gemcitabine 
sensitivity in pancreatic cancer cells. Whereas MK2 activity is needed to carry out the 
chemotherapeutic effects of gemcitabine, Chk1 activity seems to mediate the effect of 
gemcitabine consistently only in terms of DNA damage signaling and is in that context 
antagonized by simultaneous MK2 inhibition. In the subset of pancreatic cancer cell lines 
where Chk1 inhibitors act as chemosensitizers this effect completely relies on MK2.  
 
4.2   Optimization of systematic high-content cell screening in 
gemcitabine-treated pancreatic cancer cells 
 
While gemcitabine is the predominating chemotherapeutic drug in pancreatic 
adenocarcinoma, the survival after diagnosis of this type of cancer has not improved 
substantially over the years. Investigating Chk1 and MK2 in the gemcitabine response, we 
could show that the cellular fate following this treatment highly relies on DNA damage 
mediators. To shed light on novel factors which influence the cellular response to 
gemcitabine treatment, we performed a high-content screen using RNA interference (RNAi) 
to deplete pancreatic cancer cells of single proteins. After that, we treated the cells with 
gemcitabine and used the immunofluorescence-based quantification of γH2AX 
accumulation as global readout for DNA damage signaling. We aimed to identify so far 
unknown mediators of the gemcitabine response in pancreatic cancer cells. The screening 
conditions were optimized as follows. 
   
4.2.1  siRNA-mediated knockdown efficiency and cell growth morphology 
The efficiency of RNAi does not only depend on sequence and quality of the siRNA 
construct, but strongly varies between cell types and reagents. As RNAi is the method on 
which the high-content screen for DNA damage mediators was based, knockdown 
conditions needed to be optimized in a way that at least established siRNA constructs 
reliably led to the depletion of the respective target protein. Therefore, we first tested the 
siRNA-mediated knockdown with standardly used siRNAs and transfection reagents. Of 
all reagents, LF 2000 achieved the best cell survival and knock down efficiency after trans-
fection (data not shown). To quantify knockdown efficiency, all were transfected with siRNA  
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to p53 and absolute p53 levels were determined using quantitative immunofluorescence 
analysis (Fig. 4.6, right column). Although BxPC-3 cells have the lowest absolute p53 levels, 
knockdown of this protein was not successful. This excluded the cell line for the screening 
procedure. All other cell lines displayed good knockdown efficiencies. 
Another aspect in a cell line’s suitability for quantitative immunofluorescence is the 
accessibility of the region of interest (ROI). As we defined the nucleus as ROI, it is essential 
that the image processing software can separate neighboring cell nuclei. This is not possible 





























efficiency and cell 
growth morphology of 
pancreatic cancer 
cells.  
(a) BxPC-3, (b) MIA 
PaCa-2, (c) PANC-1 and 
(d) PaTu8902 were 
transfected with siRNA 
targeting p53 and 
fixation and staining for 
immunofluorescence 
was performed 48 h after 
transfection. p53 levels 
were determined using 
quantitative 
immunofluorescence 
and total p53 levels were 
used as criteria for the 
RNAi potential of the cell 
line. Light microscopic 
pictures of control-
transfected cells were 
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of the different cell lines at different levels of confluence (Fig. 4.6, left column), showing that 
MIA PaCa-2 and PANC-1 cells tend to detach from the dish surface and MIA PaCa-2 and 
PaTu8902 cells grow in multiple cell layers. Both effects resulted in a substantial cell 
population not available for quantitative immunofluorescence analysis. 
Thus, BxPC-3 could not be used for efficient transfection, while all other cell lines had 
restrictions which led to a decrease in ROIs suitable for γH2AX quantification. 
 
4.2.2  Treatment and readouts 
Gemcitabine-induced H2AX phosphorylation occurs in a dose- and time-dependent 
manner. Gemcitabine dose and treatment time were optimized to be high enough to 
distinguish γH2AX levels in treated and in untreated cells but not to induce maximum γH2AX 
which would overlay the effects of a knockdown. In the screen, we wanted to be able to 
examine the influence of knockdowns on γH2AX at a time point when other mediators of 
the DDR are still activated and later onset processes as DNA repair and apoptosis do not 
predominate yet. 
As expected, γH2AX levels increased with gemcitabine concentrations (data not shown). At 
intermediate concentrations of gemcitabine (200 nM), increased H2AX phosphorylation was 
evident 24 h after the beginning of treatment and further intensified after that.  
In contrast, Chk1 phosphorylation, considered earlier in the DDR than H2AX 
phosphorylation, started to increase already after 12 h of gemcitabine treatment and peaked 
after 24 h with markedly decreasing levels after that (Fig. 4.7). The activation of Chk1 went 
along with an increase in total Chk1 protein levels, which remained elevated when Chk1 
phosphorylation already decreased. This already marks an adaption process of the cell to 
cope with enhanced replicative stress and could have influence on the readout. To further 
exclude γH2AX induction being a secondary effect of apoptosis, PARP cleavage was 
determined. In PANC-1 cells, PARP cleavage was not yet detectable after 24 h of treatment, 
but clearly present after 48 h (Fig. 4.7).  
Thus, our results demonstrate that, for our purpose, treatment of cells with 300 nM 
gemcitabine for 20 h to 24 h is ideal. We therefore chose these conditions for screening. 
As already detailed in section 1.2.2, gemcitabine mainly acts during the process of DNA 
replication. Mediators of the gemcitabine response that specifically act during that process 
are of interest for two reasons: First, if the influence of a knockdown on γH2AX is 
emphasized during S-phase, it is to assume that the knocked down protein is part of a DDR  
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specific for gemcitabine. Second, if the DDR was activated mainly during S-phase, this 
would target rapidly proliferating cells as found in cancer. 
We thus aimed to identify those cells in our screen that have entered S-phase at the time 
of gemcitabine treatment. Replicating cells incorporate the nucleoside analog 
ethinyldeoxyuridine (EdU) when incubated with it. EdU can be coupled to a fluorescent dye 
by a chemical reaction and quantified using immunofluorescence. This creates additional 
readouts to the phosphorylation of H2AX in the screen: Overall EdU incorporation is a 
measure for the influence of a knockdown on DNA replication and was used as minor 
readout. EdU incorporation can further be used as gate to identify cells which actively 
replicate their DNA. In addition to the overall accumulation of γH2AX, we gated cells for 
EdU incorporation and quantified the accumulation of γH2AX in EdU-positive cells, too. 
Our data show that incorporation of EdU into the DNA is almost completely blocked after 
gemcitabine treatment, probably due to a complete stalling of DNA replication caused by 
gemcitabine. The labeling of replicating DNA therefore needs to take place before adding 
gemcitabine to the cells. Optimization experiments revealed that the EdU labeling is useful 
as a readout if it takes place 2 h prior to gemcitabine treatment (data not shown). At that 
point replicating cells have incorporated EdU to a measurable extend and are clearly 
distinguishable from non-replicating cells. Longer EdU labeling times would lead to more 
 
 
Figure 4.7 Central indicators of the DNA damage response and apoptosis are activated in a time-
dependent manner.  
(a) MIA PaCa-2 and (b) PANC-1 cells were treated with 300 nM gemcitabine for the indicated period of time 
and cell lysates were analyzed by immunoblotting. 
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EdU-positive cells, but would exceed the objective of the procedure which is to identify 
replicating cells at the time of gemcitabine administration. 
 
4.2.3  Variability of the readout γH2AX after transfection with control siRNA 
As mentioned above, gemcitabine-induced γH2AX should vary upon depletion of DNA 
damage transmitters. The influence on γH2AX accumulation was investigated for the 
following control knockdowns: 
Ring finger protein 8 (RNF8) is a known mediator of the DDR. It mediates the ubiquitination 
at Lys63 of the histone variants H2A and H2AX, which leads to the amplification of DNA 
damage signaling on the one hand and facilitates the recruitment of DNA repair factors on 
the other hand (Mailand et al. 2007). We previously ascribed a role for MK2 in the DDR, 
and that its depletion leads to reduced H2AX phosphorylation. ATR and Chk1 are well-
characterized mediators of the response to replicative stress.  
The knockdown of RNF8 reduced γH2AX levels in gemcitabine-treated MIA PaCa-2 and 
PANC-1 cells, and knockdown of Chk1 leads to an extensive induction of γH2AX in both 
treated and untreated cells. MK2 knockdown did not reliably alter γH2AX levels in MIA 
PaCa-2 cells, but reduced γH2AX in gemcitabine-treated PANC1 cells. Interestingly, 
depletion of ATR did not induce H2AX phosphorylation in MIA PaCa-2 and PANC-1 cells, 
 
 
Figure 4.8 γH2AX level in MIA PaCa-2 and PANC-1 cells are modulated by positive and negative 
controls within the library. 
Cells were transfected with siRNA against the indicated targets and treated under screening conditions 48 h 
after transfection. Cells were fixed and stained for immunofluorescence and γH2AX levels were quantified 
and corrected for background fluorescence. 
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although its knockdown is a well-established positive control in DNA damage screens using 
U2OS cells in our lab (Fig. 4.8). 
4.2.4  Conclusions 
Overviewing all results of the optimization experiments, we chose PANC-1 to be most 
suitable for high-content screening. BxPC-3 cells are not accessible for siRNA-mediated 
knockdown, PaTu8902 cells are highly gemcitabine-resistant with hardly any variation in 
endogenous γH2AX level and MIA PaCa-2 cells tend to grow in multiple cell layers. Also, 
MIA PaCa-2 did not react to two of four control transfections in one plate.  
The screening protocol was optimized to a time period of 2 h for the label of actively 
replicating cells followed by 22 h of 300 nM gemcitabine treatment in PANC-1 cells. 
 
 
4.3  High-content screen for mediators of the DDR after 
gemcitabine treatment 
 
With the high-content screening approach, we aimed to identify mediators of the 
gemcitabine response in pancreatic cancer cells. These could either be further developed 
as biological markers which predict the patient’s response to gemcitabine or they could be 
a potential target to overcome gemcitabine resistance. We chose a list of pre-selected 
genes involved in genomic integrity which we obtained via personal communication with the 
GENICA consortium (table 2.20). 
According to the list, we customized a siRNA library of siRNAs directed against 551 target 
proteins with diverse molecular functions.  
 
4.3.1  Screening procedure 
The focused GENICA library comprised three different siRNA sequences per target gene in 
separate wells of a 96-well plate. siRNAs to MDM2, p53, MK2 and ATR served as positive 
controls within the library, and we manually added siRNAs to Chk1 and RNF8 as positive 
controls and the non-targeting SilencerSelect control siRNAs #1 and #2 as negative 
controls. Four wells of the plate containing siRNAs to the manually added controls remained 
untreated to validate efficient gemcitabine treatment.  
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The procedure of high-content siRNA screening itself is described in section 3.5.2. In short, 
PANC-1 cells were transfected with siRNAs and treated with 7.5 µM EdU for 2 h to label 
cells currently replicating their DNA, followed by 300 nM gemcitabine for 22 h. Cells were 
then fixed and stained by immunofluorescence. While γH2AX was detected by a murine 
primary antibody and stained with an Alexa-dye-coupled secondary antibody, the ethylene 
group of EdU was bound to an azide-coupled Alexa-dye using click chemistry. Quantitative 
fluorescence microscopy was used to determine the amount of EdU incorporation and 
γH2AX accumulation.  
Statistical analysis of changes in fluorescence intensities as described in section 3.2.5.3 
was used to identify candidates. The main readout was the overall induction of H2AX 
phosphorylation and the H2AX phosphorylation in EdU-positive, i.e. actively replicating cells 
(Fig. 4.9 and 4.10). EdU-incorporation itself was only used as minor readout to assess the 
influence of a candidate on DNA replication (Fig. 7.1). 
We assigned a robust z-score to every siRNA and ranked all genes according to the 
cumulative robust z-score of all three siRNAs (Fig. 4.9 for overall γH2AX and Fig. 4.10 for 
γH2AX in EdU-positive cells). If a knockdown caused a decrease in γH2AX, the assumed 
role of the corresponding protein is that it promotes the DDR or increases gemcitabine-
induced DNA damage. Increased γH2AX levels after knockdown suggest that the protein 
negatively regulates the above processes. 
 
4.3.2  Strategies to identify candidates 
We used two different approaches for the identification of candidate genes to determine the 
response to gemcitabine treatment: 
First, we considered the cumulative robust z-score. A consistent and strong effect of all 
three siRNAs for a given gene would result in a high cumulative robust z-score and identify 
this gene as a candidate. In the case that for one gene the triplet of siRNAs showed small 
or even opposing effects, i.e. positive and negative influence on γH2AX, this would result in 
a low cumulative robust z-score, and the gene would not appear in the top of the list. Still, 
candidates which have diverging but not opposite effects on γH2AX levels remain. Single 
siRNAs can be outliers due to plate-to-plate variations, because high variations in γH2AX 
levels within one plate lead to a low robust z-score of each sample and the other way 
around. To compensate for that, we established a secondary screen and either confirmed 
or rejected the respective candidate.  
 




Figure 4.9 RNAi-based screening 
identifies mediators of H2AX 
phosphorylation following 
gemcitabine treatment.  
PANC-1 cells were transfected with 
siRNAs and exposed to 300 nM 
gemcitabine for 22 h. Cells were then 
fixed and stained for immuno-
fluorescence analysis. All target genes 
were ranked according to the 
cumulative robust z-score of γH2AX 
resulting from three different siRNA 
sequences for every target gene. The 
20 target genes with the highest and 
lowest cumulative robust z-scores are 
shown in magnification. PC=positive 
control 





Figure 4.10 Results of RNAi-
based screening for γH2AX 
levels gated for DNA-replicating 
cells.  
All target genes were ranked 
according to the cumulative robust 
z-score of γH2AX in replicating 
cells only. The 20 target genes 
with the highest and lowest 
cumulative robust z-scores are 
shown in magnification. 
PC=positive control 
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The 20 top genes whose knockdown caused increased or decreased H2AX phosphorylation 
are shown in figure 4.9 and 4.10. For the gene products with most influence on EdU 
incorporation, see supplementary figure 7.1. 
Second, we assumed that, if at least two of three siRNAs led to a significant change in our 
readouts, this was due to a true effect. In this approach, we considered those genes 
candidates which achieved a robust z-score of ≥ 2 or ≤ -2 with at least two of the siRNAs 
(listed in table 7.1 for overall γH2AX and in table 7.2 for γH2AX in EdU-positive cells). 
The second approach identified 27 candidates with significant changes in overall γH2AX 
levels and 39 candidates with significant changes of γH2AX levels in EdU-positive cells. 
Nine candidates were identified with both readouts, leading to a total number of 56 potential 
mediators of the gemcitabine response in pancreatic cancer cells using the second 
approach. 
After we had identified 56 candidates as hits with the second approach, we were interested 
whether, among them, certain relevant processes are overrepresented. We therefore used 
the DAVID functional annotation tool to find biological processes that are associated with 
the hits (Huang da et al. 2009b). Not surprisingly, with DNA repair and DDR, two major 
processes were overrepresented in a pre-selected library. Nucleotide metabolism and cell 
cycle regulation are also described in the gemcitabine response. A process which has not 
yet been studied in detail is the modification and remodeling of DNA and chromatin in 
response to gemcitabine. A plethora of histone modifications as consequence of DNA 
damage is known, and inhibitors which target histone modification enzymes, for example 
histone deacetylases, are under investigation for their clinical use (see also 1.7.1). 
However, not much is known about their role in the response to gemcitabine and even less 
about the underlying mechanisms. Several chromatin remodeling complexes are regulators 
of the DDR, but none of them has been connected to the clinics or at least to the cellular 
fate after gemcitabine treatment. We were therefore especially interested in candidates 
associated with chromatin remodeling processes.  
 
4.3.3  Control-based validation of the screen confirms mediators of the DNA 
damage response to gemcitabine in different cell lines 
While a statistical approach was needed for hit identification in a high throughput procedure, 
most of the experiments to further investigate candidates would be based on controls. We 
therefore chose a control-based approach for a secondary screen in PANC-1 cells with 29 
of the candidates identified in our primary screen. The candidates to be tested 
in a secondary screen were chosen because they either had shown a very strong effect on  
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H2AX phosphorylation or appeared promising to us after literature research. 
Three siRNAs for each candidate were collected on one 96-well plate in a random order 
together with triplicates of Chk1 siRNA and RNF8 siRNA as positive controls and triplicates 
of two different non-targeting siRNAs as negative controls. Thereafter, the procedure 
resembled that for screening, but while one plate was treated with gemcitabine, another 
plate was left untreated to investigate if the candidates already influenced our readout in 
untreated cells. Some of the previously identified candidates could be confirmed in the 
control-based experiment, while others showed no significant change in γH2AX levels 
compared to controls (see Fig. 4.11 for overall γH2AX levels and Fig. 7.2 and 7.3 for γH2AX 
levels in EdU-positive cells and for EdU intensities, respectively).  
 
Figure 4.11 Control-based validation of main hits confirms various known and novel mediators of the 
DNA damage response.  
PANC 1 cells were transfected with siRNAs as indicated and (a) left untreated or (b) exposed to 300 nM 
gemcitabine for 22 h. Cells were then fixed and stained for immunofluorescence analysis. All candidates were 
ranked according to cumulative relative changes in γH2AX and were normalized to γH2AX intensities of a 
control knockdown. Results from three different siRNA sequences for every target gene are shown.  
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Based on the secondary screen, we conducted a second selection of candidates and aimed 
to investigate their ability to influence the DDR in other cells than PANC-1. Thereby, we 
would be able to exclude that our candidates executed cell line-specific effects. We used 
the previously introduced pancreatic cancer cell lines MIA PaCa-2 with intermediate and 
PaTu8902 with low sensitivity towards gemcitabine, both harboring p53 mutations. The 
MK2/Chk1-system was primarily investigated in U2OS cells that are highly gemcitabine-
sensitive and that are extensively used for studies of the DDR. Therefore, we knocked down 
our hits in this cell line, too. As an additional aspect, U2OS cells are p53 proficient and can 
therefore give insight in p53-dependent effects (see Fig. 7.4-6 for details). 
Based on the secondary screen and the applicability to other cell lines, we selected four 
candidates, CHD8, HELLS, MCM10 and STAG2 for conformation experiments. 
CHD8 (Chromodomain-helicase-DNA binding protein 8) has not yet been investigated in 
the context of the DDR. It is reported to be a regulator of p53 activity, cell cycle progression 
and Wnt signaling. Also, it might be needed to sustain clearly defined borders between eu- 
and heterochromatin (detailed in Section 1.8.3). 
 
4.3.4  Knockdown efficiency and confirmation experiments of the main candidates 
We conducted another quality control of the four hits that we selected for further 
investigation. First, we confirmed the knockdown efficiency of each siRNA using reverse 
transcription and qPCR to ensure that the influence on DNA damage signaling was not 
primarily attributable to off-target effects (Fig. 4.12). We then aimed to ascertain the effect 
on γH2AX accumulation using immunoblot analysis. Unfortunately, it is not possible to 
isolate a pure population of replicating cells with this method. While the changes in γH2AX 
levels were no longer detectable for HELLS knockdown, we could still identify a slight 
increase of γH2AX levels in STAG2-depleted PANC-1 cells and a strong increase in 
MCM10- and CHD8-depleted cells (Fig. 4.13). Furthermore, we excluded changes in 
γH2AX levels being an off-target effect in consequence of reduced levels of the DNA 
damage factor Rad51. This has been identified to be a frequent source of false positives in 
high throughput DNA damage screens (Fig. 7.7) (Adamson et al. 2012).  
Based on all validation experiments and because it has, in contrast to other ATP-dependent 
chromatin remodeling factors, never been ascribed to DNA damage signaling before, we 
decided to further characterize the role of CHD8 in the DDR to gemcitabine. For a short 
discussion of the other candidates HELLS, MCM10 and STAG2 see section 4.2. 
 






Figure 4.12 Knockdown efficiency of siRNAs against the main hits of the screen.  
PANC-1 cells were transfected with the indicated siRNA and RNA was extracted 48 h after transfection. 
Relative mRNA levels of the indicated genes were quantified using qPCR and compared to 36B4 levels. The 
same experiment was repeated with GAPDH as control and resulted in comparable knockdown efficiency 
(data not shown). Error bars represent mean +/- SD of three technical replicates. 
 
 
Figure 4.13 DNA damage modulators after depletion of candidate proteins.  
According to screening conditions, PANC-1 cells were transfected with the indicated siRNAs and treated with 
300 nM gemcitabine for 22 h. Cell lysates were prepared for immunoblot analysis. 
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4.4  CHD8 is a mediator of the DNA damage response 
 
4.4.1  CHD8-depleted cells show enhanced DNA damage signaling after 
gemcitabine treatment 
 
After analysis and hit validation of the high-content siRNA screen, we found CHD8 to be the 
most promising candidate. We could repeatedly confirm that CHD8 knockdown increased 
H2AX phosphorylation in PANC-1 cells and now addressed the question whether CHD8 
has influence on other main regulators of the DDR. To this end, we depleted PANC-1 cells 
of CHD8 and subjected them to gemcitabine treatment. First, we demonstrated that CHD8 
levels are not influenced by gemcitabine-induced DNA damage. Further, we could validate 
 
 
Figure 4.14 Enhanced DNA damage response in CHD8-depleted PANC-1 cells is not a secondary 
effect due to the induction of apoptosis.  
PANC-1 cells were depleted of CHD8 as indicated and treated with 300 nM gemcitabine for 22 h. At the same 
time, 50 µM z-VAD was added to inhibit the caspase cascade leading to apoptosis. Cells were harvested and 
protein lysates were prepared for immunoblot analysis. 
  
 
Figure 4.15 CHD8 does not 
accumulate after DNA damage 
induction following gemcitabine 
treatment.  
PANC-1 cells were seeded, 
transfected as indicated and treated 
with 300 nM gemcitabine for 24 h or 
left untreated. Protein lysates were 
obtained for immunoblot analysis.  
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the knockdown of CHD8 on protein level (Fig. 4.14). Then, we knocked down CHD8 in 
PANC-1 cells using three different siRNAs and treated them with gemcitabine together with 
either DMSO or the caspase (cysteinyl-aspartate specific protease) inhibitor z-VAD to inhibit 
apoptosis (for the efficiency of z-VAD see Fig. 4.20). As shown in Fig. 4.15, gemcitabine 
treatment led to strong accumulation of pChk1 and pChk2, but depletion of CHD8 did not 
further influence pChk1 or pChk2 accumulation. Mutant p53 of PANC-1 cells is extensively 
phosphorylated upon gemcitabine treatment, but the phosphorylation is significantly 
reduced after CHD8 knockdown. Interestingly, mutant p53 total protein levels are reduced 
in PANC-1 cells by CHD8 depletion, in seeming contrast to the previously assigned role of 
CHD8 to suppress wild type p53 levels (Nishiyama et al. 2009). Importantly, we could 
exclude that the accumulation of γH2AX induced by CHD8 is a secondary effect of 
apoptosis, as caspase inhibition did not rescue the increased DDR after CHD8 knockdown 
(Fig. 4.15). This led us to assume that CHD8 is not part of the MK2/Chk1 system, but limits 
DNA damage signaling in a different way. Taken together, these results suggest that CHD8 
depletion increased the DDR upstream of the induction of apoptosis. 
 
4.4.2  CHD8 is a determinant of the DDR following UV irradiation 
UV irradiation causes damage in the DNA mainly through the formation of covalent bonds 
between nucleobases, which are CPDs and 6-4-PPs (see 1.2.1). Although the mechanism 
of damage is primarily different from that of gemcitabine as UV irradiation targets the DNA 
in every state and not only replicating DNA, the signaling pathways activated are similar. 
Both forms of DNA damage lead to stalled replication forks and the accumulation of ssDNA, 
which is then processed into DSBs (see 1.2.1 and 1.2.3). 
Technically, the advantage of UV irradiation as damaging agent is that high spatiotemporal 
resolution of induced DNA damage is achievable. For instance, it is possible to irradiate 
only parts of the cells and the duration of damage induction is precisely restricted to the 
time of irradiation. Gemcitabine, in contrast, can be washed out, but an uncertain amount 
of the drug remains in the cell and will continue to damage DNA.  
We therefore wanted to see if the results that we obtained in CHD8-depleted and 
gemcitabine-treated cells can be transferred to UV irradiation. We first determined the time-
dependent onset of UVC-induced DNA damage in PANC-1 cells and found that Chk1 
phosphorylation culminates one hour after irradiation and subsequently starts decreasing, 
while H2AX phosphorylation is delayed and reaches its peak after four hours (Fig. 4.16 a). 
We have previously shown delayed but similar patterns after gemcitabine treatment (Fig. 
4.7). 
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We then depleted PANC-1 cells of CHD8 using three different siRNAs, subjected the cells 
to UV irradiation and determined the phosphorylation of the kinases Chk1 and Chk2 as well 
as the accumulation of γH2AX using immunoblot. While an accumulation of phospho-Chk2 
(pChk2) was not detectable after gemcitabine treatment (Fig. 4.15), this is distinctly the case 
after UV irradiation (Fig 4.16b). Likewise, pChk1 levels accumulate stronger after UV 
irradiation than after gemcitabine treatment. Importantly, γH2AX, as the primary readout of 
our high-content screening approach to identify CHD8, accumulates in CHD8 depleted cells 
following UV irradiation more strongly than in control cells. This is consistent with the effect 
seen with gemcitabine. 
We therefore conclude that CHD8 is a regulator of the DDR to UV irradiation and CHD8 
depletion amplifies the response in this context. 
 
 
4.4.3  Overexpression of CHD8 enhances the accumulation of γH2AX 
If the amount of CHD8 is a decisive factor in its role in the response to gemcitabine or UV, 




Figure 4.16 CHD8 depletion in PANC-1 cells 
causes increased DNA damage response 
following UV irradiation.  
(a) Time course after UV irradiation in 
untransfected cells. PANC-1 cells were harvested 
at the indicated time points after irradiation with 
20 J/m2 UV-C.  
(b) Central indicators of increased DDR 
accumulate after CHD8 depletion in a time-
dependent manner. Cells were transfected as 
indicated and harvested at the indicated timepoints 
after irradiation with 20J/m2 UV-C.  
Protein lysates where analyzed by immunoblotting 
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diminishing a cell’s amount of CHD8 leads to increased DDR, its increase should lead to 
the opposite. To investigate this, we used an expression vector to overexpress HA-tagged 
CHD8 in PANC-1 cells and used a large human isoform of approximately 290 kDa as well 
as a small murine isoform of 110 kDa. The small murine isoform led to higher expression of 
CHD8 than the large human isoform (Fig. 4.17.a). While γH2AX level were not affected by 
CHD8 overexpression in the overall cell population (data not shown), γH2AX levels were 
increased in those cells expressing CHD8 (Fig. 4.17.b) in the presence or absence of 
gemcitabine or UV irradiation. 
4.4.4 DNA damage signaling after DNA double-strand induction is increased in 
CHD8-depleted cells 
We next addressed the question whether CHD8 specifically acts in the response to DNA 
damaging agents that cause ssDNA accumulation or whether CHD8 has a broader function 
in the DDR. DSBs activate a different, though crosstalking pathway than the one induced 
by ssDNA. DSBs also occur after the processing of stalled replication forks induced by 
gemcitabine. We therefore investigated the role of CHD8 in response to DSBs alone, like 
they are induced by radiotherapy in the clinics. For this purpose, we used the drug 
neocarzinostatin (NCS) which induces DSBs and was developed to mimic ionizing γ-
radiation (1.2.5). CHD8 depletion led to increased H2AX phosphorylation after NCS 
treatment, as quantified using immunofluorescence (Fig. 4.18). 
 
Figure 4.17 Overexpression of CHD8 does not show opposing effects to CHD8 depletion but causes 
increased DNA damage response.  
PANC-1 cells were transfected with CHD8 expression vectors, then treated with either gemcitabine or 
irradiated with UV-C. Cells were fixed and stained for immunofluorescence analysis and levels of the HA-
tagged CHD8 protein (a) and γH2AX levels (b) were quantified. 
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CHD8 is thus not part of a signaling cascade clearly restricted to one kind of DNA damage, 
but attenuates the DDR to treatments which primarily induce ssDNA as well as to treatments 
causing DSBs.  
 
4.4.5 CHD8 depletion increases DNA damage signaling in the p53 wild type 
osteosarcoma-derived cell line U2OS 
The pancreatic cancer cell line PANC-1 was selected for the high-content siRNA screen 
because of its intermediate gemcitabine sensitivity, the variability of readouts and its 
suitability for follow-up experiments. Still, we were interested whether higher gemcitabine 
sensitivity as well as a wild type p53 status affect our findings. We used the osteosarcoma-
derived cell line U2OS for transfer experiments. U2OS are widely used for DNA damage 
experiments and thus our results would be comparable to other studies.  
First, we addressed the question whether depletion of U2OS cells from CHD8 results in 
phosphorylation of Chk1, Chk2 and H2AX in response to gemcitabine treatment and UV 
irradiation in a similar manner as observed in PANC-1 cells. To obtain a higher temporal 
resolution and a sudden onset of DNA damage after gemcitabine treatment, we chose 
higher gemcitabine concentrations for a shorter period of time. Indeed, CHD8-depleted 
U2OS cells display activation of both, the Chk1 and the Chk2 pathway, following 
gemcitabine treatment and UV irradiation, in line with increased accumulation of γH2AX 
(Fig. 4.19 a) We could also show an activation of MK2 and Chk1 as well as an accumulation 













Figure 4.18 CHD8 depletion leads to increased 
H2AX phosphorylation after induction of double 
strand breaks. 
PANC-1 cells were depleted of CHD8 by siRNA-
mediated knockdown and exposed to 100ng/ml 
neocarzinostatin for 2 h. Cells were then fixed and 





Results                      104 
 
CHD8-depleted U2OS cells with NCS and again used quantitative immunofluorescence to 
assess the induction of γH2AX (Fig. 4.19 b). Here, knockdown of CHD8 increased γH2AX 
accumulation after DSB induction even more clearly than in PANC-1 cells. 
In contrast to PANC-1, U2OS harbor wild type p53 which is phosphorylated and 
accumulated after DNA damage to subsequently induce cell cycle arrest and apoptosis. We 
aimed to exclude that the pronounced effects of CHD8 depletion on DNA damage signaling 
are due to the induction of apoptosis by wild type p53, too. Therefore, we knocked down 
CHD8 in U2OS cells and added either DMSO or the caspase inhibitor z-VAD at the same 
time when the transfection mix was replaced by fresh medium. Then, we irradiated the cells 
with UV (Fig. 4.20). Remarkably, CHD8 knockdown induced apoptosis as displayed by the 
cleavage of PARP, and this was inhibited in z-VAD treated cells. However, z-VAD treatment 
did not influence Chk1 phopsphorylation, which was still increased in UV-irradiated cells af- 
 
Figure 4.19 Depletion of CHD8 increases the DNA damage response in U2OS cells.  
(a) Cells were depleted from CHD8 by siRNA-mediated knockdown and were harvested after 4 h of 500 nM 
gemcitabine treatment or 1h after irradiation with 20 J/m2 UV-C. Cell lysates were analyzed by immunoblotting 
(b) As in figure 4.19, U2OS cells were depleted from CHD8 using RNAi and treated with 100 ng/ml NCS for 
2 h, then fixed and stained for immunofluorescence analysis and γH2AX levels were quantified (c) U2OS 
cells were depleted of CHD8 UV-irradiated as in (a), cell lysates where analyzed by immunoblotting. 
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ter CHD8 knockdown. Overall levels of γH2AX are reduced in z-VAD-treated cells, which is 
likely attributable to the early inhibition of apoptosis that is already induced by cellular stress 
during transfection. Still, while γH2AX levels are generally lower in z-VAD-treated cells, 
CHD8 depletion causes strong H2AX phosphorylation. 
Thus, the role of CHD8 in reducing the DDR is not cell type specific and DNA damage 
signaling induced by CHD8 knockdown occurs upstream of the induction or independently 
from the onset of apoptosis, and it activates the damage-responsive MK2/Chk1 system. 
 
4.4.6  Overexpressed CHD8 does not relocalize in response to  
UV-induced DNA damage 
In response to ssDNA breaks and DSBs, DNA damage transmitters localize to sites of DNA 
damage and either sense damaged DNA or recruit mediators which amplify the signal or 
recruit DNA repair factors. We investigated whether CHD8 relocalizes following UV-induced 
DNA damage. To this end, we overexpressed HA-tagged CHD8 in U2OS cells. At that time, 
there was no antibody against CHD8 available which was able to detect its endogenous 
levels and which was suitable for immunofluorescence. We UV-irradiated U2OS cells in a 
time course and stained UV-induced CPDs and HA-tagged CHD8 for immunofluorescence 
analysis using confocal microscopy. UV irradiation took place either completely or through 
a micro pore filter. The latter resulted in small fields of UV-dependent DNA lesions in the 
nucleus, which were then marked by CPD-staining. 
 
Figure 4.20 CHD8 depletion also causes apoptosis in the presence of p53. 
U2OS cells were transfected with CHD8 siRNA as indicated. 24 h after transfection, the transfection mix was 
replaced by fresh culture medium containing DMSO or z-VAD. Cells were incubated for another 24 h and 
thereafter received irradiation with 20 J/m2 UV-C and were harvested 1h after treatment. 
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In untreated cells, overexpressed CHD8 was localized to the nucleus of the cell with a 
uniform distribution. Some subnuclear structures were excluded from CHD8 occupation that 
possibly represent nucleoli. Upon UV irradiation, overexpressed CHD8 was neither 
exported from the nucleus, nor did it display spontaneous foci formation. Also, after UV 
irradiation of certain nuclear regions through the micro pore filter, there was no relocalization 
to or exclusion from those regions detectable (Fig. 4.21).  
 
Figure 4.21 Overexpressed CHD8 does not relocalize in response to UV-induced DNA damage.  
U2OS cells were transfected with a pcDNA3-CHD8 construct. Cells were then covered with a UV light filter 
with pores of 3 µm and irradiated with 500 J/m2 or left uncovered and then were irradiated with 50 J/m2. Cells 
were fixed and stained for immunofluorescence analysis and pictures were obtained using confocal 
microscopy. Conducted with Dr. Frederik Köpper. 
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4.5  CHD8 regulates progression through the cell cycle and 
apoptosis 
 
Known hallmarks of cancer cells are disturbances of the tight regulation of cell cycle, 
resistance to apoptotic stimuli and increased proliferation. We were interested whether 
CHD8 as mediator of the gemcitabine response has impact on these processes typical for 
malignant tumors. 
 
4.5.1  Knockdown of CHD8 facilitates cell cycle progression 
Checkpoints of the cell cycle are mainly mediated by protein kinases and the 
phosphorylation-dependent activation or degradation of cell cycle mediators. The 
antagonizing kinases MK2 and Chk1 that we characterized as mediators of the gemcitabine 
response in pancreatic cancer cells significantly influence cell cycle progression. We 
wanted to know wether alterations in cell cycle progression are a feature of CHD8, too. To 
address this question, we depleted U2OS cells of CHD8 and analyzed their cell cycle profile 
(Fig. 4.22). The depletion of MDM2 served as positive control for a pronounced G1-arrest. 
In unsynchronized cells, no obvious changes were detectable when CHD8 knockdown was 
compared to a control transfection (Fig. 4.22 a). We then explored whether CHD8 exhibits 
more delicate functions in the cell cycle than complete checkpoint activation or checkpoint 
abrogation that would not be detectable in an unsynchronized cell population. We used cells 
synchronized in G2/M-phase in order to analyze whether a more subtle influence by CHD8 
knockdown was detectable. U2OS cells were depleted of CHD8 and premitotic cells were 
enriched and synchronized by treating them with the mitosis inhibitor nocodazole. Premitotic 
cells detached easily and were shaken off from the dish surface. After release from the 
nocodazole block, cells were harvested in a time course and the cell cycle profile was 
analyzed. Interestingly, and in contrast to previous characterization of CHD8, depleting 
U2OS cells of CHD8 promoted cell cycle progression: The cells entered S-phase earlier as 
compared to control knockdown (Fig. 4.22b).  
We therefore conclude that CHD8 controls progression through the cell cycle with depletion 
of CHD8 helping cells to proceed from G1 to S-phase. 
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4.5.2  Depleting CHD8 causes apoptosis independent of the presence or 
functionality of p53 
The induction of growth arrest and apoptosis in malignant cells is the major aim of 
chemotherapeutic treatment as with gemcitabine. The induction of γH2AX is a final common 
event of DNA damage signaling which is enhanced by CHD8 knockdown, and it inversely 
correlates with cell proliferation in all pancreatic cancer cells used. In mice, CHD8 knockout 
is lethal between embryonic day 5.5 and 7.5, with a massive enhancement of apoptosis 
detectable. The amount of apoptosis is reported to be rescued by simultaneous knockout 
of p53, and survival of the mice improved very little, but significantly, suggesting that CHD8 
controls apoptosis by the suppression of p53 activity (detailed in 1.8.3.2). As previously 
 
 
Figure 4.22 CHD8 depletion promotes progression through S-phase.  
(a)  U2OS cells were depleted of CHD8 and MDM2 as control, respectively. Cell cycle analysis was performed 
by flow cytometry. (b) U2OS cells were depleted of CHD8 by siRNA-mediated knockdown and trapped in 
mitosis by a nocodazole block. Mitotic cells were shaken off, released into G1/S-phase and harvested for cell 
cycle analysis at the indicated time points after release. Cell cycle analysis was performed by flow cytometry. 
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stated, our results demonstrate that phosphorylation and total levels of mutant p53 and total 
levels of wild type p53 decrease after CHD8 knockdown, which contradicts the results 
obtained in mice experiments. Therefore, we were interested whether the accumulation of 
γH2AX after CHD8 knockdown is followed by the induction of apoptosis, and if this is the 
case, whether this is p53-dependent. 
We depleted PANC-1 and U2OS cells of CHD8, p53 or both and either left the cells 
untreated or induced DNA damage by UV irradiation. After 12 h, a period of time long 
enough to allow apoptosis to start, we harvested the cells. In p53-proficient U2OS cells, 
already untreated cells started apoptosis after CHD8 depletion, whereas the depletion of 
p53 itself did not alter the cleavage of PARP and caspase 3, which were used as apoptosis 
indicators (Fig. 4.23). Remarkably, co-depletion of p53 in CHD8-depleted cells did not 
 
Figure 4.23 CHD8 depletion causes apoptosis independent of the presence or functionality of p53. 
(a) U2OS (wt p53) and (b) PANC-1 (mutant p53) cells were depleted of CHD8 or p53 by siRNA-mediated 
knockdown as indicated. 24 h after transfection, the transfection mix was replaced by fresh culture medium. 
Cells were incubated for another 24 h and thereafter received irradiation with 20 J/m2 UV-C. Then, culture 
medium with either DMSO or 50 µM z-VAD was added and cells were harvested 12 h after treatment. Protein 
lysates were prepared and analyzed by immunoblotting. 
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rescue the induction of apoptosis. After UV irradiation, apoptosis was enhanced in CHD8-
depleted cells and again not rescued by p53 depletion. H2AX phosphorylation was not 
detectable in untreated U2OS cells, possibly due to their low endogenous γH2AX levels, 
and was not influenced by CHD8 knockdown 12 h after UV irradiation. This is attributable 
to the massive onset of apoptosis, which consequently induces high levels of γH2AX that 
overlay direct H2AX phosphorylation. We did not expect different results in the p53 mutant 
PANC-1 cells, which have abundant, but unfunctional p53. Indeed, the depletion of CHD8 
caused apoptosis already in untreated cells, accompanied by the accumulation of γH2AX, 
and showed the same relations 12 h after UV irradiation (Fig. 4.23). Likewise, p53 depletion 
itself has no influence on the onset of apoptosis alone and in CHD8-depleted cells. 
Thus, we conclude that CHD8 depletion induces apoptosis independently of the presence 
or functionality of p53. 
 
4.6    CHD8 influences phosphorylation and total protein      
levels of p53 
 
4.6.1  P53 accumulation after DNA damage relies on CHD8 
Following DNA damage, the tumor suppressor p53 is phosphorylated and thereby 
stabilized. Our results have shown that even mutant p53 in PANC-1 cells was extensively 
phosphorylated and accumulated after 22 h of gemcitabine treatment, but failed to do so 
upon CHD8 depletion (Fig. 4.15). We therefore aimed to investigate the effect of CHD8 on 
p53 activation. To this end, we again used PANC-1 cells, depleted them of CHD8, and 
harvested the cells 1 and 4 hours after UV irradiation. We observed that total p53 levels 
had not yet been altered significantly by CHD8 depletion after a short period of time 
following DNA damage induction (Fig. 4.24 a). However, the phosphorylation of p53 was 
reduced in a time-dependent manner with increasing reduction of the protein over time after 
the onset of DNA damage. We then wanted to know the influence of CHD8 on wild type 
p53, which underlies physiological regulation. To this end, we depleted U2OS cells of CHD8 
and either treated them with gemcitabine or UV (Fig. 4.24 b). Unfortunately, phospho-p53 
levels are not detectable in U2OS cells due to low expression of the entire protein and the 
very low ratio of its phosphorylated form. After CHD8 knockdown, p53 levels were already 
reduced without DNA damage induction, but the effect was more pronounced in 
gemcitabine-treated cells and even more evident after UV irradiation. To test whether this 
was maybe due to an influence of CHD8 on the p53 pathway, we stained for the main nega- 
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tive regulator of p53 in wild type U2OS cells, where MDM2 downregulates p53. Indeed, also 
MDM2 levels were reduced in CHD8-depleted U2OS cells. 
The transcription and therefore the level of MDM2 itself is regulated by p53, with p53 
inducing its own downregulation. Therefore, from the above results, we cannot conclude 
that CHD8 influences p53 levels through an influence on MDM2. Still, CHD8 is necessary 
for the efficient phosphorylation and accumulation of p53 in a cell, with a special emphasis 
on p53 induction after DNA damage. 
  
4.6.2  Decreased p53 levels in CHD8-depleted cells are not or only partially due to 
modulated protein stability  
MDM2 targets p53 for proteasomal degradation (see 1.5.1). If the proteasome is inhibited, 
for example by the proteasome inhibitor MG132, the ubiquitination by MDM2 should no 
longer have an influence on p53 stability. To address physiological p53-regulating 
 
Figure 4.24 CHD8 depletion reduces activated and overall wild type and mutant p53 levels.  
(a) High levels of mutated p53 in PANC-1 cells are decreased in CHD8-depleted cells. Cells were depleted 
of CHD8 and irradiated with 20 J/m2 UV-C 48 h after transfection. Cells were harvested 1 h after irradiation 
and protein lysates were analyzed by immunoblotting. (b) Wild type p53 levels are reduced in CHD8-depleted 
U2OS cells with and without DNA damage induced by gemcitabine and UV irradiation. Cells were depleted 
of CHD8 and harvested either 4 h after treatment with 500 nM gemcitabine or 1 h after irradiation with 20 
J/m2 UV-C. Cell lysates were analyzed by immunoblotting. 
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mechanisms, we used U2OS cells, depleted them of CHD8 and added DMSO or MG132. 
Whereas p53 levels were decreased in DMSO-treated and CHD8-depleted cells, this was 
only partially rescued by the inhibition of proteasomal degradation (Fig. 4.25). Due to the 
low staining intensity, there is no evidence for MDM2 levels in DMSO-treated cells. After 
MG132 treatment, however, MDM2 was stabilized to a high extend, with no effect of CHD8 
knockdown in untreated cells but a reduction of MDM2 levels after UV irradiation. 
Thus, whereas the regulation of MDM2 by CHD8 does not rely on protein degradation, 
CHD8 might sustain the protein stability of wild type p53. 
4.7  A genome-wide microarray analysis after CHD8 knockdown 
identifies DNA damage response genes as potential 
mediators of CHD8 knockdown effects 
 
According to literature research, CHD8 is involved in virtually every step of gene 
transcription. It would thus not be surprising if CHD8 exerts its suppressive effect on 
damage signaling through the transcriptional regulation of damage-responsive genes or 
whole signaling cascades. We therefore transfected U2OS cells with three siRNAs to CHD8 
as well as with a none-targeting one. After the extraction of total cellular RNA, we analyzed 
gene expression profiles on the mRNA level by microarray analysis. U2OS cells were 
chosen because they are an elaborated cancer cell line, and the abundance of databases 
 
Figure 4.25 Reduced p53 levels are partially based on increased protein degradation.  
U2OS cells were depleted of CHD8 by siRNA-mediated knockdown. Thereafter, cells were treated with 
DMSO or MG132 for 4 h and irradiated with 20 J/m2 UV-C or left untreated. 1 h after irradiation, cells were 
harvested and protein lysates were analyzed by immunoblotting. 
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to compare our results with would be far greater than with pancreatic cancer cells. We then 
took the top 50 candidates whose mRNA levels were influenced by CHD8 knockdown as 
listed in table 4.1. Non-protein coding genes were part of the plot but exceeded our question, 
so that we reduced the list to protein-coding genes only.  
We then chose genes with a false discovery rate of less than 5 % as generally practiced 
and a relative change in mRNA expression of less than 0.5 times or more than 1.5 times 
compared to control, and obtained an even larger plenty of potentially regulated genes. 
When we sorted the candidate regulated genes for associated processes as shown in table 
4.2, it becomes visible that CHD8 appears not to be a distinct regulator of one signaling 
cascade but involved in transcriptional regulation of many genes. Among all are various 
candidates involved in DNA damage and DNA repair as well as DNA replication, apoptosis 
and p53 regulated processes. The latter might be of minor relevance as we would want to 
transfer our results to mutant p53 pancreatic cancer cells. Interestingly, CHD8-regulated 
processes comprise kinase signaling and cell adhesion as often dysregulated pathways in 
cancer, too. 
In conclusion, the transcriptional regulation of DNA damage factors might be a potential 
way of action for CHD8, but needs further validation and characterization. 
 
 
Table 4.1 Top candidates whose gene expression is most influenced by CHD8 
knockdown. 
  
CHD8-regulated genes sorted by the relative change of gene expression after CHD8 knockdown as determined 
by microarray analysis. This table results from the 50 top candidate genes of which the non-protein coding 














CD22 CD22 molecule 933 0,31  5,68 3,69 % 
AP4S1 adaptor-related protein complex 4, 
sigma 1 subunit 
11154 0,31  5,91 0,25 % 
USP11 ubiquitin specific peptidase 11 8237 0,31  4,08 1,92 % 
ESM1 endothelial cell-specific molecule 1 11082 0,32  6,32 0,68 % 
GDAP1 ganglioside-induced differentiation-
associated protein 1 
54332 0,33  5,41 0,01 % 
CHD8 chromodomain helicase DNA binding 
protein 8 
57680 0,35  10,85 0,00 % 
PRR3 proline rich 3 (PRR3), transcript 
variant 1 
80742 0,37  7,78 0,07 % 
ECM2 extracellular matrix protein 2, female 
organ and adipocyte specific 
1842 0,38  4,94 2,08 % 
LCE5A late cornified envelope 5A 254910 0,39  4,04 2,09 % 
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ADAMTS16 ADAM metallopeptidase with 
thrombospondin type 1 motif, 16 
170690 0,40  5,19 0,66 % 
PTX3 pentraxin 3, long 5806 0,40  10,35 0,02 % 
RIC3 
resistance to inhibitors of 
cholinesterase 3 homolog (C. 
elegans) 
79608 0,40  3,95 2,04 % 
ZNF167 zinc finger protein 167 55888 0,40  5,24 0,90 % 
ITGA2 integrin, alpha 2 (CD49B, alpha 2 
subunit of VLA-2 receptor) 
3673 0,41  5,91 1,09 % 
KSR2 Homo sapiens kinase suppressor of 
ras 2 
283455 0,41  4,60 2,78 % 
CARD8 
caspase recruitment domain family, 
member 8  
22900 0,42  7,28 0,15 % 
PRR3 proline rich 3 80742 0,43  6,11 0,09 % 
KATNAL2 katanin p60 subunit A-like 2 83473 0,45  4,05 3,46 % 
ZNF678 zinc finger protein 678 339500 0,45  5,11 0,10 % 
CNTN1 contactin 1 1272 0,45  4,82 3,64 % 
KPNA5 karyopherin alpha 5 (importin alpha 6) 3841 0,46  5,93 0,09 % 
ARL10 ADP-ribosylation factor-like 10 285598 0,46  4,90 2,26 % 
B4GALT6 UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 6 
9331 0,46  4,63 0,66 % 
FGF7 fibroblast growth factor 7 2252 0,48  4,13 2,03 % 
USP11 ubiquitin specific peptidase 11 8237 0,49  11,06 0,03 % 
AREG amphiregulin 374 0,49  10,71 0,46 % 
MBLAC1 metallo-beta-lactamase domain 
containing 1  
255374 0,49  8,73 0,12 % 
TCEANC 
transcription elongation factor A (SII) 
N-terminal and central domain 
containing 
170082 2,06  6,36 0,70 % 
B9D2 B9 protein domain 2 80776 2,07  10,95 0,09 % 
POLR3E polymerase (RNA) 2 (DNA directed) 
polypeptide E (80kD) 
55718 2,07  10,65 2,03 % 
ETV2 ets variant 2 2116 2,09  10,30 0,01 % 
PPFIA3 
protein tyrosine phosphatase, 
receptor type, f polypeptide (PTPRF), 
interacting protein (liprin), alpha 3 
8541 2,13  7,40 1,83 % 
Q5SRJ3 Zinc finger protein 452 (Fragment), 
partial (3 %)  
 
2,13  6,52 0,29 % 
ETV2 ets variant 2 2116 2,25  7,38 0,00 % 
IGFL2 IGF-like family member 2 147920 2,26  5,27 0,16 % 
SH3YL1 SH3 domain containing, Ysc84-like 1 
(S. cerevisiae) 
26751 2,36  6,90 0,07 % 
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Table 4.2 Candidate CHD8-regulated genes were grouped by cellular processes.  
 
Candidates with a false discovery rate of less than 5 % and a relative increase in gene expression by 1.5-fold 
or decrease to 0.5-fold after CHD8 knockdown compared to control were included and then grouped according 
to ascribed processes using the DAVID functional annotation tool (Huang da et al. 2009b). 











TLN1 Talin 1 7094 9,19 3,80 % 1,98 
RBM38 RNA binding motif protein 38 55544 9,70 3,74 % 1,69 
MDC1 
Mediator of DNA-damage 
checkpoint 1 
9656 11,93 0,25 % 1,64 
JMY 
Junction mediating and 
regulatory protein, p53 cofactor 
133746 7,08 2,16 % 1,52 
KAT5 K(lysine) acetyltransferase 5 10524 9,19 3,79 % 1,50 
RASGRF1 
Ras protein-specific guanine 
nucleotide-releasing factor 1 




65057 12,57 1,51 % 1,41 
HIPK2 
homeodomain interacting 
protein kinase 2 6,97 2,14 % 0,59 
      
     
DNA repair     








Topoisomerase (DNA) I, 
mitochondrial 
116447 12,77 4,81 % 1,93 
MDC1 
Mediator of DNA-damage 
checkpoint 1 
9656 11,93 0,25 % 1,64 
JMY 
Junction mediating and 
regulatory protein, p53 cofactor 
133746 7,08 2,16 % 1,52 
KAT5 K(lysine) acetyltransferase 5 10524 9,19 3,79 % 1,50 
 
 
    
 
 
    
Apoptosis     








Homo sapiens B-cell 
CLL/lymphoma 11B 
64919 4,11 1,20 % 1,76 
NUDT2 
Homo sapiens nudix 
(nucleoside diphosphate linked 
moiety X)-type motif 2 (NUDT2) 
318 10,04 0,41 % 1,58 
BCL2L11/BIM 
Homo sapiens BCL2-like 11 
(apoptosis facilitator) 
(BCL2L11) 
10018 10,18 0,70 % 1,55 
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JMY 
Homo sapiens junction 
mediating and regulatory 
protein, p53 cofactor 
133746 7,08 2,16 % 1,52 
RASGRF1 
Homo sapiens Ras protein-
specific guanine nucleotide-
releasing factor 1 
5923 7,91 2,40 % 0,68 
NGFRAP1 
Homo sapiens nerve growth 
factor receptor (TNFRSF16) 
associated protein 1 
(NGFRAP1) 
27018 13,16 4,30 % 0,67 
PPP3CB 
protein phosphatase 3, catalytic 
subunit, beta isozyme 
5532 7,37 4,41 % 0,65 
ARHGEF9 
Homo sapiens Cdc42 guanine 
nucleotide exchange factor 
(GEF) 9 
23229 6,62 0,88 % 0,63 
ADRB2 
Homo sapiens adrenergic, 
beta-2-, receptor, surface 
154 9,70 0,94 % 0,62 
KCNMA1 
Homo sapiens potassium large 
conductance calcium-activated 
channel, subfamily M, alpha 
member 1 (KCNMA1), 
transcript variant 2, mRNA 
[NM_002247] 
3778 6,66 4,72 % 0,59 
IL1RAP 
Homo sapiens interleukin 1 
receptor accessory protein 
3556 8,04 1,46 % 0,58 
SART1 
Homo sapiens squamous cell 
carcinoma antigen recognized 
by T cells 
9092 8,67 0,52 % 0,57 
TGM2 
Homo sapiens 
transglutaminase 2 (C 
polypeptide, protein-glutamine-
gamma-glutamyltransferase) 
7052 10,53 4,06 % 0,54 
CARD8 
Homo sapiens caspase 
recruitment domain family, 
member 8 
22900 7,28 0,15 % 0,42 
 
 
    
 
 
    
DNA replication     








Topoisomerase (DNA) I, 
mitochondrial 
116447 12,77 4,81 % 1,93 
GINS3 
GINS complex subunit 3 (Psf3 
homolog) 
64785 11,95 0,25 % 0,64 
AREG Amphiregulin 374 10,71 0,46 % 0,49 
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MAPKinase signaling 
    








Homo sapiens Ras protein-
specific guanine nucleotide-
releasing factor 1  
5923 7,91 2,40 % 0,68 
ARAF 
v-raf murine sarcoma 3611 viral 
oncogene homolog  
369 8,32 0,42 % 0,65 
PPP3CB 
protein phosphatase 3, catalytic 
subunit, beta isozyme 
5532 7,37 4,41 % 0,65 
ADRB2 
Homo sapiens adrenergic, 
beta-2-, receptor, surface  
154 9,70 0,94 % 0,62 
RPS6KA6 
Homo sapiens ribosomal 
protein S6 kinase, 90kDa, 
polypeptide 6  
27330 6,97 0,09 % 0,61 
RGS4 
Homo sapiens regulator of G-
protein signaling 4  
5999 5,21 0,75 % 0,54 
FGF7 
Homo sapiens fibroblast growth 
factor 7  
2252 4,13 2,03 % 0,48 
      
      
RAS signaling 
    








RAB9B, member RAS 
oncogene family  
51209 4,82 4,14 % 0,69 
RASGRF1 
Ras protein-specific guanine 
nucleotide-releasing factor 1  
5923 7,91 2,40 % 0,68 
SYTL2 Synaptotagmin-like 2  54843 10,04 4,23 % 0,50 
AGFG1 ArfGAP with FG repeats 1 3267 9,94 0,91 % 1,48 
ERRFI1 
ERBB receptor feedback 
inhibitor 1 
54206 11,91 0,67 % 0,71 
      
      
Cell adhesion 
    







TLN1 Talin 1 (TLN1) 7094 9,19 3,80 % 1,98 
MYL5 Myosin, light chain 5, regulatory  4636 7,69 0,25 % 1,76 
MADCAM1 
Mucosal vascular addressin cell 
adhesion molecule 1 
(MADCAM1) 
8174 4,65 1,94 % 1,75 
MDC1 
Mediator of DNA-damage 
checkpoint 1 
9656 11,93 0,25 % 1,64 
EMB Embigin 133418 9,14 1,82 % 1,56 
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BCL2L11 
BCL2-like 11 (apoptosis 
facilitator)  
10018 10,18 0,70 % 1,55 
HAPLN3 
Hyaluronan and proteoglycan 
link protein 3 
145864 12,45 0,61 % 1,54 
MUC4 Mucin 4, cell surface associated 4585 5,35 3,69 % 0,70 
F11R F11 receptor 50848 9,28 0,47 % 0,70 
PPFIBP1 
PTPRF interacting protein, 
binding protein 1  
8496 7,19 4,99 % 0,69 
COL6A3 Collagen, type VI, alpha 3  1293 7,43 0,64 % 0,55 
TGM2 
Transglutaminase 2 (C 
polypeptide, protein-glutamine-
gamma-glutamyltransferase) 
7052 10,53 4,06 % 0,54 
COL13A1 Collagen, type X2, alpha 1  1305 9,48 0,41 % 0,53 
CNTN1 Contactin 1 1272 4,82 3,64 % 0,45 
ITGA2 
Integrin, alpha 2 (CD49B, alpha 
2 subunit of VLA-2 receptor) 
3673 5,91 1,09 % 0,41 
ECM2 
Extracellular matrix protein 2, 
female organ and adipocyte 
specific 
1842 4,94 2,08 % 0,38 
CD22 CD22 molecule 933 5,68 3,69 % 0,31 





Despite extensive research on the treatment of pancreatic adenocarcinomas, this tumor 
identity still belongs to the most fatal cancers. The nucleoside analog gemcitabine prolongs 
median survival by a few months, but still therapeutic success ranks far behind the progress 
achieved in the treatment of other cancers. Resistance mechanisms to gemcitabine are 
poorly understood, and those we know cannot be targeted to date to improve response 
rates to this drug. Equally, cancer-driving mutations of pancreatic tumors, which are 
oncogenic KRAS activating mutations in 95 % and oncogenic missense mutations of the 
tumor suppressor p53 in 75 % of the cases, are still not druggable. A better understanding 
of the cellular response to gemcitabine as well as the identification of factors that can be 
exploited to sensitize pancreatic cancer cells to gemcitabine are a constant challenge for 
fundamental research. 
As a nucleoside analog, gemcitabine acts mainly during the S-phase of the cell cycle, where 
it is incorporated into a nascent DNA strand and causes the DNA polymerase to stall, while 
helicases continue unwinding DNA. In this way, ssDNA emerges and is recognized by 
sensor proteins, which activate a DDR. ATR and Chk1 as sensor and effector kinases then 
attenuate DNA replication and induce cell cycle arrest and stabilization of the replication 
fork. If fast repair mechanisms do not take effect, the replication of DNA cannot be resumed, 
the fork is finally cleaved and gives rise to DSBs, which eventually activate ATM and Chk2 
and induce apoptosis. 
Besides Chk1, whose depletion or inhibition strongly activates the DDR so that its inhibition 
has been subject to many clinical trials in combination with chemotherapy, another kinase 
could be identified in our lab that governs the gemcitabine response in osteosarcoma cells. 
MK2 is an antagonist of Chk1 at the level of DNA replication where it appears to inhibit the 
error-prone but pro-survival repair process of translesion synthesis, and promotes 
replication fork stalling. It was one purpose of this study to transfer the manipulation of the 
MK2/Chk1-system to pancreatic cancer cells in order to overcome gemcitabine resistance. 
Furthermore, the central objective was the identification of activated pathways and 
mediators within the DDR in order to understand the precise way in which a cell deals with 
genotoxic stress induced by gemcitabine. This could contribute to finding ways to fortify the 
impact of the drug and specify it to malignant cells. We thus performed a high-content 
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screen in gemcitabine-treated pancreatic cancer cells using a pre-selected library of siRNAs 
to genes already ascribed to DNA damage, DNA repair and genomic integrity.  
One of the resulting candidates was the ATP-dependent chromatin remodeling factor 
CHD8, whose knockdown increased γH2AX induction after gemcitabine treatment. Not 
much is known so far about this large protein, which is clinically involved in autism spectrum 
disorders. Nevertheless, as structurally related family members have well-established roles 
in DNA repair, we became interested in the characterization of CHD8 in response to DNA 
damage.   
 
5.1  MK2 and Chk1: Two kinases govern the response of 
pancreatic cancer cells to gemcitabine treatment 
 
5.1.1  MK2 in the response to replicative stress signaling and chemotherapy 
Fast proliferating tumor cells suffer a high amount of replicative stress, which is enhanced 
by the treatment with nucleoside analogs like gemcitabine. Here, we show that MK2 is a 
determinant of both the response to endogenous replicative stress and to gemcitabine-
induced stress and DNA damage. We used four different pancreatic cancer cell lines, which 
we treated with gemcitabine and found that, first, high endogenous γH2AX levels can be 
reduced by MK2 inhibition and that, second, this is also the case for exogenous 
gemcitabine-induced DNA damage signaling. We performed cell proliferation assays to 
transfer this finding to the ability of MK2 to influence tumor cell growth, which would be the 
clinical aim of MK2 manipulation. Our results suggest that MK2 activity is fundamental to 
gemcitabine sensitivity as cells obtain growth advantages when MK2 is inhibited (Fig. 4.3). 
This finding brings MK2 into clinical relevance as low MK2 levels or activity might confer 
gemcitabine resistance in pancreatic tumors. Mechanistically, MK2 appears to influence the 
DDR rather than the known resistance mechanisms mostly involved in drug metabolism, 
activation of pro-survival pathways and establishment of an anti-apoptotic tumor micro 
environment (Chand et al. 2016). On the other hand, the activation of MK2, as it is seen in 
inflammation processes, could be exploited to fortify the cellular response to gemcitabine. 
Such MK2 promotion could be carried out basically in two ways: first, by inducing MK2’s 
activating kinase p38 and second, by the inhibition of DUSP1/MKP1 (dual specific protein 
phosphatase1/MAPK phosphatase), the phosphatase of the p38/MK2 heterodimer, thus 
interrupting a negative feedback loop. Both results in higher levels of activated MK2 (Hu et 
al. 2007). 
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Interestingly, not MK2 itself but its direct downstream target hsp27 (heat shock protein 27) 
has been discussed in the response to gemcitabine in pancreatic cancers. Hsp27 is 
phosphorylated by MK2 to such extent that it can be used as readout for MK2 activity (Guay 
et al. 1997). However, observations of hsp27 being a predictor of gemcitabine sensitivity in 
pancreatic cancers are contradictory. Some studies report that total levels of hsp27 or its 
phosphorylated form mark gemcitabine sensitivity (Liu et al. 2012; Nakashima et al. 2011; 
Schafer et al. 2012) while others found contrary results and ascribe gemcitabine resistance 
to tumors with such properties (Baylot et al. 2011; Taba et al. 2010). If we take hsp27 
phosphorylation as means to quantify MK2 activity, our findings would support the first-
mentioned studies. 
Hsp27 activity is not yet an established marker for the gemcitabine response in the clinics 
and no data for patient survival correlated with hsp27 activity in pancreatic cancer samples 
is available. Nonetheless, hsp27-associated pathways have received increasing attention 
in recent years. The determination of MK2 activity in tumors is thus a promising factor in the 
search for more reliable gemcitabine sensitivity markers. 
There are more studies that focused on MK2 activity during chemotherapy. For example, it 
was proposed that MK2 can take over p53 functions as the induction of cell cycle 
checkpoints seems to rely on MK2 in p53 knockout cells (Reinhardt et al. 2007). Another 
study ascribes a synthetic lethal effect to MK2 depletion in p53-deficient cells (Morandell et 
al. 2013). In line with this, it was shown that activated p53 can induce MKP1 and thereby 
downregulate MK2, a mechanism that might not be functional in p53-deficient cells (Liu et 
al. 2008). However, the first study was performed in a lung cancer cell line and with cisplatin 
as DNA damaging agent. Cisplatin acts in a fundamentally different manner than does 
gemcitabine, and it induces DNA intra and interstrand crosslinks which already affect the 
unwinding of DNA during replication instead of DNA synthesis. Work in our lab has recently 
demonstrated that, although MK2 determines the DNA replication after gemcitabine 
treatment, it has no effect on DNA damage signaling and DNA replication after cisplatin 
treatment (Li et al. 2018). As platinum adducts induce different DDR and repair pathways 
than does gemcitabine, the results of the above studies do not necessarily contradict our 
findings of a protective effect of MK2 inhibition that we consistently found in p53-wild type 
and p53-mutated cell lines.  
In summary, cancer cells might respond differentially to MK2 inhibition dependent on their 
genetic background and the treatment regimen. MK2 specifically mediates the cellular 
response to replicative stress as induced by gemcitabine, by UV and endogenously. The 
cellular background and the chemotherapeutic in use would have to be precisely tested 
before the inhibition of MK2 could be approved for clinical use, but the assessment of MK2 
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activity as well as its inhibition is a promising strategy, especially to exploit replicative stress 
as a cytotoxic treatment strategy. 
 
5.1.2  MK2 and Chk1: two antagonizing kinases in the DNA damage response and 
cell survival 
Work in our lab has previously shown that MK2 and Chk1 activity antagonize each other at 
the level of DNA replication. While Chk1 activity promotes translesion synthesis, MK2 
activity appears to reduce this damage tolerance mechanism, which results in opposing 
effects of both kinases on γH2AX accumulation (Kopper et al. 2013). We now transferred 
this finding to pancreatic cancer cells and could show that knockdown or inhibition of Chk1 
leads to increased γH2AX accumulation in gemcitabine sensitive cell lines, while MK2 
inhibition as well as depletion completely rescued this effect. Taking DNA damage signaling 
as a reliable marker for chemosensitivity, we may conclude that high MK2 activity could not 
only be used to predict chemosensitivity, but that it also promotes the success of Chk1 
inhibition, whereas low MK2 activity could diminish this effect. This function of MK2 has to 
be taken into account when we reflect the mode of action of an older generation Chk1 
inhibitor, UCN-01, which also blocks MK2 to a relevant extent and may therefore be less 
efficient than a new generation of highly selective Chk1 inhibitors. Further, the use of 
multikinase inhibitors in combination with replicative stress-inducing agents could turn out 
to be ineffective if MK2 is blocked to a relevant extent, as well. 
 
5.1.3 Two sides of a coin: Chk1 inhibitors in chemotherapy 
Where chemotherapy alone is not able to induce apoptosis of a cell, the simultaneous 
inhibition or depletion of another factor can sometimes do so, an effect called synthetic 
lethality. Chk1 is an example of such a factor and its inhibition has been extensively studied 
in combination with different chemotherapeutics in a wide range of tumor species. In nearly 
all cases, Chk1 inhibition has a chemosensitizing effect (Ma et al. 2011). Chk1 inhibition 
abrogates the intra-S-phase checkpoint that usually, when active, gives the cell a chance 
to repair damage or at least delay further DNA replication to allow damage tolerance 
mechanisms to take effect. Abrogation of Chk1 signaling therefore leads to the massive 
accumulation of DNA damage. This effect seems to be pronounced in p53-deficient cells, 
which are unable to induce the G1/S checkpoint and therefore heavily rely on other cell cycle 
checkpoints (Ma et al. 2011). A recent study using cell line-based screening found that 
especially in KRAS-driven cancers that potentially have a high amount of replicative stress, 
the combined inhibition of Chk1 and MK2 shows a synergistic effect that drives the cells 
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into mitotic catastrophe (Dietlein et al. 2015). First, however, our results demonstrate that 
the cytotoxic effect of Chk1 inhibition is independent of the KRAS status of a cell as two of 
the cell lines we used, U2OS and BxPC-3, harbor wild type KRAS and can be sensitized by 
Chk1 inhibition. Second, we find a protective effect of MK2 inhibition after gemcitabine 
treatment in all cell lines tested, irrespective of their KRAS status. 
On the contrary, when investigating the impact of a selective Chk1 inhibitor on proliferation, 
we were surprised to observe that only one pancreatic cancer cell line, MIA PaCa-2, proved 
sensitive to Chk1 inhibition at all, and that this is the case despite increased DNA damage 
accumulation following inhibition or depletion of Chk1, which we reliably observe in all cell 
lines. In MIA PaCa-2 and in osteosarcoma U2OS, MK2 inhibition led to a complete rescue 
of DNA damage and growth arrest or apoptosis after Chk1 inhibition. In the other three cell 
lines, Chk1 inhibition even conferred a protective effect in untreated as well as in 
gemcitabine-treated conditions independent of or despite the induction of DNA damage 
signaling. 
Our results thus contradict the above-mentioned study in which MK2 and Chk1 act in line 
to prevent DNA damage, and suggest that MK2 confers chemosensitivity during 
endogenous and induced replicative stress. Further, and in contrast to most clinical and 
preclinical trials, only a subset of cells respond to Chk1 inhibitors, but in those, this effect is 
completely rescueable by MK2 inhibition. 
This raises the question whether a model of synthetic lethality after Chk1 inhibition still and 
generally holds true for gemcitabine treatment. The fact that Chk1 inhibition as well as Chk1 
knockdown increase DNA damage signaling in all cell lines tested, and that this effect can 
be rescued by simultaneous MK2 inhibition or depletion (Fig. 4.4) makes it unlikely to be an 
effect of poor inhibitor selectivity. Additionally, Chk1 inhibition does decrease proliferation 
in MIA PaCa-2 cells and an osteosarcoma cell line, and this toxicity mediated by Chk1 
inhibition can be clearly rescued by the parallel inhibition of MK2. 
 
5.1.4  Putative mediators of Chk1 resistance 
 
5.1.4.1  Checkpoint signaling 
There are only few studies that have dealt with Chk1 inhibitor resistance. In this context, the 
most examined feature of Chk1 is its ability to prevent progression through S-Phase upon 
replicative stress. When cell cycle checkpoints are abrogated by Chk1 inhibition, this 
increases the sensitivity to a variety of cytotoxic agents including gemcitabine (Matthews et 
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al. 2007; Xiao et al. 2003). This impact of Chk1 inhibition to interfere with checkpoint 
signaling has been specified in an analysis of Chk1 downstream targets in response to its 
inhibition in the absence of chemotherapy: First and as a surprising result, only the minority 
of cell lines was sensitive to the applied Chk1 inhibitor and, second, resistant cell lines were 
characterized by a failure to accumulate Cdc25A after Chk1 inhibition and therefore fail to 
activate CDK2 (compare to Fig 5.1 and (Sakurikar et al. 2016)). In line with this, several 
studies demonstrated a role for Chk1 kinase function during unperturbed S-phase, when 
the activation of the S-phase checkpoint, an event which is carried out by the 
phosphorylation of Chk1 target genes, predominates to attenuate DNA replication. The 
activation of CDKs is the rate limiting step for increased origin firing, ssDNA accumulation 
and ATR kinase activity after Chk1 inhibition and leads to extensive firing of dormant origins 
with the accumulation of stalled replication forks as consequence. This effect can be 
completely rescued when CDKs are simultaneously inhibited and Chk1 inhibitor resistant 
cells seem to somehow circumvent CDK activation (Sakurikar et al. 2016; Syljuasen et al. 
2005). Furthermore, the inhibition of Wee1, a kinase which can directly phosphorylate CDK2 
without the interim step of CDC25A phosphorylation and degradation, increases 
gemcitabine toxicity even in those cell lines that are resistant to Chk1 inhibition, in 
unperturbed condition as well as after chemotherapy (Saini et al. 2015; Sakurikar et al. 
2016). 
In summary, the above-mentioned mechanisms suggesting CDK2 activity as mediator of 
chemoresistance to Chk1 inhibitors would also implicate a lack of DNA damage 
accumulation after Chk1 inhibition. However, this view is challenged by our findings and 
 
 
Figure 5.1 A model for the induction of resistance to Chk1 inhibitors. 
In response to DNA damage, ATR phosphorylates Chk1 to increase its activity. When Chk1 is inhibited, ATR 
continues to activate Chk1 due to a lacking negative feedback loop. Chk1 inhibition can now result in pathway 
A, leading to the activation of CDK1 to increase origin firing and DNA damage. It can also result in pathways 
B, which is the induction of TLS as an error prone but fast damage tolerance mechanism to resume 
replication. If we expand our view to late S-phase, pathway C would lead to the abrogation of the G2 /M 
checkpoint. While pathway A and C are kinase-dependent and therefore influenced by Chk1 inhibition, the 
kinase-independent pathway B is not. 
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those of Parsels et al., according to which neither the induced levels of γH2AX nor the 
activation of cell cycle arresting degradation of Cdc25a appears to be predictive for Chk1 
inhibitor sensitivity in pancreatic cancer cells after gemcitabine treatment ((Parsels et al. 
2009), data not shown).   
Furthermore, Chk1 activity promotes DNA repair through the induction of HR. This pathway 
is potentially defective when Chk1 is inhibited. However, pancreatic cancer cells which have 
impaired HR through a mutation of the tumor suppressor BRCA1 do show reduced 
sensitivity to gemcitabine, but no difference in γH2AX accumulation after Chk1 inhibition in 
BRCA1 mutant and wild type cells (Hattori et al. 2011). In our model, this effect is of minor 
relevance as none of the used cell lines have described defects in BRCA1. 
 
5.1.4.2  Translesion synthesis 
The promotion of TLS by Chk1 is of minor relevance if replicative stress is comparably low. 
However, when cells suffer extensive replicative stress after gemcitabine therapy, the 
activation of checkpoints and induction of DNA repair is overburdened to ensure a proper 
replication of the genome. Then, cells are forced to undergo apoptosis or activate the Chk1-
dependent damage tolerance mechanism of TLS. Interestingly, this is, compared to 
checkpoint activation, carried out independently of Chk1 kinase function (Speroni et al. 
2012; Yang et al. 2008). Two scenarios arise in which checkpoint signaling after Chk1 
inhibition loses relevance: It is possible that in the subset of pancreatic cancer cells found 
resistant to Chk1 inhibition, checkpoint signaling is already fully activated without 
gemcitabine and additional DNA damage largely exceeds the cellular capacities of DNA 
damage and DNA repair mechanisms. Otherwise, it is reasonable that S-phase checkpoint 
adaptation is one of the oncogenic features those pancreatic cancer cells already bring 
along, so that Chk1 activation following DNA damage can hardly induce cell cycle delay. 
Under those conditions, kinase-dependent functions of Chk1 would step back behind 
kinase-independent functions of the phosphorylated Chk1 protein. Chk1 could then only act 
through the mediation of TLS, a process that, when activated, leads to a resumption of DNA 
replication, promoting gemcitabine resistance and genomic instability (see Fig. 5.1). 
A role for kinase-independent functions of Chk1 in response to gemcitabine therapy is 
fortified by our and others´ findings that there is an increase in total Chk1 and Ser317-
phosphorylated Chk1 levels after inhibition of its kinase domain (data not shown). The 
Ser317 phosphorylation site is necessary for the release of Chk1 from chromatin and the 
promotion of TLS following DNA damage (Smits et al. 2006; Speroni et al. 2012). Increasing 
Chk1 levels would thus further support the induction of TLS. If Chk1 pSer317 was of central 
importance for the induction of TLS, reducing it should mediate gemcitabine toxicity in cells 
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which are resistant to Chk1 inhibition. Indeed, the inhibition of ATR not only reduces Chk1 
pSer 317, but also increases gemcitabine toxicity in the same cell lines which we identified 
as resistant to Chk1 inhibition (Saini et al. 2015).  
Our findings of increased cell proliferation after Chk1 inhibition are supported by the results 
of Syljuasen et al. who demonstrate that Chk1 kinase activity rather controls the 
maintenance of the G2/M checkpoint. The authors show that ionizing radiation-induced G2-
arrest requires Chk1 activation on several phosphorylation sites, and that cells can be 
forced to enter mitosis despite high γH2AX signaling when the kinase function of Chk1 is 
inhibited (Syljuasen et al. 2006). This may play a role for Chk1 inhibitor resistance in 
combination with gemcitabine (Fig 5.1): In the model that we propose, inhibition of Chk1 
does not only help cells through S-phase despite high levels of DNA damage. At the same 
time it also helps cells to abrogate the following G2/M checkpoint and divide in the presence 
of damaged or not fully replicated DNA. Thus, treating Chk1 inhibitor-resistant tumor cells 
with Chk1 inhibitor would not only have no positive effect, but would even promote genomic 
instability and cancer progression when the cell can avoid to die of mitotic catastrophe.  
Despite promising in vitro results, the transfer of Chk1 inhibitors to bedside has been 
disappointing. Chk1 inhibitors display inacceptable side effects and, when lowered to doses 
which make those tolerable, only have low anti-tumor effectivity (Ma et al. 2011; Manic et 
al. 2015). Our results suggest that the lack of anti-tumor activity of Chk1 inhibition is not 
only a dosage effect, but is also due to chemotherapy resistance mediated by increased 
damage tolerance and checkpoint abrogation after Chk1 inhibition. 
 
5.2  Validation of screening quality of a high-content siRNA 
screen in pancreatic cancer cells to identify new regulators 
of the DNA damage response 
 
High-content siRNA screening is an established approach to identify regulators of a distinct 
response to a treatment and has been used for the identification of DNA damage 
transmitters before (Adamson et al. 2012; Higgins et al. 2010). Among our hits were known 
mediators of the gemcitabine response confirming the design of our approach. As we 
expected for a cell line with mutant p53, we did not find explicit regulators of the p53 pathway 
among the candidates, underlining that our candidates have roles in the gemcitabine 
response independent of p53 modulation. Only ATR, Chk1 (both positive controls), PCNA, 
RBM38, RPA1 and CHD8 have previously been shown to influence p53 activity. However, 
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they all exhibit extensive functions apart from that and some are involved in the DDR. 
Interestingly, p53 itself ranged among the top 20 candidates whose knockdown led to 
γH2AX accumulation, but none of the p53 siRNAs achieved a robust z-score higher than 2. 
Thus, knockdown of mutant p53 does not have a significant effect on H2AX phosphorylation 
in PANC-1 cells, a finding that we confirmed during the following experiments. Additionally, 
we found the negative controls ranging around the median of each plate and found the 
positive controls MK2 and ATR among the candidates. Our manually added controls RNF8 
and Chk1 strongly down- and upregulated H2AX phosphorylation, respectively. Another 
surprising result was that every ATR siRNA for control as well as the three ATR-siRNAs 
that where part of the library significantly reduced γH2AX levels (see Fig. 4.9), although 
functional ATR was repeatedly reported to limit the DDR through the activation of 
checkpoints (also see 1.3.2). One possible explanation is that ATR might be responsible for 
the majority of γH2AX phosphorylation in response to replicative stress and that ATM is not 
directly able to take over that function. This assumption is supported by the fact that the 
reduction of γH2AX following ATR knockdown is more pronounced in replicating, thus EdU-
positive cells, as it is the case for γH2AX accumulation following Chk1 knockdown (Fig. 
4.10). Both knockdowns do not influence EdU incorporation itself (Fig 7.1) 
Generally, the robust z-scores we achieved during our screen are surprisingly low given 
that chemotherapy impacts cellular homeostasis on various levels and processes. For the 
identification of hits in high throughput analysis, a robust z-score of 3 or more is generally 
accepted for candidate identification (Brideau et al. 2003). We further observe high variance 
between the three siRNAs of different sequences. This can basically have two major 
reasons: First and besides the sequence-specific binding of siRNAs, a dose-dependent off-
target effect due to the unspecific interference with gene transcription is one of the major 
limitations of this method. False conclusions can be minimized by the utilization of different 
siRNAs of which replicable results can be rated specifically. Second, the robust z-score is 
highly sensitive to in-plate variations of the readout. Having various readout-influencing 
factors on one plate would lead to high standard deviations and low robust z-scores in the 
following. This is especially critical for pre-selected libraries like ours, where an influence 
on the readout of a comparably large scale of siRNAs is likely. Furthermore, this makes it 
necessary to perform a control-based approach to evaluate primary candidates.  The 
amount and distribution of control transfections then need to be sufficient to ensure a 
reliable basis of comparison. 
In the end, differences between cell type account for the fact that a gene which proved to 
have significant influence on the readout might not be suitable for transfer experiments. This 
should be kept in mind when concentrating on the highly represented proportion of 
chromatin remodeling enzymes among the candidates resulting from our screen. Especially 
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chromatin perturbations that result from the respective knockdown of a chromatin 
remodeling enzyme can be highly cell type specific (Lans et al. 2012). 
We decided to further characterize CHD8 in the gemcitabine response for two reasons: 
First, because it is a representative of the large family of chromatin remodeling enzymes 
that have been identified in the screen. Second, because it appeared promising to us 
according to literature research. Likewise, the following listed candidates have promising 
roles in cell biology that could account for an effect during replicative stress and DNA 
damage: 
HELLS (Helicase, lymphoid-specific) is required for DNA methylation and maintenance as 
well as establishment of stemness (Briones and Muegge 2012). A role for HELLS in the 
DDR has recently been established: HELLS seems to be necessary for efficient H2AX 
phosphorylation in response to ionizing radiation. Depletion of HELLS leads to reduced 
γH2AX levels and to less efficient formation of MDC1 and 53BP1 foci, thus less efficient 
DNA repair and reduced cell proliferation (Burrage et al. 2012). How exactly H2AX-
phosphorylation is reduced upon HELLS knockdown or knockout remains unclear. HELLS 
has not yet been investigated in the response to replicative stress. 
MCM10 (Minichromosome maintenance complex component 10) is involved in DNA 
replication. It is required for unwinding of DNA and its presence on the eukaryotic replicative 
DNA helicase is necessary to activate replication origins and to recruit DNA polymerases, 
although it does not belong to and has no structural relation to the core minichromosome 
maintenance (MCM) 2-7 helicase (Kanke et al. 2012; van Deursen et al. 2012). DNA 
Polymerase α (Pol α) and Pol δ can only be bound to DNA in the presence of MCM10, and 
through its binding to Pol α, MCM10 might have a role in lagging strand synthesis. In 
addition to its ability to bind polymerases and PCNA, MCM10 can bind to RNA and ssDNA. 
As it is found to bind transiently to ssDNA at replication forks and is crucial for the 
association of RPA at these sites, it might have a role in ssDNA stabilization. Depletion of 
MCM10 results in cell cycle arrest in G2/M-Phase, a reduced entry into S-Phase and the 
accumulation of γH2AX (Chattopadhyay and Bielinsky 2007; Thu and Bielinsky 2013). So 
far, MCM10 was not characterized in response to chemotherapy and has never been 
investigated for the sensitization of cells towards gemcitabine, but the described 
mechanisms suggest a role for MCM10 in this context. 
STAG2 (Stromal antigen 2) is a subunit of the cohesion complex that is responsible for the 
separation of sister chromatids during mitosis. Loss or mutation of STAG2 causes 
aneuploidy in cell lines with a previously stable karyotype. Its cleavage in metaphase is a 
prerequisite for the adequate separation of sister chromatids (Kleyman et al. 2014; Solomon 
et al. 2011). STAG2 has been shown to be mutated or deleted as well as overexpressed in 
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various solid and mesenchymal tumors, and is an independent prognostic marker for 
pancreatic adenocarcinoma where its loss correlates with good response to platinum-based 
regimens (Evers et al. 2014). So far, STAG2 is not known to play a role in the DDR, 
especially not for S-phase targeting agents as gemcitabine. 
 
5.3  CHD8 modulates the DNA damage response after various 
types of damage 
 
5.3.1  A role for CHD8 in the DNA damage response and checkpoint signaling 
Our follow-up experiments confirmed the screen results in that CHD8 knockdown increases 
DNA damage signaling. This is not only true for replicative stress-inducing DNA adducts as 
achieved by gemcitabine and UV treatment, but also and even stronger after the induction 
of DSBs (Fig. 4.19, 4.20b). We therefore reasoned that CHD8 is not part of a damage-
specific signaling cascade, but executes a broader function in the response to damaged 
DNA.  
In CHD8-depleted PANC-1 and U2OS cells, γH2AX induction is increased when combining 
CHD8 knockdown with all types of damaging agents we used. This effect was less 
pronounced after longer treatment times, which is possibly due to secondary effects that 
have already taken place over time like the onset of DNA repair or apoptosis. The 
phosphorylation of checkpoint kinases is an early event after DNA damage. Therefore, we 
checked for the induction of pChk1 and pChk2. The lack of accumulation of pChk1 after 
long-time gemcitabine treatment might be attributable to the low temporary precision of 
gemcitabine treatment and the pronounced time dependency of Chk1 phosphorylation: 
While those cells which were hit early during the administration time for gemcitabine have 
already decreased pChk1 levels when the cells are harvested, those cells that enter S-
phase later only start to accumulate pChk1 at that time (see also Fig. 4.7). However, the 
accumulation of γH2AX after CHD8 knockdown was still significant enough to identify CHD8 
as a mediator of the DDR in our screen after long gemcitabine treatment time. After the 
administration of gemcitabine for only four hours and after the timely precise UV irradiation, 
the increased accumulation of γH2AX as well as of pChk1 and pChk2 was clearly 
detectable. 
Consistent with the accumulation of γH2AX, we thus observed an induction of both main 
DDR pathways: the phosphorylation of Chk1 as well as the phosphorylation of Chk2. We 
excluded that those findings were a secondary effect after the induction of apoptosis, which 
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usually results in DNA damage signaling induced by fragmented chromatin. Interestingly, 
although the activation of checkpoint signaling should cause a cell to slow down progression 
through cell cycle, we observed the opposite to be true: CHD8-depleted, synchronized 
U2OS cells have a slightly accelerated passage through S-phase. In line with this, we 
observed that CHD8-depleted cells incorporate more EdU in untreated cells as well as after 
gemcitabine treatment (Fig. 7.1 and 7.3-6). This contradicts a study of Subtil-Rodriquez et 
al. who found CHD8 to be necessary for the progression through S-phase during 
unperturbed replication (Subtil-Rodriguez et al. 2014). The authors identified two CHD8-
dependent, S-phase specific transcribed genes, TYMS (thymidylate synthetase) and 
CCNE/Cyclin E1, and found that depletion of CHD8 as transcription factor of both causes a 
G1 arrest. However, in our microarray analysis, we did not find the above-mentioned 
proteins to be less transcribed in a CHD8 knockdown condition. We did find some 
alterations in cell cycle attributable genes, for example a 1.5-fold increase in the tumor 
suppressor Rb1L, but we cannot state whether this is a direct effect of CHD8 depletion or 
induced by for example checkpoint signaling. It would thus be of future interest to test if 
CHD8 depletion has influence on CDKs and CDC25s as indicators for active checkpoint 
signaling or if it has a pronounced role in transcription-dependent cell cycle regulation. 
CHD8 did not cluster at DNA damage sites induced by UV irradiation (Fig 4.22). At such 
foci, DDR and DNA repair usually take place and some immobilized damage response 
factors cluster here, while others diffuse throughout the cell to carry out their function. There 
are chromatin remodeling enzymes such as CHD4 that do cluster to ionizing radiation-
induced foci in a time-dependent manner. However, CHD8 is one of the largest CHD family 
members and constitutively immobilized to chromatin. Even major regulators of the DDR do 
not cluster in certain conditions, for example ATM does not cluster at sites of 
heterochromatic DNA damage, but only in open chromatin structures (Soria et al. 2012). As 
we see no difference in CHD8 levels and chromatin attachment after DNA damage (Fig. 
4.15), we presume that CHD8 is a house keeping chromatin remodeler. Further, all our 
colocalization experiments were done with overexpressed CHD8, which leads to a flooding 
of the cell with the protein possibly covering moderate spatiotemporal changes.  
Overexpressed CHD8 also failed to rescue the induction of γH2AX after DNA damage. 
Already the transfection of the vector led to a strong apoptotic response, which could 
partially contribute to the accumulation of γH2AX. Given that CHD8 is a house keeping 
chromatin remodeler, and that already haploinsufficiency of CHD8 leads to strong 
developmental defects, any change in CHD8 levels might cause a chromatin response and 
DNA damage signaling. 
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5.3.2  Consequences of CHD8 in the regulation of wild type and mutant p53 
 
5.3.2.1  Induction of apoptosis 
The activation of p53 is a major consequence of DNA damage signaling. We were especially 
interested in the characterization of p53-independent modulators of the gemcitabine 
response to meet the most frequent condition of pancreatic cancers in humans. CHD8 was 
first described to suppress the transcription of p53-dependent genes in mice embryonic 
fibroblasts and human cultured cells (Nishiyama et al. 2009). While CHD8 knockout mice 
die early during embryogenesis due to the widespread onset of apoptosis, the simultaneous 
knockout of p53 only slightly but significantly rescues the apoptotic phenotype.  
In our experiments, we observed the induction of apoptosis after CHD8 knockdown in a p53 
wild type as well as in a p53 mutant context in U2OS and PANC-1 cells, respectively 
(figures. 4.16, 4.21). This is of note because the major loss of function feature of mutant 
p53 is its inability to induce apoptosis, letting us assume that induction of DNA damage 
signaling and apoptosis in CHD8-depleted cells is not mediated by activated p53. Indeed, 
we could show that the accumulation of γH2AX as well as of apoptosis markers is not 
decreased after the combined knockdown of CHD8 and p53 (figure 4.24). At this point, our 
results contradict the findings of Nishiyama and colleagues, but also underline a much 
broader function for CHD8 beyond the modulation of the p53 response (Nishiyama et al. 
2009). Cells which lack functional p53 can still undergo apoptosis, and some of the 
mechanisms for that are known although their significance for chemotherapy-induced 
apoptosis remains unclear to date. One possibility is that CHD8 suppresses the p53 
homologues p63 and p73 (Walerych et al. 2015). 
 
5.3.2.2  CHD8 impacts the cellular homeostasis of p53  
We also found that a cell’s ability to sustain p53 active and at high levels relies on the 
presence of CHD8. After CHD8 knockdown, not only wild type p53 is lowered, but also the 
high levels of mutant p53 in PANC-1 cells are reduced, as is its phosphorylation. Although 
not discussed by them, Nishiyama et al. could detect the same effects in their wild type p53 
experiments (figure 1f in Nishiyama et al., 2009). This is of particular interest as p53 is one 
of the best characterized proteins, and a plethora of p53-inducing and stabilizing factors are 
known. However, hardly any pathway is described to down-regulate p53 if not via the activity 
of p53 itself. Usually, in p53 mutant cancer cells, high levels of p53 as well as of MDM2 as 
the main ubiquitin ligase for p53 and thus its main antagonist are detectable. While p53 
induces the transcription of MDM2 in a wild type setting, either this transcription or the 
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interaction between MDM2 and p53 are lost when p53 is mutated. To test whether CHD8 
limits p53 degradation, we stained for the cellular levels of MDM2. We found that in wild 
type as well as in mutant conditions, MDM2 levels decrease after CHD8 knockdown in line 
with p53 levels, suggesting that MDM2 is not the missing link between CHD8 depletion and 
loss of p53 levels. Furthermore, we find p53 levels to be decreased after CHD8 knockdown 
when the proteasome is blocked. This makes it unlikely that CHD8 exerts its effect on p53 
levels by influencing other stabilizing factors that would normally target p53 for proteasomal 
degradation. 
How does CHD8 then influence the cellular homeostasis of p53? If we assume that CHD8 
indeed represses the transcription of p53-dependent, pro-apoptotic genes, then it should 
also be able to limit the transcription of p53 itself. However, during our microarray analysis 
we found p53 mRNA to be reduced to 66 % in p53 wild type U2OS cells after CHD8 
knockdown, with a false discovery rate of 11 %. Although we have not confirmed reduced 
p53 transcription in mutant p53 PANC-1 cells, we expect p53 mRNA to be reduced to match 
the changes we see of high mutant p53 protein levels (Fig 4.25). 
 
5.3.2.3  Regulation of mutant p53 in tumor biology 
Why is the decrease of mutant p53 levels of particular biological and clinical interest? 
Oncogenic signaling and elevated levels of DDR are key features of a developing malignant 
cell and are kept under control by the constant activation of p53. This leads to a high 
selective pressure for loss of function mutations of the tumor suppressor, which accounts 
for the fact that p53 is mutated in around 50 % of tumors (Hollstein et al. 1991; Kandoth et 
al. 2013). Nonsense mutations account for only 10 % of occurring p53 interruptions, and 
while deletions of p53 mainly occur in hematological malignancies, around 75 % are 
missense mutations as found for pancreatic cancers (Leroy et al. 2014). Those missense 
mutations occur mainly in the DNA binding domain, while the transactivation domain 
remains unaffected. Mutations thus interfere with p53-dependent transcription but conserve 
the ability to activate gene transcription when bound to DNA in an alternative manner (Oren 
and Rotter 2010). Missense-mutated p53 leads to the flooding of a cell with dysfunctional 
p53 protein, mainly because it is withdrawn from feedback loops and unable to induce the 
transcription of its main negative regulator MDM2. Mutant p53 is not more stable than its 
wild type counterpart, but is rather stabilized in the same manner, which is the constantly 
elevated DDR in tumor cells (Oren and Rotter 2010). Interestingly, many oncogenic gain of 
function features of missense p53 mutations have been reported that, dependent on the 
mutated sequence and expression level, render mutant p53 a heterogenic group of cancer 
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driving proteins (Bykov et al. 2018). Stabilizing mutant p53 by the above-mentioned 
mechanisms enhances its oncogenic potential. 
These gain of function mutations enable p53 to suppress other family members, for example 
p63 and p73, which usually take over some of p53 functions in knockout experiments 
(Gaiddon et al. 2001). Mutant p53 collaborates with activated Ras signaling, the most 
common oncogenic pathway in pancreatic cancer, to promote tumor cell transformation 
(Suh et al. 2011). . 
At a DDR level, mutant p53 can inactivate proper DNA damage signaling by preventing 
ATM activation. The mutated p53 protein binds to MRE11, which is part of the ahead 
mentioned MRN complex (Section 1.3.3). Mutant p53 impairs complex assembly which 
further is critical for the tethering of ATM to damaged DNA and its activation (Song et al. 
2007). Thus, mutant p53 drives cancer cell malignancy through transcriptional interference, 
as well as altered protein binding and recruitment compared to wild type p53, and by 
impairing tumor suppressive functions of other factors (Oren and Rotter 2010). 
It is thus of interest for anti-cancer therapy and matter of debate and research for years how 
wild type functions of mutant p53 can be restored or how the abundance of mutant p53 can 
be downregulated (Bykov et al. 2018). 
To our knowledge, there are only few known factors whose manipulation can lower the 
cancer cells’ load of mutant p53. One of those is the HSP 90 (heat shock protein 90) which 
stabilizes gain of function mutant p53 in colorectal cancers and whose inhibition suppresses 
p53 levels and tumor growth (Schulz-Heddergott et al. 2018). It is thus of interest to obtain 
a more detailed view of the interference of CHD8 with the transcription of mutant p53.One 
question is whether a decrease of the entire CHD8 protein is necessary for this effect or 
whether the inhibition of a certain domain of CHD8 by small molecules is already sufficient. 
The latter would make CHD8 a potentially druggable target for mutant p53 malignancies 
such as pancreatic cancer, even more so if we take into account that a slight disturbance 
of p53 activity can be sufficient for extensive effects to be seen (Vousden and Lane 2007). 
 
5.4  CHD8-dependent transcription of DNA damage response 
factors 
 
In the literature, CHD8 is characterized mainly as to its regulation of transcription by various 
mechanisms (see also 1.8). We therefore grouped the results from microarray analysis 
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according to cellular functions (Table 4.2). Of those, some candidates appeared promising 
to us because they are already mechanistically involved in the DDR.  
The downregulation of USP11 (Ubiquitin-specific protease 11) following CHD8 knockdown 
has already been found before (Rodriguez-Paredes et al. 2009) and could be detected and 
confirmed via qPCR and on a protein basis in our lab (data not shown). USP11 is an 
established DDR factor acting in the BRCA2-dependent HR pathway. While patients with 
germline BRCA2 mutations have a high risk to develop pancreatic and other tumors, 
sporadic BRCA2 mutations in pancreatic cancer samples are comparatively rare. 
Pancreatic cancer cells with an intact HR pathway are susceptible to mitoxantrone 
treatment that is, among its conventional DNA damaging properties, able to potently inhibit 
USP11 (Burkhart et al. 2013). However, while this study found mitoxantrone being much 
more effective to reduce pancreatic cancer cell proliferation than is gemcitabine, it did not 
find a significant cytoreductive effect with RNAi-mediated USP11 depletion to 60 % in 
untreated cells. Possibly, mitoxantrone exhibits its cytoreductive effect through other 
mechanisms than via USP11 inhibition. Nonetheless, the RNAi-mediated reduction of 
cellular USP11 levels did have a sensitizing effect for gemcitabine treatment, making it 
plausible that the enhanced DDR after CHD8 depletion is a secondary effect mediated by 
the suppression of USP11. Still, the knockdown of CHD8 in our experiments reduces 
USP11 levels more than does the knockdown of USP11 itself in the above-mentioned 
publication, which is to 31 % instead of 60 %. Another study showed that USP11 binds to 
BRCA2 to ubiquitinate it, and it sensitized cells to mitomycin C treatment only in a BRCA2 
wild type condition. However, cellular levels of BRCA 2 were not lowered after USP11 
depletion, so that it the question remains whether USP11 specifically promotes HR or 
whether BRCA2 defective cells exhibit high chemoresistance in general (Schoenfeld et al. 
2004). Of note, USP11 stabilizes p53 by reducing its ubiquitination, leading to a pro-
apoptotic response of a cell (Ke et al. 2014). In the same way it stabilizes p21 to promote 
cell cycle arrest and senescence (Deng et al. 2018). Besides the influence on protein 
turnover, USP11 promotes the transcription of IKKα in response to NF-κB signaling and its 
depletion leads to reduced p53 expression in p53 wild type conditions (Yamaguchi et al. 
2007). 
Although we cannot detect a p53-stabilizing effect following CHD8 knockdown, the known 
features of USP11 depletion would well explain at least some of our observations like cell 
cycle progression and reduced p53 levels in CHD8-depleted cells. Still, it is not known 
whether USP11 has any effect on the transcription of mutant p53.  
With its DNA repair and p53/p21-promoting properties, USP11 would rather act as a tumor 
suppressor and its knockdown should lead to an increase in DDR through impaired HR, but 
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also to apoptosis resistance through reduced p53 levels and cell survival after DNA 
damage. 
The downregulation of the scaffolding protein KSR2 (kinase-suppressor of Ras 2) connects 
CHD8 to cellular stress and proliferation signaling cascades. KSR2 positively regulates Ras 
signaling, which is a signaling cascade connecting receptor tyrosine kinase signaling to 
DNA damage and transcriptional responses of a cell. The most common tumor driving 
mutation of pancreatic cancer, an activating KRAS mutation, leads to a constant induction 
of this kinase cascade. While oncogenic KRAS activations cannot be targeted yet, the 
inhibition of downstream kinases such as ERKs induces DNA damage signaling and 
apoptosis (Kirkpatrick et al. 2013) as well as p53 phosphorylation and stabilization 
(Melnikova et al. 2003). KSR2 positively regulates receptor tyrosine kinase-mediated ERK 
signaling and might thus have tumor-promoting functions, but the KSR2-dependent growth 
induction of several tumor cell lines is independent of upstream kinase signaling (Fernandez 
et al. 2012). Based on the above-mentioned, the decrease in KSR2 levels could also be a 
mediator of the effects of CHD8 knockdown on DNA damage signaling and apoptosis.  
When we focused on genes whose transcription is induced upon CHD8 knockdown, two 
DNA repair factors are noticeable: First, the 1.5-fold induction of the histone acetylase 
KAT5/TIP60 links CHD8 to the repair of DSBs, too. Following the induction of DSBs, the 
acetylation of H4 by the histone acetyl transferase TIP60 is required for efficient recruitment 
of repair proteins like ATM, which itself is acetylated by KAT5 to increase its activity (Murr 
et al. 2006; Sun et al. 2005). TIP60 further acetylates γH2AX as a prerequisite for H2AX 
ubiquitination and removal from DNA after damage is repaired (Ikura et al. 2007). If CHD8 
acted via KAT5, CHD8-deficient tumor cells would hyper-activate ATM, DNA repair and, if 
not defective for it, apoptosis. 
Second, with MDC1, another DNA repair protein is induced after CHD8 knockdown. MDC1 
is a large scaffolding protein which has a central role in the activation of ATM and therefore 
the spreading of γH2AX away from the actual DNA lesion to promote not only DDR, but 
also apoptosis (see section 1.3.3). Indeed, high expression levels of MDC1, although a 
repair protein, are associated with chemoresistance in malignant cells. The cause seems 
to be a general activation of the DNA repair machinery in response to an amplification of 
DNA damage signaling after drug-induced damage, leading to high levels of γH2AX on the 
one hand, but fast DNA repair and the resumption of cell cycle progression and tumor 
proliferation on the other hand. MDC1 recruits the ubiquitin ligases RNF8 and RNF168 to 
chromatin, where they ubiquitinate histone H2A as a prerequisite for BRCA1-dependent 
repair of DSBs (Luijsterburg and van Attikum 2011). MDC1 is increased to 1.6-fold after 
CHD8 depletion, so to a much lower extent as usually seen for transcriptional responses in 
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signaling cascades. Still, as MDC1 acts far upstream of the DDR and its abundance 
delicately influences the intensity of DNA damage signaling, already small changes would 
have a dramatic effect. Interestingly, MDC1 was among the main candidates whose 
knockdown robustly lowered γH2AX levels in our siRNA screen showing that it promotes 
H2AX phosphorylation in response to gemcitabine treatment (Fig. 4.12, table 7.1 and 7.2). 
5.5  A model of chromatin reorganization induced by CHD8 
depletion for efficient promotion of DNA repair after UV and 
gemcitabine treatment 
 
Higher order chromatin structure profoundly influences genome maintenance and DNA 
repair. Chromatin structures are non-randomly distributed within the nucleus, one of the 
best examples being the organization of DNA into euchromatin and heterochromatin. 
Euchromatin contains actively transcribed genes, and facultative heterochromatin occurs 
by gene silencing for example during cellular differentiation (Nair and Kumar 2012). 
Constitutive heterochromatin represents around 25 % of the genome and is characterized 
by low gene density but highly repetitive sequences that increase the risk for recombination 
and might necessitate an even tighter control of genome maintenance (Goodarzi and Jeggo 
2012; Soria et al. 2012). Although chromatin is undoubtedly needed for the regulation of 
virtually all DNA-associated processes to take place, it primarily forms a barrier to efficient 
DNA repair. High compaction in heterochromatin hinders the access for repair factors even 
more, but due to its high abundance, it forms the major environment in which the whole 
DDR takes place (Bakkenist and Kastan 2015). A cell deals with such a challenge and threat 
to genomic integrity by tightly regulated mechanisms:   
When damaged DNA is encountered, chromatin needs to be opened first to elicit a fully 
activated DDR and needs to be restored when damage is repaired. One well characterized 
process is the CHD3-dependent relaxation of heterochromatin: ATM, when activated, 
phosphorylates the heterochromatin-associated protein KAP-1, which loosens contact to 
DNA and to CHD3, which in turn diffuses from chromatin to open it. After repair, the 
restoration of KAP-1 to DNA tethers CHD3 to the NuRD complex, again leading to the 
reformation of heterochromatin (Klement et al. 2014). 
Indeed, spreading of γH2AX is impaired when meeting heterochromatin border and γH2AX 
foci form slower in heterochromatin (Brunton et al. 2011; Soria et al. 2012). Also, repair of 
DSBs seems to occur 2-fold slower in heterochromatin than in euchromatin and is 
predominantly dependent on ATM, whereas in euchromatin some studies found that it is 
not (Goodarzi et al. 2008).  
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Heterochromatin is refractory to the spreading of γH2AX and γH2AX foci occur mutually 
exclusively with heterochromatin marks but cluster in the periphery of those (Goodarzi and 
Jeggo 2012). In yeast, γH2AX spreading is immediately stopped when encountering a 
heterochromatic region (Kim et al. 2007).  
The generation of global chromatin environments requires boundary elements, to which 
chromatin modifying enzymes are recruited. One of those boundary elements is CTCF. 
Indeed, we observed that the induction of DNA damage signaling upon CHD8 kd is 
dependent on the presence of CTCF in a preliminary result, but here both factors appear to 
have antagonistic effects on the DDR (Fig. 5.2). 
The relevance of the above-mentioned becomes clear when we take into account that, 
indeed, an open chromatin structure as found in stem cell like populations confers higher 
chemoresistance through a higher capacitie to repair DNA. CHD8 can be integrated in a 
model of chromatin organization to modulate the DDR and chemoresistance as follows: The 
linker histone H1 has been found to delicately influence chemoresistance as its deletion 
leads to an open chromatin structure and hyperresistance to a variety of DNA damaging 
agents (Hargreaves and Crabtree 2011; Murga et al. 2007). CHD8 could do the same by 
providing an open chromatin environment. It evidently binds histone H1 to chromatin 
(Nishiyama et al. 2009) and it would be of interest whether depletion of CHD8 leads to a  
 
Figure 5.2 Depletion of CTCF does not increase the cellular DNA damage response but rescues the 
effect of CHD8 depletion in UV-treated cells. 
U2OS and PANC-1 cells were depleted of CHD8 and CTCF as indicated and treated with 20 J/m2 UV-C or 
left untreated. One hour after treatment, cells were harvested and analyzed by immunoblotting. 
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phenotype comparable to H1 depletion. However, open chromatin structures do not 
unilaterally promote DNA repair and cell survival. Decompacted DNA  becomes hydrolyzed 
easily activating the DDR (Walerych et al. 2015). Further, facilitating DDR leads to an 
apoptotic response (Bakkenist and Kastan 2015). As a consequence, decompaction of 
chromatin may initially lead to increased γH2AX accumulation and cell death, but in the long 
term increases the fraction of chemoresistant cells. If we apply this model to the phenotype 
we see after CHD8 knockdown, we should not only observe increased DNA damage 
response but also chemoresistance. Indeed, as a preliminary result, we do see a slight -- 
though not significant -- reduction of cell growth in CHD8-depleted, gemcitabine-treated 
cells initially. This is independent of the presence of p53. As soon as cells start to recover 
 
Figure 5.3 Influence of CHD8 knockdown on cell proliferation after gemcitabine treatment. 
U2OS cells were transfected with the siRNAs as indicated. After the replacement of transfection mix and 
recovery, they were trypsinized, counted and seeded and either treated with gemcitabine or left untreated as 




Figure 5.4 A model for CHD8 in the DNA damage response.  
This speculative model integrates transcription and chromatin remodeling functions of CHD8. Either the 
decompaction of chromatin after CHD8 knockdown or the enhanced transcription lead to accumulation of 
DNA damage and repair factors, resulting in increased DNA damage signaling and apoptosis on the one 
hand but a higher fraction of cells which can repair their DNA and therefore resume proliferation and acquire 
chemoresistance on the other hand. 
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from gemcitabine treatment, CHD8-depleted cells show a slight growth advantage (Fig. 
5.3). Furthermore, we observe increased EdU incorporation and slightly faster progression 
through cell cycle after CHD8 depletion.  
Thus, a speculative model emerges bringing together the decompaction of chromatin as 
potential mechanistic basis for CHD8’s role in the DNA damage response together with the 
expression of KAT5 and MDC1 following CHD8 knockdown (see Fig. 5.4): CHD8 
knockdown could either specifically activate the transcription of KAT5 and MDC1 or both 
factors could be induced as a secondary effect of chromatin decompaction after CHD8 
knockdown. The acetylation of histones by KAT5 supports an open chromatin structure, 
which facilitates the clustering of highly transcribed MDC1 even more. Both initially leads to 
increased DNA damage signaling but also the activation of ATM and DNA repair pathways, 
leading to a low response to DNA damaging agents. 
 
5.6 Conclusions and future perspectives 
 
In the work presented here we transferred a newly discovered function of MK2 as antagonist 
of Chk1 to the treatment of pancreatic cancer cells with gemcitabine. We could confirm a 
protective effect of MK2 inhibition to chemotherapy in all cell lines tested. This suggests 
MK2 as a novel predictor of gemcitabine sensitivity and its activation to be a promising drug 
target in pancreatic cancers. Interestingly, when we approached the transferability of the 
antagonism of MK2 and Chk1 to pancreatic cancers, we found the system to work in only 
one of four tested cell lines. All other cell lines acquired chemoresistance to gemcitabine 
when Chk1’s kinase function was impaired. This puts the break to the enthusiasm of 
applying checkpoint kinase inhibitors as chemosensitizers.  
In our high throughput approach to find novel modulators of the gemcitabine response we 
identified the chromatin remodeling factor CHD8, which has been described with 
contradicting properties in terms of its role in tumor biology and DNA-associated processes. 
In our experiments, knockdown of CHD8 led to increased DNA damage signaling, i.e. the 
induction of γH2AX, but also to increased phosphorylation of the checkpoint kinases Chk1 
and Chk2. This was true for UV, gemcitabine as well as for the radiomimetic NCS, 
suggesting a broad function for CHD8 in the DDR and possibly the involvement of numerous 
pathways. The effect of CHD8 knockdown was most pronounced when the induction of 
DNA damage was restricted to a short period of time, and even stronger after the induction 
of DSBs. As a consequence, we could detect the onset of apoptosis in CHD8-depleted cells, 
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irrespective of p53. We further detected faster resumption of cell cycle progression, 
increased incorporation of nucleotides into DNA and a debatable advantage in terms of the 
recovery after gemcitabine treatment. It is of note that CHD8-deficient cells display 
diminished levels of wild type as well as oncogenic mutant p53, whose non-targetable 
abundance remains a challenging task in research on tumor biology. We expand the still 
small library of mutant-p53 regulating factors by one. 
However, other scientists have reported features for CHD8 that apparently contradict our 
findings. It will thus be of future interest to shed more light on CHD8-regulated processes in 
the DDR, which we could only roughly outline in this work. To specify CHD8’s role in cell 
cycle regulation, it would be of interest to determine CDK and Cdc25 activity in a cell cycle-
specific manner. If cell cycle progression were resumed faster after the induction of DNA 
damage by gemcitabine or other agents, it would suggest faster repair of damaged DNA. 
Finally, it would be of interest to find the underlying mechanism for the decrease of p53 
levels in CHD8-depleted cells, and whether this is attributable to CHD8’s transcriptional 
function or a secondary effect of general interference of CHD8 with transcription or 
chromatin reorganization. We further gained ideas for CHD8-regulated processes through 
our microarray analysis: The downregulation of USP11 as well as the upregulation of Tip60 
would promote HR, a DNA repair pathway which we have not analyzed in detail so far. In 
particular, CHD8 knockdown upregulates MDC1, whose levels and binding to chromatin 
increase DNA damage signaling. Therefore, the levels and activity of ATM should be 
determined more directly than via the phosphorylation of Chk2, which we clearly observe in 
CHD8-depleted cells as first evidence for increased ATM-dependent signaling in our 
experiments. If this were the case, DNA damage signaling would lead to faster recovery 
after DNA damage. The preliminary result that CHD8-depleted cells resume proliferation 
faster after chemotherapy require replication. Further, established markers of eu- and 
heterochromatin may serve as a readout for the influence of CHD8 on chromatin 
organization.   
Summarized, the data presented in this work does not only establish MK2 as a determinant 
in the gemcitabine response in pancreatic cancer cells, but challenges the strategy of 
applying checkpoint inhibitors as cancer therapeutics. Furthermore, our findings 
demonstrate for the first time a role for CHD8 in the DDR. Mechanistic details need to be 
analyzed to clarify the contradicting findings for CHD8 in cancer cell biology before one 
could exploit it as prognostic factor or drug target. Our results rather open a new door for 
the understanding of a chromatin response to DNA damage, which is well examined in 
hematological malignancies but is only beginning to be appreciated in terms of cancer 
promotion in solid tumors. The relaxation and restoration of chromatin is a tightly regulated 
and ATP-consuming process and therefore susceptible to dysregulation in cancers. It would 
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be no surprise if a balanced activation and silencing of CHD8 turned out to be a cellular 
mechanism for resistance as well as for the response to chemotherapy. More generally, 
instead of inhibiting a single molecule, it seems to be reasonable to target whole pathways 
and physiological cellular responses in order to account for genetic heterogeneity and the 
fast acquirement of drug resistance seen in pancreatic cancer. For this purpose, chromatin 
modifying enzymes are potential candidates as their loss of function broadly affects cellular 
homeostasis in terms of various signaling pathways.
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6. Abstract  
 
 
DNA damage occurs and accumulates in every cell and is cause and consequence of 
cancerogenesis. Massive induction of exogenous DNA damage has its use in 
chemotherapy as it causes growth arrest and apoptosis in malignant cells. The cellular 
response to replicative stress and DNA damage consists of a signaling network called DNA 
damage response. 
The chemotherapeutic drug gemcitabine is a nucleoside analog selectively acting during S-
phase of the cell cycle and therefore affects mainly highly proliferative cells like those found 
in tumors. Its main application is the treatment of pancreatic cancer, which is characterized 
by poor therapeutic response and fast development of chemoresistance. Manipulating DNA 
damage and repair pathways in order to sensitize tumors to this drug has been part of many 
clinical trials. In this context, the knockdown or inhibition of the DNA damage effector kinase 
Chk1 highly activates the DNA damage response and apoptosis. Another DNA damage 
kinase, MK2, was previously identified in our lab as antagonist of Chk1 in the response to 
DNA replicative stress caused by gemcitabine.  
In the first part of this work, the antagonism of the two kinases MK2 and Chk1 was 
established as determinant of the sensitivity to gemcitabine in a variety of pancreatic cancer 
cell lines. Interestingly, the inhibition of Chk1 induces apoptosis only in one cell line while it 
mediates chemoresistance to gemcitabine in the others. This remarkable observation adds 
a new aspect to the criticism of Chk1 inhibitors as cancer therapeutics. 
The second part of this work focuses on identifying new determinants of the gemcitabine 
response. To this end, a high throughput screen in gemcitabine-treated pancreatic cancer 
cells was performed using RNA-interference to deplete cells of 551 gene products which 
have a previously assigned function in the DNA damage response and genomic integrity. 
The screen identifies the chromatin remodeling factor CHD8 to protect cells from the early 
consequences of gemcitabine treatment. Its knockdown causes the accumulation of DNA 
damage and apoptosis markers after replicative stress induced by gemcitabine and 
ultraviolet radiation as well as after DNA double strand breaks induced by the radiomimetic 
neocarzinostatin. In contrast to these seemingly chemosensitizing effects, cells depleted of 
CHD8 obtain a growth advantage through faster recovery after gemcitabine treatment. The 
transcriptional expression of a number of factors involved in the DNA damage response is 
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found to be influenced by CHD8, as demonstrated by microarray analysis. These effects 
are independent of the presence or functionality of the tumor suppressor p53, whose mRNA 
expression as well as protein levels are diminished in CHD8-depleted cells. Remarkably, 
CHD8 depletion can also reduce the abundance of oncogenic mutant p53. This is of 
potential clinical relevance as there are only few ways known to achieve this reduction. In 
summary, we identify CHD8 as a modulator of chemosensitivity with influence on the 
expression of central DNA damage response genes.  
 
Appendix                      144 
 
7. Appendix  
 
 
Table 7.1 Screen candidates based on overall γH2AX levels. 
Screen candidates were defined as genes whose knockdown led to a robust z-score < -2 or > 2 of overall γH2AX 
levels with at least two of three siRNAs. All candidates were sorted by their achieved cumulative robust z-scores 
in γH2AX levels. Column A to C indicate the respective siRNA of the library. Robust z-scores of the candidates 
in EdU-positive cells and their influence on EdU incorporation are coated blue and green, respectively. 
Candidates which were further validated are marked red. Candidates achieving a robust-Z-score < -2 or > 2 in 
EdU-positive cells are marked blue. 
 
γH2AX in all cells γH2AX in EdU-positive cells EdU incorporation 
Gene 
Symbol 
Gene Name robust z-score robust z-score robust z-score 
A B C Cum. A B C Cum. A B C Cum. 
REC8 REC8 homolog (yeast) -5,03 -2,71 -0,83 -8,57 -6,20 1,09 -0,36 -5,47 -0,16 -2,00 1,78 -0,38 
HDAC5 Histone deacetylase 5 -3,73 0,10 -4,78 -8,41 -1,21 -1,07 -0,05 -2,33 -0,93 0,00 -0,77 -1,70 
RUVBL2 RuvB-like 2 (E. coli) -2,46 -0,26 -5,34 -8,06 -2,98 1,86 7,63 6,51 -1,02 0,75 -1,70 -1,97 
TERF2IP 
Telomeric repeat 
binding factor 2, 
interacting protein -4,51 -2,28 -1,21 -7,99 -0,05 13,00 -0,06 12,90 -1,58 -1,74 -0,95 -4,27 
MDC1 
Mediator of DNA-
damage checkpoint 1 -3,04 -1,96 -2,66 -7,65 -1,44 -2,87 -2,35 -6,66 -1,00 -0,96 1,27 -0,70 
RAD23B 
RAD23 homolog B (S. 
cerevisiae) -2,79 -1,68 -3,02 -7,49 -1,59 0,44 -0,76 -1,91 -1,33 -0,63 -0,78 -2,74 
ARID1A 
AT rich interactive 
domain 1A (SWI-like) -3,40 -2,52 -1,14 -7,06 -0,05 -1,24 -1,06 -2,36 -0,96 -1,04 0,15 -1,85 
CCNO Cyclin O -1,53 -2,55 -2,85 -6,93 1,65 -1,73 -5,40 -5,48 -0,69 -0,85 1,37 -0,17 
ATR1 
Ataxia telangiectasia 
and Rad3 related -2,24 -1,75 -2,27 -6,26 -3,90 -3,00 -5,02 
-
11,92 1,28 1,47 2,40 5,16 
SOX15 
SRY (sex determining 
region Y)-box 15 -2,01 -3,32 -0,40 -5,72 -1,23 0,00 0,95 -0,28 -0,96 -4,01 -0,88 -5,86 
UBE2N 
Ubiquitin-conjugating 
enzyme E2N (UBC13 
homolog, yeast) -2,60 -0,27 -2,52 -5,39 0,20 -0,38 -0,60 -0,78 -1,16 -0,12 -0,95 -2,23 
C9orf102 
Chromosome 9 open 
reading frame 102 -0,86 -2,09 -2,11 -5,06 1,73 -1,82 1,62 1,53 -1,31 -0,98 -0,99 -3,28 
HELLS 
Helicase, lymphoid-
specific -2,93 -2,36 0,25 -5,03 -3,18 -2,08 -0,49 -5,75 -0,35 -0,63 1,99 1,02 
EP400 
E1A binding protein 








-2,05 -3,35 0,63 -4,77 0,78 0,46 1,15 2,40 -1,10 -1,04 7,57 5,44 











DNA glycosylase 1 -2,24 0,16 -2,49 -4,57 -0,51 -0,28 2,51 1,72 -1,51 3,66 -1,70 0,46 
H1FX 
H1 histone family, 
member X 2,21 0,03 2,27 4,51 0,79 0,17 1,83 2,80 3,29 -0,44 3,79 6,65 
GTF2H4 
General transcription 
factor IIH, polypeptide 
4, 52kDa -0,17 1,05 3,79 4,66 -2,13 0,46 9,49 7,82 -0,55 -0,69 -0,65 -1,89 
PARP2 
Poly (ADP-ribose) 




chromosomes 2 2,77 0,44 2,16 5,36 1,41 -0,08 6,09 7,42 3,80 -0,90 -1,10 1,80 
RBM38 
RNA binding motif 
protein 38 2,29 3,14 0,24 5,66 2,26 2,80 0,33 5,40 5,17 6,09 1,33 12,59 




component 10 6,62 5,68 -1,05 11,25 2,48 5,13 0,78 8,40 2,17 21,00 -0,63 22,54 
CHD8 
Chromodomain 
helicase DNA binding 
protein 8 7,49 1,70 3,46 12,65 6,99 1,66 3,79 12,44 15,65 2,74 0,72 19,11 
CHEK1 
CHK1 checkpoint 
homolog (S. pombe) 11,91 6,97 0,83 19,71 13,76 10,58 0,87 25,21 1,35 -0,61 -0,99 -0,24 
 
 
Table 7.2 Screen candidates based on γH2AX levels in EdU-positive cells. 
Screen candidates were defined as genes whose knockdown led to a robust z-score < -2 or > 2 of γH2AX levels 
in EdU-positive cells with at least two of three siRNAs. All candidates (coated blue) were sorted by their achieved 
cumulative robust z-score in EdU-gated γH2AX levels. Column A to C indicate the respective siRNA of the 
library. Robust z-scores of the candidates in all cells and their influence on EdU incorporation are coated grey 
and green, respectively. Candidates which have been further validated are marked red. Candidates achieving 
a robust z-score < -2 or > 2 in overall γH2AX levels are marked blue. 
 




robust z-score robust z-score robust z-score 
A B C Cum. A B C Cum. A B C Cum. 
ATR1 
 Ataxia telangiectasia 
and Rad3 related -3,90 -3,00 -5,02 -11,92 -2,24 -1,75 -2,27 -6,26 1,28 1,47 2,40 5,16 
RNF8 Ring finger protein 8 -3,28 -1,33 -4,19 -8,81 -1,40 -1,21 -1,29 -3,90 0,20 2,02 1,08 3,29 
ATRIP ATR interacting protein -3,71 -3,05 -0,90 -7,66 -1,45 -0,48 0,45 -1,47 -0,59 2,20 1,60 3,21 
MDC1 
Mediator of DNA-
damage checkpoint 1 -1,44 -2,87 -2,35 -6,66 -3,04 -1,96 -2,66 -7,65 -1,00 -0,96 1,27 -0,70 
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CIB1 
Calcium and integrin 
binding 1 (calmyrin) -1,59 -2,60 -2,26 -6,45 -0,61 -2,28 -1,00 -3,89 -0,65 -2,00 -0,82 -3,47 
CDC45L 
CDC45 cell division 
cycle 45-like (S. 
cerevisiae) -3,14 -2,63 -0,37 -6,14 -1,90 -2,93 -1,30 -6,13 -0,79 -1,29 -0,90 -2,98 
HUS1 
HUS1 checkpoint 




group A -0,46 -2,38 -3,00 -5,85 -0,02 -2,34 -2,49 -4,85 3,36 -1,18 -0,83 1,36 
HELLS 
Helicase, lymphoid-
specific -3,18 -2,08 -0,49 -5,75 -2,93 -2,36 0,25 -5,03 -0,35 -0,63 1,99 1,02 
CENPH Centromere protein H -2,23 -1,04 -2,31 -5,59 0,92 0,75 -1,45 0,21 1,12 2,04 -0,63 2,53 
PCNA 
Proliferating cell 
nuclear antigen 2,16 -0,63 2,30 3,84 1,01 -0,83 0,55 0,72 -1,05 -1,12 3,01 0,84 
ZNFX1 
Zinc finger, NFX1-type 




repair enzyme) 1 3,19 -0,57 2,01 4,63 -0,95 -2,02 -0,13 -3,10 -1,41 -1,69 0,36 -2,73 
RPAIN RPA interacting protein 3,44 2,83 -1,01 5,26 -0,01 1,06 0,45 1,50 -1,03 -0,84 0,24 -1,62 
TLK2 Tousled-like kinase 2 2,04 0,36 2,93 5,32 -1,77 0,01 2,59 0,83 -0,54 -0,52 6,16 5,09 
TOP2A 
Topoisomerase (DNA) II 
alpha 170kDa 2,21 0,27 2,91 5,39 -0,91 -0,45 -3,96 -5,32 -0,84 -0,74 -2,45 -4,04 
RBM38 
RNA binding motif 
protein 38 2,26 2,80 0,33 5,40 2,29 3,14 0,24 5,66 5,17 6,09 1,33 12,59 
RFC3 
Replication factor C 
(activator 1) 3, 38kDa 1,03 2,46 1,99 5,48 -0,46 1,25 1,79 2,58 -1,91 -1,24 -0,67 -3,82 
POLD4 
Polymerase (DNA-
directed), delta 4 2,27 3,00 0,39 5,66 -0,19 0,99 1,62 2,43 -1,35 -0,82 7,30 5,12 
SHPRH 
SNF2 histone linker 
PHD RING helicase -0,16 3,41 2,76 6,02 1,18 2,20 1,00 4,37 1,75 -0,39 -1,09 0,27 
HAP1 
Huntingtin-associated 
protein 1 2,69 2,74 0,71 6,14 -1,03 1,30 0,04 0,32 -1,16 -0,26 -0,42 -1,85 
POLA1 
Polymerase (DNA 
directed), alpha 1, 
catalytic subunit 2,50 3,27 0,43 6,19 0,99 2,65 -0,82 2,82 -0,65 5,01 -0,74 3,63 
HIST1H1C Histone cluster 1, H1c -0,43 3,52 3,35 6,44 0,88 3,37 -1,45 2,80 0,33 0,26 -1,18 -0,59 
PHB Prohibitin 3,13 4,68 -1,29 6,52 2,53 -1,49 -0,57 0,47 3,42 -1,65 0,50 2,27 
CHMP1A 
Chromatin modifying 
protein 1A 1,72 2,58 2,23 6,54 -0,27 -2,89 0,47 -2,69 -1,41 -1,43 -0,67 -3,51 
RPA4 Replication protein A4 2,84 2,70 1,64 7,17 0,71 2,32 1,31 4,34 0,90 8,49 -0,39 9,00 
ALKBH1 
AlkB, alkylation repair 
homolog 1 (E. coli) 1,86 3,35 2,08 7,30 0,82 -1,43 -0,60 -1,22 -0,69 -1,35 -0,85 -2,90 
SOD1 
Superoxide dismutase 
1, soluble -1,70 6,90 2,43 7,63 -0,81 -0,13 -1,04 -1,98 -1,20 -1,35 -1,27 -3,83 




component 10 2,48 5,13 0,78 8,40 6,62 5,68 -1,05 11,25 2,17 21,00 -0,63 22,54 
VCP 
Valosin-containing 
protein -0,08 3,68 5,17 8,77 0,82 -0,34 0,38 0,86 0,25 -0,58 -0,48 -0,81 




to zinc finger domain, 
2A 0,40 6,40 2,38 9,17 0,63 0,87 0,85 2,34 -0,96 -1,42 8,57 6,19 
RNF25 Ring finger protein 25 0,56 2,32 6,49 9,37 -1,19 -4,47 2,71 -2,95 -0,84 -1,27 -0,30 -2,41 
RPA1 Replication protein A1 2,64 5,18 2,55 10,37 2,50 1,87 1,80 6,17 2,70 -0,41 3,94 6,22 
POLD1 
Polymerase (DNA 
directed), delta 1, 
catalytic subunit 
125kDa 5,34 3,79 2,00 11,13 -4,06 -1,27 -0,48 -5,81 -1,93 -1,65 -0,88 -4,45 
SRCAP 
Snf2-related CREBBP 
activator protein 7,26 1,56 2,33 11,15 0,06 1,08 -0,86 0,28 -1,25 1,20 -1,81 -1,87 
CHD8 
Chromodomain 
helicase DNA binding 
protein 8 6,99 1,66 3,79 12,44 7,49 1,70 3,46 12,65 15,65 2,74 0,72 19,11 
RFC1 
Replication factor C 
(activator 1) 1, 145kDa 17,72 2,76 1,78 22,26 1,07 3,60 1,57 6,24 -1,97 5,71 2,36 6,09 
CHEK1 
CHK1 checkpoint 
homolog (S. pombe) 13,76 10,58 0,87 25,21 11,91 6,97 0,83 19,71 1,35 -0,61 -0,99 -0,24 
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Table 7.3 Relevant biological processes associated with screen candidates. 
All gene products whose knockdown caused a significant change in γH2AX levels, i.e. a robust z-score >2 of at 
least 2 of 3 siRNAs (see table 7.1 and 7.2) were annotated to functional categories using the DAVID functional 
annotation tool for gene ontology of biological processes. A selection of biological processes which are relevant 
for the cell’s reaction to chemotherapy is displayed in the table, corresponding to figure 5.11. 
 
Biological process Candidates whose knockdown causes 
decreased γH2AX levels 
Candidates whose knockdown 
causes increased γH2AX levels 
DNA damage 
response 
ATR, ATRIP, CCNO, CIB1, C9ORF102, 
FANCA, HUS1, MDC1, MYC, RAD23B, 
RNF8, RUVBL2, SMUG1, TERF2IP, 
UBE2N 
ALKBH1, APEX1, CHEK1, GTF2H4, 
PARP2, PCNA, POLD1, POLD4, 
RBM38, RFC1, RFC3, RPA1, RPAIN, 
SHPRH, SOD1, TLK2, TOP2A, VCP  
DNA repair RAD23B, HUS1, SMUG1, MDC1, CCNO, 
FANCA, ATRIP, CIB1, C9ORF102, 
UBE2N, RNF8, RUVBL2, 
ALKBH1, APEX1, CHEK1, GTF2H4, 
PARP2, PCNA, POLD1, POLD4, 
RFC1, RFC3, RPA1, RPAIN, SHPRH, 
SOD1, TOP2A, VCP 
ds-break repair UBE2N, RNF8, HUS1, CIB1 RPA1, VCP, SOD1  
BE repair SMUG1, CCNO POLD1, PCNA, APEX1, PARP2 
NE repair 
 








ATRIP, ATR, RAD23B, HUS1, TERF2IP, 
SMUG1,  MDC1, MYC, CCNO, FANCA, 
HELLS, CIB1, C9ORF102,  UBE2N, RNF8,  
RUVBL2,  
ALKBH1, APEX1, BAZ2A, CHEK1, 
GTF2H4, MCM10, PARP2, PCNA, 
PHB, POLD1, POLD4, REC8, RFC1, 
RFC3, RPA1, RPA4, RPAIN, SHPRH, 
SOD1, TOP2A, VCP 
nucleotide metabolic 
process 
ARID1A, ATR, CCNO, HDAC5, HELLS, 
HUS1, MYC, SMUG1, SOX15, TERF2IP, 
UBE2N 
 BAZ2A, CHD8, CHMP1A, PHB,   
DNA replication HUS1, TERF2IP ATR, PCNA, POLD1, POLD4, RFC1, 
RFC3, RPA1, RPA4, RPAIN 
apoptosis  HELLS, MYC CHD8, PHB, SOD1, TOP2A, VCP 
cell cycle ATRIP, CENPH, FANCA, HELLS, HUS1, 
MDC1, MYC, REC8, RNF8, SUV39H2      
ATR, CHD8, CHEK1, CHMP1A, 
POLD1, RBM38, RPA1, SMC2, TLK2 
DNA and chromatin 
modification and 
remodeling 
ARID1A, CENPH, EP400, HELLS, HDAC5, 
REC8, RNF8, RUVBL2, TERF2IP, SOX15, 
SUV39H2, UBE2N 
BAZ2A, CHD8, CHMP1A, HIST1H1C, 
H1FX, PHB, RFC1, RPA1, SHPRH, 
SMC2, SRCAP, TLK2, TOP2A 
chromatin remodeling ARID1A, HDAC5, HELLS, SUV39H2 BAZ2A, CHD8  
chromatin assembly HELLS, SUV39H2 CHD8, HIST1H1C, H1FX, SHPRH  
DNA methylation HELLS BAZ2A 
chromatin 
modification 
ARID1A, EP400, HDAC5, HELLS, RNF8, 
RUVBL2 SUV39H2, UBE2N  
BAZ2A, CHD8, PHB, SRCAP, TLK2  
histone acetylation EP400, RUVBL2  
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histone deacetylation HDAC5  BAZ2A, PHB 




ARID1A, HDAC5, HELLS, MYC, RUVBL2, 
SOX15, SUV39H2, TERF2IP, UBE2N 
BAZ2A, CHD8, CHMP1A, GTF2H4, 
PHB, RFC1, SRCAP, ZNFX1 




Figure 7.1 Results of RNAi-
based screening for EdU 
levels as measure for DNA 
replication.  
Supplementary data 
corresponding to Figure 4.6. All 
target genes where ranked 
according to the cumulative 
robust z-score of EdU 
incorporation. The 20 target 
genes with the highest and 
lowest cumulative z-scores are 
shown in magnification. 
PC=positive control 
 






Figure 7.2 Control-based validation of main hits in EdU-positive cells.  
PANC-1 cells were transfected with siRNAs as indicated and (a) left untreated or (b) exposed to 300 nM 
gemcitabine for 22 h. Cells were then fixed and stained for immunofluorescence analysis. H2AX 
phosphorylation was quantified in EdU-positive cells. All candidates were ranked according to cumulative 
relative changes in γH2AX compared to control knockdown resulting from three different siRNA sequences 
for every target gene. The relative γH2AX induction by each siRNA is shown for every target gene.  





Figure 7.3 Relative changes in EdU levels caused by main hits of the screen.  
PANC-1 cells were transfected with siRNAs as indicated and (a) left untreated or (b) exposed to 300 nM 
gemcitabine for 22 h. Cells were then fixed and stained for immunofluorescence analysis. EdU incorporation 
was quantified and compared to control transfection. All candidates were ranked according to cumulative 
relative changes in EdU levels compared to control knockdown resulting from three different siRNA 
sequences for every target gene. The relative γH2AX induction by each siRNA is shown for every target 
gene.  





Figure 7.4 Control-based validation of selected hits in MIA PaCa-2 cells.  
Genes whose depletion proved to have influence on H2AX phosphorylation in PANC-1 cells and which were 
of interest as novel DNA damage mediators were selected and tested in MIA PaCa-2 cells. Cells were 
transfected with siRNAs as indicated and either left untreated (left column) or exposed to 300 nM gemcitabine 
for 22 h (right column). Cells were fixed and stained for immunofluorescence analysis and EdU as well as 
γH2AX levels were quantified. Relative changes in (a) overall γH2AX levels, (b) γH2AX levels in EdU-positive 
cells and (c) incorporation of EdU are ranked according to the cumulative changes of all three siRNAs against 
the respective target gene. The relative change of every readout is displayed for each siRNA individually. 
 





Figure 7.5 Control-based validation of selected hits in PaTu8902 cells.  
Genes whose depletion proved to have influence on H2AX phosphorylation in PANC-1 cells and which were 
of interest as novel DNA damage mediators were selected and tested in PaTu8902 cells. Cells were 
transfected with siRNAs as indicated and either left untreated (left column) or exposed to 300 nM gemcitabine 
for 22 h (right column). Cells were then fixed and stained for immunofluorescence analysis and EdU as well 
as γH2AX levels were quantified. Relative changes in (a) overall γH2AX levels, (b) γH2AX levels in EdU-
positive cells and (c) incorporation of EdU are ranked according to the cumulative changes of all three siRNAs 
against the respective target gene. The relative change of every readout is displayed for each siRNA 
individually. 
 




Figure 7.6 Control-based validation of selected hits in U2OS cells.  
Genes whose depletion proved to have influence on H2AX phosphorylation in PANC-1 cells and which were 
of interest as novel DNA damage mediators were selected and tested in U2OS cells. Cells were transfected 
with siRNAs as indicated and either left untreated (left column) or exposed to 300 nM gemcitabine for 22 h 
(right column). Cells were fixed and stained for immunofluorescence analysis and EdU as well as γH2AX 
levels were quantified. Relative changes in (a) overall γH2AX levels, (b) γH2AX levels in EdU-positive cells 
and (c) incorporation of EdU are ranked according to the cumulative changes of all three siRNAs against the 
respective target gene. The relative change of every readout is displayed for each siRNA individually. 
 






Figure 7.7 Effect of candidate gene 
knockdown on γH2AX is not 
attributable to a decrease in Rad51 or 
p53 levels.  
PANC-1 cells were transfected with the 
indicated siRNAs and all wells were 
treated with 300 nM gemcitabine for 
22 h according to screening conditions. 
Cell lysates were analyzed by immuno- 
blotting. 
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